CONFIDENTIAL    
Protocol ADXS -503-101 
 
1 
                                                                                                                    
 
Title Page  
A Phase 1 /2, Open -Label Study of ADXS -[ADDRESS_919632] s with Metastatic  Squamous or Non-Squamous  
Non-Small Cell Lung Cancer  
 
Protocol Number : ADXS -503-101 
Compound Number / Name : [CONTACT_679794] -503 
Sponsor Name [CONTACT_29560]:  
Advaxis , Inc. 
[ADDRESS_919633], Suite K -1 
Monmouth Junction, NJ [ZIP_CODE]  
Regulatory Agency Identifying Number (s): IND #:  018284  
 
This study will be conducted under Food & Drug Administration IND regulations (CFR Part 
312).  
 
 
Protocol Version and Date :  
Original Protocol, Version 1.0 dated 21 -JUN-2018  
Amendment # 1, Version 2.0 dated 06 -AUG -2018  
Amendment # 2, Version 3.0 dated 17 -SEP-2018  
Amendment # 3, Version 4.[ADDRESS_919634] -2019  
Amendment #4, Version 5.0, dated 19-JUN-2021  
(see Section 13 for summary of protocol changes)  
 
Confidentiality Statement  
The information contained herein is confidential and proprietary and may not be disclosed, 
reproduced, or circulated without the prior written consent of Advaxis, Inc.    

CONFIDENTIAL    
Protocol ADXS -503-101 
 
2 
  
PROTOCOL APPROV AL  
 
A Phase 1 /2, Open -Label Study of ADXS -503 Alone and in Combination with 
Pembrolizumab in Subjects with Metastatic  Squamous or Non-Squamous  
Non-Small Cell Lung Cancer   
Protocol Number : ADXS -503-101 
Protocol Version  and Date:  
 
Original protocol, Version 1.0 dated 21 -JUN-2018  
 
Amendment # 1 , Version 2.0 dated 06 -AUG -2018   
 
Amendment # 2, Version 3.0 dated 17-SEP-2018  
 
Amendment # [ADDRESS_919635] -2019  
 
Amendment #4 , Version 5.0 dated 19-JUN-2021  
 
 
 
 
 ________________________________ _____    _________________________  
Signature  [CONTACT_679833] A Gutierrez , MD, PhD 
Chief Medical Officer EVP - Advaxis, Inc.  
 
 
  
June 22, 2021
CONFIDENTIAL    
Protocol ADXS -503-101 
 
3 
 INVESTIGATOR SIGNATURE [CONTACT_1783]  
A Phase 1/2, Open -Label Study of ADXS -503 Alone and in Combination with 
Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non -Small Cell 
Lung Cancer  
Protocol Number : ADXS -503-101 
Protocol Version  and Date:  
 
Original protocol, Version 1.0 dated 21 -JUN-2018  
 
Amendment # 1 , Version 2.0 dated 06 -AUG -2018   
 
Amendment # 2 , Version 3.0 dated 17-SEP-2018  
 
Amendment # [ADDRESS_919636] -2019  
 
Amendment #4, Version 5.[ADDRESS_919637] (IRB)/Ethical Review Committee (ERC).  
This study  will be conducted  in accordance  with Good  Clinical  Practices  (GCP),  International  
Conference  on Harmonisation  (ICH)  Guidelines,  the Declaration  of Helsinki,  and local  ethical  
and legal  requirements.  
 
Investigator Name:  
 
 ________________________________ _____    _________________________  
Signature  [CONTACT_1782]  
 
_____________________________________  Site #:  __________  
Printed Name  
  
[CONTACT_679834] -503-101 
 
4 
 Table of Contents  
1. Trial Summary  ................................ ................................ ................................ ................ 8 
1.1. Synopsis  ................................ ................................ ................................ ............................ 8 
2. Schedule of Activ ities (SoA)  ................................ ................................ ......................... 17 
2.1. Safety Phase Part A: ADXS -503 Monotherapy  ................................ .............................. 17 
2.2. Part B (Safety & Efficacy Phases) and Part C: ADXS -503 + 
Pembrolizumab  ................................ ................................ ................................ ............... [ADDRESS_919638]  ................................ ................................ .............. 33 
3.4.2.  Mechanism of Action  ................................ ................................ ................................ ......33 
3.4.3.  Nonclinical Studies with ADXS -503 ................................ ................................ .............. 35 
3.4.4.  Clinical Experience with ADXS -503................................ ................................ .............. 36 
3.4.5.  Combination of Lm-Based  Immunotherapy with an Immune 
Checkpoint Inhibitor  ................................ ................................ ................................ .......41 
3.5. Study Rationale and Selected Patient Population  ................................ ........................... 43 
3.6. Overall Benefit/ Risk Assessment  ................................ ................................ .................. 47 
3.6.1.  Potential Benefits  ................................ ................................ ................................ ............ 47 
3.6.2.  Potential Risks  ................................ ................................ ................................ ................ 47 
4. Study Objectives and Endpoints  ................................ ................................ ................. 51 
5. Investigational Plan  ................................ ................................ ................................ ......53 
5.1. Study Design  ................................ ................................ ................................ ................... 53 
5.1.1.  Safety Phase  ................................ ................................ ................................ .................... 57 
5.1.2.  Efficacy Phase  ................................ ................................ ................................ ................. 60 
5.1.3.  Summa ry of Study Procedures/Assessments  ................................ ................................ ..61 
5.2. Scientific Rationale for Study Design  ................................ ................................ ............ 65 
5.2.1.  Rationale for Starting Dose  ................................ ................................ ............................. 65 
5.2.2.  Rationale for 3+3 Dose Escalation/De -Escalation and Dose -
Expansion Design  ................................ ................................ ................................ ........... 65 
5.3. Number of Sub jects Enrolled  ................................ ................................ .......................... 66 
5.4. End of Study Definition  ................................ ................................ ................................ ..66 
6. Study Population  ................................ ................................ ................................ ........... 66 
6.1. Inclusion Criteria  ................................ ................................ ................................ ............ 66 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
5 
 6.2. Exclusion Criteria  ................................ ................................ ................................ ........... 71 
6.3. Lifestyle Restriction  ................................ ................................ ................................ ........ 74 
6.4. Screen Failures  ................................ ................................ ................................ ................ 74 
7. Treatments  ................................ ................................ ................................ ..................... 74 
7.1. Treatments Administered  ................................ ................................ ................................ 75 
7.1.1. ADXS -503 Monotherapy (Part A)  ................................ ................................ .................. 75 
7.1.2.  ADXS -503 + Pembrolizumab (Part B Dose -Escalation and Dose -
Expansion)  ................................ ................................ ................................ ...................... 76 
7.1.3.  ADXS -503 + Pembrolizumab (Part C)  ................................ ................................ ........... 79 
7.2. Preparation/ Handling/ Storage/ Accountability  ................................ ............................. 81 
7.3. Treatment Compliance  ................................ ................................ ................................ ....82 
7.4. Method of Treatment Assignment  ................................ ................................ .................. 82 
7.5. Blinding  ................................ ................................ ................................ .......................... 82 
7.6. Treatment Modification and Discontinuation Guidelines for 
Toxicity  ................................ ................................ ................................ ........................... 83 
7.6.1.  ADXS -503: Treatment Modification and Discontinuation 
Guidelines  ................................ ................................ ................................ ....................... 83 
7.6.2.  Pembrolizumab: Treatment Modification and Discontinuation 
Guidelines  ................................ ................................ ................................ ....................... 85 
7.7. Concomitant Therapy  ................................ ................................ ................................ .....87 
7.7.1.  Concomitant Medications  ................................ ................................ ............................... 87 
7.7.2.  Prohibited Medications/ Therapy  ................................ ................................ .................... 88 
7.7.3.  Major and Minor Surgeries and ADXS -503 Treatment  ................................ ................. 89 
7.8. Treatment after the End of the Study  ................................ ................................ .............. 89 
8. Discontinuation/ Withdrawal Criteria  ................................ ................................ ........ 89 
8.1. Discontinuation of Study Treatment  ................................ ................................ ............... 89 
8.1.1.  Treatment after Initial Evidence of Radiologic Disease 
Progression  ................................ ................................ ................................ ...................... 90 
8.1.2.  Treatment/ Enrollment Stoppi[INVESTIGATOR_1869]  ................................ ................................ .......... [ADDRESS_919639] of Appendices  
Appendix 1  Abbreviations and Terms  ................................ ................................ ................  134 
Appendix 2  Clinical Laboratory Tests  ................................ ................................ ................  139 
Appendix 3  Study Governance Considerations  ................................ ................................ .. 141 
Appendix 4  Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -
up and Reporting  ................................ ................................ ................................ .........................  [ADDRESS_919640] of In -Text Tables  
Table 1: Treat ment -Related Adverse Events Reported ≥5% with ADXS11 -001 Monotherapy in 
Advaxis Sponsored Trials  ................................ ................................ ................................ .............  38 
Table  2: Treatment -Related Adverse Events, All Treated  ................................ ............................  40 
Table  3: Treatment -Related Adverse Events >10% with ADXS -PSA Alone (Part A) and in 
Combination with Pembrolizumab (Part B) in Metastatic Castrate -Resistant Prostate Cancer 
(mCRPC) ................................ ................................ ................................ ................................ ....... 42 
Table 4: Organ Function Requiremen ts for Study Inclusion  ................................ ........................  70 
Table 5: Treatment in Part A: ADXS -503 Monotherapy  ................................ ..............................  75 
Table 6: Treatment in Part B: ADXS -503 + Pembrolizumab  ................................ .......................  77 
Table 7: Treatment in Part C: ADXS -503 + Pembrolizumab  ................................ .......................  79 
Table 8: Treatment Modifications/Discontinuation for ADXS -503-Related Toxicity  .................  84 
Table 9: Treatment Modificat ions/ Discontinuation for Pembrolizumab -Related Toxicity  .........  85 
Table 10: Populations for Statistical Analysis  ................................ ................................ ............  [ADDRESS_919641] of In -Text Figures  
Figure 1. Study Design  ................................ ................................ ................................ .................  15 
Figure 2. Driver mutations in non -small cell lung cancer.  ................................ ...........................  27 
Figure 3. Lm -based immunotherapi[INVESTIGATOR_679694] -L1 on tumor cells and tumor -
infiltrating macrophages in a HPV+ murine tumor model.  ................................ ..........................  35 
Figure 4. Both ADXS -503 and ADXS -Kras G12D, an Lm -based vector targeting a single Kras 
hotspot mutation, significantly inhibit the growth of CT26 tumors.  ................................ ............  36 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
8 
 1. Trial Summary  
1.1. Synopsis  
Study Title  A Phase 1/2, Open -Label Study of ADXS -503 Alone and in Combination with Pembrolizumab 
in Subjects with Metastatic Squamous or Non -Squamous Non -Small Cell Lung Cancer  
Trial Phase  Phase 1/2  
Clinical Indication  Non-Small Cell Lung Cancer  
Trial Type  Interventional , Simon’s Two -stage design for Part B  
Interventions  • ADXS -503: a live attenuated Listeria monocytogenes (Lm) -based immunotherapy 
bioengineered to elicit potent T cell responses against 22 tumor antigens that include           
1) 11 peptide antigens derived from frequently occurring and commonly shared hotspot 
mutations in patients with squamous and non -squamous NSCLC and 2) 11 peptide antigens 
derived from sequence -optimized tumor -associated antigens ( TAAs ) that are differentially 
expressed or overexpressed in NSCLC tumors.  
• Pembrolizumab : a programed death receptor -1 (PD -1)- blocking antibody.  
Type of control  None  
Route of administration  Intravenous  
Trial Blinding  Unblinded, Open -label  
Estimated duration of trial  The sponsor estimates that for the duration of patient participation,  the trial will require 
approximately [ADDRESS_919642]’s last visit  (which includ es therapy for up to [ADDRESS_919643]’s last visit or upon discontinuation from therapy with ADXS -
503, whichever comes first ). Approximate duration of trial: 4 years .  
Study Phases/ Parts   Safety phase  
• Part A: ADXS -503 monotherapy dose escalation  
• Part B:  ADXS -503 + pembrolizumab dose escalation  
 Efficacy phase  
• Part B: ADXS -503 + pembrolizumab dose expansion  
• Part C: ADXS -503 + pembrolizumab  
See 
 
Figure  [ADDRESS_919644] Population  Safety phase  (Part A and Part B):  
 
Part A  will enroll subjects  with metastatic squamous or non -squamous NSCLC who have 
become refractory or intolerant to standard therapy. To be eligible for Part A, subjects must have 
previously received, and then progressed or been intolerant to up to [ADDRESS_919645] 1 prior line of 
approved targeted therapy to be eligible for Part A.  
Part B  dose-escalation will enroll subjects with metastatic squamous or non -squamous NSCLC 
who meet the following criteria:  
• Are undergoing treatment with pembrolizumab monotherapy as last t herapy  for metastatic 
NSCLC  
      
           
             
                               
                                                      
                                 
                     
              
                               
                         
              
          
                        
                                         
                                                  
         
                                                 
                          
                                    
                                             
                                                                                      
                                                                
                                                      
                                                                  
                                                                    
                                                  
                                                                    
                                                               
               
               
                            
                           
                   
                                         
                         
                            
                                              
                         
              
                            
                                               
CONFIDENTIAL    
Protocol ADXS -503-101 
 
9 
 OR 
• Are undergoing  combination therapy with pembrolizumab plus platinum -based 
chemotherap y as last treatment  
                                                                               OR 
• Are receiving pembrolizumab + pemetrexed as maintenance therapy , as last tre atment after 
completing treatment with pembrolizumab plus platinum -based chemotherapy  
• The subject ’s most recent tumor assessment is consistent with progressive disease (PD) 
according to RECIST v1.1  
• There is n o evidence of rapid disease progression or clinical deteri oration that would 
preclude continuation of pembrolizumab  for up to 12 weeks before ADX S-503 is added -on. 
• In Part B, s ubjects must receive the first dose of ADXS -503 within 12 weeks  of the  initial 
tumor assessment  showing PD (while on last treatment with pembrolizumab monotherapy  or 
pembrolizumab + platinum -based chemotherapy or pembrolizumab + pemetrexed  as 
maintenance therapy ). ADXS -[ADDRESS_919646] consent to allow the acquisition of fresh or archival formalin -fixed paraffin embedded 
(FFPE) tumor tissue, either a block or unstained slides along with a matching blood at baseline, 
for performance of sequencing analysis . 
 
Efficacy phase (Part B expansion and Part C):  
 
Part B  expansion will enroll subjects with metastatic squamous or non -squamous NSCLC who 
meet the same criteria as Part B dose escalation mentioned above.  Based on Stage I of Simon’s 
Two-stage design, 18 patients will be accrued in this study arm. Sponsor may de cide to accrue 
additional 25 subjects for a total of 43 patients in Stage II. Accrual of patients to Part B dose 
level 2 (ADXS -503 at 5x108 CFU in combination with 200  mg pembrolizumab) is pending 
Sponsor decision to commence  
Part C  will enroll  subjects with metastatic squamous or non -squamous NSCLC who have 
received no prior systemic treatment in the metastatic setting, and who will be treated in 
accordance with the approved Product Label for pembrolizumab monotherapy for first -line 
treatment.  Clinical site must provide documentation of tumor PD -L1 expression and EGFR 
mutation and/or ALK translocation status as evaluated by [CONTACT_8415] -approved tests in all patients. 
Baseline tumor samples must express PD -L1 [TPS (Tumor Proportion Score) ≥1%] as 
determin ed by [CONTACT_13247] -approved test  at a local lab oratory facility , with no EGFR or ALK 
genomic tumor aberrations for subjects to be eligible for Part C.  Subject must consent to allow 
the acquisition of fresh or archival FFPE tumor tissue, either a block or unstain ed slides along 
with a matching blood at baseline, for performance of sequencing analysis . 
Study Objectives  Primary  
• To evaluate the safety and tolerability of ADXS -503 monotherapy in Part A  and ADXS -503 
+ pembrolizumab in Part B , and to determine the MTD or MAD.  
• To characterize the preliminary anti -tumor activity of  ADXS -503 + pembrolizumab  in Part B 
and Part C per RECIST v1.1.  
Secondary  
• To characterize the preliminary anti -tumor activity of ADXS -503 monotherapy in dose 
escalation Part A and ADXS -503 + pembrolizumab in Part B per RECIST v1.1.  
• To determine PFS and PFS rate at [ADDRESS_919647] v1.1, for subjects treated with 
ADXS -503 mo notherapy in Part A and ADXS -503 + pembrolizumab in Part B and Part C.  
• To determine OS and 6 - and 12-month milestone OS rates for subjects treated with ADXS -
CONFIDENTIAL    
Protocol ADXS -503-101 
 
10 
 503 monotherapy in Part A and ADXS -503 + pembrolizumab in Part B and Part C.  
• To evaluate the safety  and tolerability of ADXS -503 + pembrolizumab in Part C.  
Exploratory  
• To characterize the preliminary anti -tumor activity, PFS and PFS rate at [ADDRESS_919648] for subjects treated with ADXS -503 monotherapy in Part A, and ADXS -503 + 
pembrolizumab in Pa rt B and Part C.  
• To evaluate correlates of immune response and biomarkers in peripheral blood and biopsy 
samples pre - and on -treatment in Part A , Part B  and Part C . 
Treatment Groups  Safety Phase  
• Part A : ADXS -503 monotherapy dose escalation (3+3 design)  
ADXS -503 monotherapy will be evaluated at 2 planned escalating dose levels : 
o Dose level 1:  1x108 CFU of ADXS -503, IV, every 3 weeks until disease 
progression, unacceptable toxicity, or another treatment discontinuation criterion 
is met.  
o Dose level 2:  5x108 CFU of ADXS -503, IV, every 3 weeks until disease 
progression, unacceptable toxicity, or anothe r treatment discontinuation criterion 
is met.  
• Part B : ADXS -503 + pembrolizumab dose escalation (3+3 design)  
ADXS -503 will be evaluated at 2 planned escalating dose levels in combination with a fixed 
dose of pembrolizumab  (with second dose level commencing upon Sponsor’s decision) : 
o Dose level 1:  1x108 CFU of ADXS -503 + 200 mg of pembrolizumab , IV, every 
3 weeks for up to 2 years  or until disease progression, unacceptable toxicity, or 
another treatment discontinuation criterion is met.  Upon Investigator assessment, 
Investigator could shift the schedule of therapy with 1x108 CFU of ADXS -503 + 
[ADDRESS_919649] year of study treatment . 
o Dose level 2:  5x108 CFU of ADXS -503 + 200  mg of pembrolizumab, IV, every 
3 weeks for up to 2 years  or until disease progression, unacceptable toxicity, or 
another treatment discontinuation criterion is met.  Upon Investigator assessment, 
Investigator could shift the schedule of therapy with 1x108 CFU of ADXS -503 + 
[ADDRESS_919650] year of study treatment . 
Efficacy Phase  
• Part B -Expansion : ADXS -503 + pembrolizumab dose expansion (Simon’s Two -stage 
design)  
o Dose -expansion (DL -1): 1x108 CFU  of ADXS -503 + 200 mg of pembrolizumab, 
IV, every 3 weeks for up to 2 years  or until disease progression, unacceptable 
toxicity, or another treatment discontinuation criterion is met.  Upon Investigator 
assessment, Investigator could shift the schedule of therapy with 1x108 CFU of 
ADXS -503 + [ADDRESS_919651] year of study treatment . 
• Part C: ADXS -503 + pembrolizumab  
o 1x108 CFU of ADXS -503 + 200 mg of pembrolizumab, IV, every 3 weeks for up 
to 2 years  or until disease progression, unacceptable toxicity, or another treatm ent 
discontinuation criterion is met.  Upon Investigator assessment, Investigator could 
shift the schedule of therapy with 1x108 CFU of ADXS -503 + [ADDRESS_919652] year of 
study treatment.  
 
Number of trial subjects  Safety phase:  Up to approximately 24 subjects will be enrolled in the safety phase; up to 12 
subjects in Part A and up to 12 subjects in Part B based on a 3+3 dose escalation design at 2 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
11 
 escalating dose levels. Up to approximately 25 subjects may also be enrolled in a Part A 
expansion cohort.  
 
Efficacy phase:  Up to approximately 165 subjects may be enrolled in the efficacy  phase  (Part B -
expansion and Part C combined) . Up to 43  subjects may be enrolled in Part B expansi on of DL1 
in the  Simon’s Two-stage study cohort (S1  [n=18], and S2  [n= 25]) and up to a total of 140 
thereafter. Approximately up to 25 subjects may be enrolled in Part C.  
Study Design  This is a Phase 1/2, open -label, multi -center study of ADXS -503 administered alone and in 
combination with pembrolizumab in subjects with metastatic squamous or non -squamous 
NSCLC. This study will be performed in 2 phases, a safety phase and an efficacy phase , as 
described below. Refer t o 
 
Figure  1 for a schematic of the study design. Simon’s Two -stage design has been incorporated 
for evaluation of subjects in Part B expansion Efficacy  phase . 
Safety Phase  
The purpose of the safety phase is to evaluate the safety and tolerability of ADXS -503, 
administered as monotherapy  (Part A)  and in combination with pembrolizumab  (Part B -dose 
escalation ), and to determine the MTD or MAD. The preliminary clinical and immunological 
activity of ADXS -[ADDRESS_919653] population to be enrolled in Part A and Part B is described 
above.  
In Part A, ADXS -503 will be administered as monotherapy at 2 planned escalating dose levels  
(dose level 1 [1x108 CFU] and dose level 2 [5x108 CFU]) . In Part B, ADXS -503 will be 
      
           
             
                               
                                                      
                                 
                     
              
                               
                         
              
          
                        
                                         
                                                  
         
                                                 
                          
                                    
                                             
                                                                                      
                                                                
                                                      
                                                                  
                                                                    
                                                  
                                                                    
                                                               
               
               
                            
                           
                   
                                         
                         
                            
                                              
                         
              
                            
                                               
CONFIDENTIAL    
Protocol ADXS -503-101 
 
12 
 administered at 2 planned escalating dose levels  (dose level 1 [1x108 CFU] and upon  Sponsor’s 
decision, may be escalated to dose level 2 [5x108 CFU])  in combination with a fixed dose of 200 
mg of pembrolizumab, as described above . Dose escalation in Part A and Part B will proceed 
according to a 3+3 dose escalation design.  
If treatment with ADXS -503 monotherapy is safe and tolerable at dose level 1 in Part A (based 
on DLT criteria), escalation to dose level 2 in Part A will proceed in parallel with accrual at dose 
level 1 in Part B -dose escalation . If treatment with ADXS -503 + pembrolizum ab is safe and 
tolerable at dose level 1 in Part B (based on DLT criteria), this dose can be considered the 
recommend ed dose for use in Part B -expansion and Part C. In parallel, escalation to dose level 2 
in Part B will proceed (upon Sponsor’s decision) in parallel with accrual in Part C.  
Prior to declaring the MTD in Part A or Part B , dose level (s) previously established to be safe 
may be expanded or intermediate dose levels may be investigated. If a MTD is not established, a 
higher dose level may be eval uated  with agreement between the Investigators and the Sponsor  
or study will continue with the recommended dose from Part B -escalation that is demonstrated 
to be safe and well tolerated . Dose escalation rules (cohort size, DLT evaluation interval, etc.) 
will apply to the expanded or additional cohorts.  
Upon completion of dose escalation in Part A, ADXS -503 monotherapy may be evaluated in an 
expansion cohort. This Part A expansion cohort may commence enroll ment following 
consultation and agreement be tween study Investigators and the Sponsor. Th e expansion cohort 
may be restricted to the tumor type(s) found to be responsive to ADXS -503 monotherapy. The 
dose of ADXS -503 selected for the monotherapy expansion will not exceed the MTD 
established in Part A . However, the dose may be intermediate to those tested in Part A if 
recommended by [CONTACT_58439]. Up to approximately 25 subjects will be 
enrolled in this expansion cohort . 
Efficacy Phase  
Upon confirming treatment with ADXS -503 + pembr olizumab is safe and tolerable at dose level 
1 in Part B -escalation  (based on DLT criteria), accrual will be  initiated in Part B expansion and 
Part C. Hence, the planned dose in Part B -expansion  and in Part C will be ADXS -503 1x108 
CFU in combination with 200 mg of pembrolizumab.   
Part B -dose expansion will evaluate preliminary efficacy using a Simon’s Two-stage study 
design in subjects who have failed prior systemic treatment with 1) pembrolizumab 
monotherapy as last therapy or 2) while receiving combinati on therapy with pembrolizumab and 
platinum based -chemotherapy as last treatment or 3)  while receiving pembrolizumab + 
pemetrexed maintenance therapy as last treatment  in the metastatic setting. Part B dose -
expansion may enroll up to 43 subjects in the Simon’s Two -stage design (ie, S1  [n=18], and S2  
[n=25]) and up to a total of [ADDRESS_919654] received no prior systemic treatment in 
the metastatic setting, and whose tumors express PD -L1 [TPS (Tumor Proportion Score) ≥1%] 
as determined by [CONTACT_13247] -approved test, with no EGFR o r ALK genomic tumor aberrations.  
Toxicities will be evaluated on an ongoing basis in Part B-dose expansion and Part C. If the 
aggregate rate of treatment -related toxicities that meet the DLT criteria exceeds 33% at any time 
(across all subjects in Part B dose -expansion and Part C), the findings will be discussed between 
the Sponsor and study Investigators, and furt her enrollment may be interrupted. Depending on 
the nature and grade of the toxicities and after assessing the risk/ benefit, treatment may be 
adjusted to a lower dose of ADXS -503 or an alternative treatment schedule. In all cases, the 
dose of pembrolizuma b will be fixed at 200 mg.  
Overall treatment and enrollment stoppi[INVESTIGATOR_679695] 8.1.2 . 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
13 
 Summary of study 
assessments/ procedures  • In Part B, s ubject must consent to allow the acquisition of fresh or archival FFPE tumor 
tissue, either a block or unstained slides along with matching blood at baseline, for 
performance of sequencing analysis . 
• At least 30 minutes prior to each ADXS -503 infusion, all subjects will receive a pre -
infusion prophylactic regimen of adequate hydration, NSAIDs, antihistamines and 
antiemetics to mitigate the potential  for “flu -like” symptoms  during or after  treatment 
infusion . Vital signs will be monitored every 30 minutes (±5  minutes) starting immediately 
prior to each ADXS -503 infusion, until 4 hours after the end of each ADXS -503 infusion. 
To ensure the clearance of Lm, subjects will receive a 7 -day course of oral antibiotics 
starting approximately 48 hours after each ADXS -503 infusion. After the final dose of 
ADXS -503, a 3 -week course of oral antibiotics will be administered to ensure the clearance 
of Lm, which will be confirmed by a blood culture .  
• Safety will be assessed throughout this study by [CONTACT_320113], physical examination 
findings, vital sign measurements, monitoring of performance status, and clinical laboratory 
values. Adverse events will be graded in severity according CTCAE v4.03.  
• Tumor  imaging will be performed by [CONTACT_22242] -enhanced CT/MRI as follows:  
o Part A (ADXS -503 monotherapy): Screening (baseline), at Week 8 (±3 days), at 
Week 16 (± 7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) thereafter, until 
confirmed disease progression or treat ment discontinuation, whichever occurs 
later.  
o Part B  dose-escalation  and Part B dose -expansion  (ADXS -503 + pembrolizumab) : 
Screening (baseline ) [which corresponds to the most recent tumor assessment that 
is consistent with PD (according to RECIST v1.1 ) while on treatment with 
pembrolizumab monotherapy , or while  receiving combination therapy with 
pembrolizumab + platinum -based chemotherapy or while receiving  
pembrolizumab + pemetrexed maintenance therapy in the metastatic  setting  as the 
last systemic ther apy] . Subsequent scans will  be performed at Week 8 (± 7 days), 
at Week 16 (± 7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) thereafter, until 
confirmed disease progression or treatment discontinuation, whichever occurs 
later.  As described above, the first dose of ADXS -503 added to pembrolizumab 
will be administered within 12 weeks  of the  initial assessment of PD . 
o Part C (ADXS -503 + pembrolizumab): Screening (baseline),  at Week 8 (± 7 days), 
at Week 16 (± 7 days), followed by [CONTACT_679770] 9 weeks (±7 days), until confirmed 
disease progression or treatment discontinuation, whichever occurs later.  
• Tumor response will be evaluated by [CONTACT_737] (or designee) according to RECIST 
v1.1 as the basis for the primary analysis of tumor resp onse-based endpoints. Exploratory 
analysis of tumor -response will be performed by [CONTACT_1034] (or designee) according to 
iRECIST.  
o In Part A and Part C, s ubjects may receive study treatment beyond initial 
Investigator -assessed, RECIST v1.[ADDRESS_919655] systemic therapy in metastatic setting 
(ie, pembrolizumab alone , or combination therapy with pembrolizumab + 
platinum -based chemotherapy , or pembrolizumab + pemetrexed as maintenance 
therapy ) (if eligibility criteria are met) . 
o In Parts A, B , and C, any apparent CR or PR must be confirmed ≥[ADDRESS_919656] subsequently discontinue 
treatment . 
o The following subjects may be eligible for re -treatment upon disease progression, 
with agreement between the Sponsor and Investigator:  
▪ Subjects who achieve a confirmed CR during initial study treatment (Parts 
A, B , and C).  
▪ Subjects in Part B and Part C who stop trial therapy after 2 years of 
treatment for reasons other than disease progression or intolerability.  
Note: Tumor response data collected during the re -retreatment period will 
not be used for the primary analysis of tumor response endpoints.  
• In Parts A, B and C, evaluable tumor biopsy tissue (fresh or archival ) with matched 
peripheral blood samples  must be collected at baseline . to evaluate biomarkers and 
correlates of immune response.   Additional blood samples for correlative work will be 
collected during the treatment phase.  
• Following treatment discontinuation, all subjects will enter a 1-year survival/treatment and 
Lm surveillance ( LmS) follow -up period.  Survival status will be confirmed remotely with  
the subject, their physician , or their legally authorized representative every 3 months (±2 
weeks) for 1 year. In addition, during  the LmS Follow -up Period, subjects will be contact[CONTACT_679771] 3 months (±2 week) for [ADDRESS_919657] experienced 
for several days, the following symptoms that could potentially be associated with delayed 
listeremia: fever or ch ills, headache, nausea, confusion , or changes in alertness (for over 72 
hours). As part of the End of T herapy  procedures, upon completing the LmS Follow -up 
Period, site staff should instruct subjects to contact [CONTACT_679772], as applicable.  
 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
15 
  
 
Figure 1. Study Design  
a. Escalation to DL2 in Part A will occur in parallel with accrual at DL1 in Part B  
b. Upon completion of DL1 in Part B, Dose -expansion of DL1 in Part B will occur in parallel with accrual in Part C . (Accrual in Part B  Dose Level 2  may occur upon Sponsor’s decision ). Upon 
Investigators’  assessment  and decision , treatment schedule with 1x108 CFU of ADXS -503 + [ADDRESS_919658] year 
of study therapy . 
      
           
             
                               
                                                      
                                 
                     
              
                               
                         
              
          
                        
                                         
                                                  
         
                                                 
                          
                                    
                                             
                                                                                      
                                                                
                                                      
                                                                  
                                                                    
                                                  
                                                                    
                                                               
               
               
                            
                           
                   
                                         
                         
                            
                                              
                         
              
                            
                                               
CONFIDENTIAL    
Protocol ADXS -503-101 
 
16 
 c. If treatment is not safe/tolerable at DL1 in Part A or Part B  dose-escalation , a lower dose level (DL -1; 0.5x108 CFU of ADXS -503) will be evaluated before proceeding with Part B and Part C, 
respectively.  
d. Upon completion of dose escalation in Part A, ADXS -503 monotherapy may be evaluated in an expansion cohort.  
Abbreviations: DL: dose level.  
 
 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919659] ivities (SoA)  
2.1. Safety Phase Part A: ADXS -[ADDRESS_919660] 12 weeks of treatment  2 Week 13 
to EOT 3 End of  
Therapy  
(EOT)4 
 
 Safety  
Follow -
Up21 
 
 1-year   
Survival/  
Treatment  
& LmS 
Follow -up 
Period22 Days 
-[ADDRESS_919661]  7 X                 
Demographics  X                 
Medical history 8 X                 
Surgical history 9 X                 
Prior cancer history 10 X                 
Prior/Concomitant medications 11 X <------------------------------------------------------------------------------------------------------- > X X X 22 
Non-drug treatment/Procedures 12 X <-------------------------------------------------------------------------------------------------------- > X X  
Clinical Procedures  
Review adverse events 13 X <-------------------------------------------------------------------------------------------------------- > X X  
Physical examination 14 X X   X   X   X   X X   
ECOG performance status 15 X X   X   X   X   X X   
Vital signs 16 X X   X   X   X   X X   
Tumor imaging/ assessments 17 X        X     X X   
Pre-infusion prophylaxis 18  X   X   X   X   X    
Administer ADXS -503 19  X   X   X   X   X    
Administer/dispense prophylactic 
antibiotics 20  X   X   X   X   X X   
Safety follow -up phone call/ visit 21                X  
Survival /LmS remote monitoring 22                 X 
Laboratory Procedures  
Virology 23 X                 
Coagulation profile 24 X                 
Complete Blood Count (CBC) with 
differential [ADDRESS_919662] 12 weeks of treatment  2 Week 13 
to EOT 3 End of  
Therapy  
(EOT)4 
 
 Safety  
Follow -
Up21 
 
 1-year   
Survival/  
Treatment  
& LmS 
Follow -up 
Period22 Days 
-30 to -1 Wk  
1 Wk 
2 Wk 
3 Wk  
4 Wk 
5 Wk 
6 Wk  
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Wk 13  
to EOT  
Tumor biopsy sample 27 X        X      X   
Blood draw for cytokine s/ 
chemokines 28  X   X   X   X       
Blood draw for immune correlative 
studies 29 X X X   X   X     X X   
Blood sample for Lm culture 30                X  
1 Screening procedures will be performed within 28 days (±2 days)  prior to the first dose of study treatment  to determine study eligibility.  
[ADDRESS_919663] 12 weeks of study treatment.  
3 Procedures noted here will be performed from Week 13 u p to the end of therapy (EOT) . Refer to Table and indicated footnotes . Subjects will receive study treatment 
until a treatment discontinuation criterion is met (see  Section  8.1). 
[ADDRESS_919664]’s routine clinical management 
and obtained before signing the Informed Consent Form, may be utilized for Screening or basel ine purposes provided the procedures meet the protocol -specified 
criteria.  
[ADDRESS_919665]  eligibility (Inclusion/ Exclusion Criteria) must be review ed during Screening and confirmed prior to the start of study treatment on Day [ADDRESS_919666] is enroll ed in a clinical trial of an experiment al agent that may be associated 
with immune -mediated toxicity , induced by [CONTACT_679773].  
8 Medical history will include all active conditions and any prior conditions that are considered by [CONTACT_679774].  Medical history will also 
include an assessment of smoking history.  
9 Document any non -cancer surgeries, including, but not limited to the placement of artificial (prosthetic) joints, implants and/or devices, suc h as port/stent implant placed 
prior t o study enrollment.  
10 Document prior cancer history, including prior cancer treatments, surgeries and medications . 
11 Prior/concomitant medications will be documented from 30 days prior to Screening until 30 days  after the final dose of study treatment.  
12 Document any non -drug treatment and surgical procedures including, but not limited to, artificial (prosthetic) joints, implants and/or devices.  
[ADDRESS_919667] dose of study treatment . 
ESIs will be reviewed as they are reported and will be discussed at the time of the dose escalation meetings, and periodically aft erwards . All AEs/ECI/S AEs will be 
followed through resolution. All AEs/ ESI/SAEs experienced during this period must be recorded on the eCRF . See Section  9.1.5  and Appendix 4 . 
14 A physical examination (PE) must be completed at Screening and within 72 hours prior to the start of each ADXS -503 infusion. Body height will be m easured only at 
Screening. Body weight  will be measured  at all physical examination timepoints.  
15 ECOG performance status to be evaluated at Screening and within 72 hours prior to the start of each ADXS -503 infusion  (see Append ix 11). 
[ADDRESS_919668] and will include temperature, systolic and diastolic blood pressure, pulse,  oxygen 
saturation,  and respi[INVESTIGATOR_697]. Vital signs to be measured at Screening . Vital signs will also be measured  every 30 minutes (± 5 minutes) starting immediately prior to 
each ADXS -[ADDRESS_919669] of care.  
17 Tumor response will be evaluated by [CONTACT_737] (or designee) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.[ADDRESS_919670]/MRI during Screening (baseline), at Week 8 (± 7 days), at Week 16 (±7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) thereafter, until 
confirmed disease progression or treatment discontinuation, whichever occurs later. Tumor imaging will occur at this schedu le, independent of any adjustments to 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919671] 12 weeks of treatment  2 Week 13 
to EOT 3 End of  
Therapy  
(EOT)4 
 
 Safety  
Follow -
Up21 
 
 1-year   
Survival/  
Treatment  
& LmS 
Follow -up 
Period22 Days 
-30 to -1 Wk  
1 Wk 
2 Wk 
3 Wk  
4 Wk 
5 Wk 
6 Wk  
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Wk 13  
to EOT  
the treatment schedule . Note: The tumor scan at Week [ADDRESS_919672] be performed before the scheduled tumor biopsy at Week 8  (see footnote # 27) . See Section  9.4.[ADDRESS_919673] 30 
minutes before the start of each ADXS -503 infusion.  
19 Administer ADXS -503 as a single IV infusion over 60 ( ±10) minutes, every [ADDRESS_919674] occur wi thin 3 days  of the scheduled infusion day (every 3 weeks  ±2 days ) unless a delay in dosing is 
required to allow for the resolution of AEs as outlined in Section  7.6. The interval between each ADXS -[ADDRESS_919675] dose of antibiotics will be ad ministered 
approximately 72 hours after the ADXS -503 infusion. After the final dose of ADXS -503, a 3 -week course of oral antibiotics will be administered to ensure the clearance 
of Lm (the first dose administered approximately 48 hours after the final ADXS -503 infusion) . See Section [IP_ADDRESS]  for the antibiotic regimen.  
21 Safety follow -up phone call/ visit to be made 30 days ( ±5 days) after final dose of study treatment to confirm resolution of any new or ongoing AEs, ESI or SAEs.  
22 Following treatment discontinuation, all subjects  will enter a 1-year survival /treatment  and Lm surveillance Follow -up Period . 
• Survival status will be confirmed remotely with  the subject , their physician , or their legally authorized representative every 3 months (± 2 weeks ) for up to 1 
year.  
• Any subsequent anti -cancer treatment received by [CONTACT_679775] 1 -year period will be recorded.  
• During the Lm surveillance Follow -up Period, subjects will be contact[CONTACT_679776] 3 months (± 2 week) to determine whether they have experienced 
for several days, the following symptoms that could potentially be associated with  delayed listeremia: fever or chills, headache, nausea, confusion or 
changes in alertness (for over 72 hours). As part of EOT  procedures, upon completing the Lm Surveillance period, site staff should instruct subjects to 
contact [CONTACT_679777], as applicable.  
23 HBsAg and HCV screening is required for subjects with a history of active hepatitis B or hepatitis C infection.  
24 PT/INR and aPTT must be measured during Screening. Subsequent testing is to be performed only as clinical ly indicated.  
[ADDRESS_919676] recently acquired archived tumor biopsy sample may be used for analysis (date of biopsy w ithin 3 years of Screening). For archived  
tumor biopsy samples, sufficient tumor samples should be acquired to allow biomarker testing (eg, at least  12-15 unstained slides ). Tumors biopsied at screening will be 
designated as pretreatment biopsies . The baseline biopsy must be from a location that has  not been radiated. In addition, a fresh on -treatment biopsy must be obtained 
from a suitable lesion, preferably from a non -target lesion, at Week 8 ( ± 7 days)  or, if not possible, 1 week (±3 days) after next ADXS -503 infusion (Week 11) . This on -
treatment biopsy sample must be obtained after the scheduled tumor scan at Week 8 (see Section 9.4.1  and Section  9.5). Note: tumor biopsy samples may not be 
collected after the first [ADDRESS_919677] is discontinued before Week 7 (3rd dose)  Additional matched biopsy tissue and blood samples at baseline and post treatment or End of 
treatment samples may be collected by [CONTACT_679778] A expansion coho rt is opened.  
28 Blood samples for cytokine/chemokine analysis will be collected for the first 4 ADXS -503 infusions (Weeks 1, 4 , 7, and 10 ) as follows:  
• Within 30 minutes prior to the start of each ADXS -503 infusion and 2 hours after the end of each ADXS -503 infusion (± 15 minutes).  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919678] 12 weeks of treatment  2 Week 13 
to EOT 3 End of  
Therapy  
(EOT)4 
 
 Safety  
Follow -
Up21 
 
 1-year   
Survival/  
Treatment  
& LmS 
Follow -up 
Period22 Days 
-30 to -1 Wk  
1 Wk 
2 Wk 
3 Wk  
4 Wk 
5 Wk 
6 Wk  
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Wk 13  
to EOT  
29 Blood samples for immune correlative studies ( eg, RNAseq , cfDNA, flow cytometry , and ELISpot analysis) will be collected during Screening , Week 1 (ie, right before 
the first infusion)  and 7 days ( ± 2 days)  after the end of  each of the first 3 ADXS -503 infusions (Weeks 2, 5 , and 8). To monitor the durability of T cell responses, 
subsequent blood samples for PBMCs will be taken at Week 25 (±1 week) and/or at EOT .  
30 7 days ( ±3 days) after the completion of the [ADDRESS_919679] should receive treatment as  outlined in Section  [IP_ADDRESS] . 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
21 2.2. Part B (Safety & Efficacy Phase s) and Part  C: ADXS -503 + Pembrolizumab  
Procedure  
 
 
 
 Screening1 
First 12 weeks of treatment 2 Week 
13 to 
EOT 3  
End of  
Therapy 
(EOT)4 
 
 Safety  
Follow -
Up23 
 
 
  
1-year 
Survival/  
Treatment  
& LmS 
Follow -up 
Period [ADDRESS_919680] 7 X                  
Demographics  X                  
Medical history 8 X                  
Surgical history 9 X                  
Prior cancer history 10 X                  
Prior/Concomitant medications 
11 X <-------------------------------------------------------------------------------------------------------- >  X X X 24 
Non-drug treatment/Procedures 
12 X <-------------------------------------------------------------------------------------------------------- >  X X  
 Clinical Procedures  
Review adverse events 13 X <-------------------------------------------------------------------------------------------------------- >  X X  
Physical examination 14 X X   X   X   X   X  X   
ECOG performance status 15 X X   X   X   X   X  X   
Vital signs 16 X X   X   X   X   X  X   
Tumor imaging/ assessments 17 X        X17 
    X  X   
Administer Pembrolizumab 18,19  X18   X18   X18   X18   X18     
ADXS -503 Pre -infusion 
prophylaxis 20  X   X   X   X   X     
Administer ADXS -503 21  X18   X18   X18   X18   X18     
Administer/dispense 
prophylactic antibiotics 22  X   X   X   X   X  X   
Safety follow -up phone call/ 
visit 23                 X  
Survival/ follow up and LmS 
remote monitoring24                  X 
 Laboratory Procedures  
Virology [ADDRESS_919681] 12 weeks of treatment 2 Week 
13 to 
EOT 3  
End of  
Therapy 
(EOT)4 
 
 Safety  
Follow -
Up23 
 
 
  
1-year 
Survival/  
Treatment  
& LmS 
Follow -up 
Period 24 Days 
-42 to -1 Wk  
1 Wk 
2 Wk 
3 Wk  
4 Wk 
5 Wk 
6 Wk  
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12  
Wk 13  
to EOT   
 
Wk 25  
Complete Blood Count (CBC) 
with differential [ADDRESS_919682] 4 weeks . In Part C, screening procedures will b e performed within 28 days (±2 days) prior to the first dose 
of study treatment  to determine study eligibility.  
[ADDRESS_919683] 12 weeks of study treatment  for Pa rt B andfor Part C . 
3 Procedures noted here will be per formed from Week 13 (Part B and Part C) up to the end of therapy (EOT) . Refer to Table and indicated footnotes . Subjects will receive 
study treatment for up to 2 years or until a treatment discontinuation criterion is met (see Section  8.1). 
[ADDRESS_919684]’s routine clinical management 
and obtained before signing the Informed Consent Form, may be utilized for Screening or baseline purposes provided the procedures meet the protocol -specified criteria.  
[ADDRESS_919685] eligibility (Inclusion/ Exclusion Criteria) must be reviewed during Screening and confirmed prior to the start of stu dy treatment on Day [ADDRESS_919686] is e nrolled in a clinical trial of an experimental agent that may be associated 
with immune -mediated toxicity, induced by [CONTACT_679773]. 
8 Medical history will include all active conditions and any prior conditions that are considered by [CONTACT_679779] s ignificant. Medical history will also 
include an assessment of smoking history.  
9 Document any non -cancer surgeries, including, but not limited to the placement of artificial (prosthetic) joints, implants and/or devices, suc h as port/stent implant placed 
prior to study enrollment.  
10 Document prior cancer history, including prior cancer treatments, surgeries and medications.  
11 Prior/concomitant medications will be documented from 30 days prior to Screening until 30 days after the final dose of study treatment.  
12 Document any non -drug treatment and surgical procedures including, but not limited to, artificial (prosthetic) joints, implants and/or devices . 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919687] dose of study treatment.  
ESIs  will be reviewed as they are rep orted and will be discussed at the time of the dose escalation meetings, and periodically afterwards.  All AEs/ECI/SAEs will be 
followed through resolution. All AEs/ESI/SAEs experienced during this period must be recorded on the eCRF. See Section 9.1.5  and Appendix4 . During the LmS 
Follow -up Period, AEs and SAEs related to listeremia will be assessed . 
14 A physical examination (PE) must be completed at Screening and within 72 hours prior to the start of study treatment on each treatment d ay. Body height will be 
measured only at Screening. Body weight will be measured at all physical examination timepoints.  
15 ECOG perfo rmance status to be evaluated at Screening and within 72 hours prior to the start of study treatment on each treatment day (s ee Appendix 11 ). 
[ADDRESS_919688] of care until the administration of ADXS -503. Vital sign monitoring for ADXS -503 will then occur every 30 minutes (± 5 
minutes) starting immediately prior to each ADXS -[ADDRESS_919689] of care.  
17 Tumor response will be evaluated by [CONTACT_737] (or designee) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.[ADDRESS_919690]/MRI during Screening (baseline), which corresponds to the most recent tumor assessment that is consistent with PD (according to RECIST 
v1.1) while on treatment with pembrolizumab monotherapy  as last therapy , while re ceiving combination therapy with pembrolizumab + platinum -based chemotherapy 
or while receiving pembrolizumab + pemetrexed as maintenance therapy , as last therapy in the metastatic setting.  The first dose of ADXS -503 will be administered 
within 12 weeks  of the initial assessment of PD . Subsequent scans will be performed  at Week 8 (±7 days), at Week 16 (±7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) 
thereafter, until confirmed disease progression or treatment discontinuation, whichever occurs later.  Simila rly, t umor imaging in Part C will be performed at Screening 
(baseline), at Week 8 (±7 days), at Week 16 (±7 days), followed by  [INVESTIGATOR_135] 9 weeks (±7 days) thereafter, until confirmed disease progressi on or treatment 
discontinuation, whichever occurs later   Tumor imaging will occur at this schedule, independent of any adjustments to the treatment schedule . Note: See Section  
9.4.[ADDRESS_919691], followed approximately 60 ( ± 15) minutes after the end of the pembrolizumab infusion by [CONTACT_679780] -503 
infusion (see footnote # 19 and footnote # 21). Treatment will continue every 3 weeks starting at Week 1 (±2 days)  until the completion of 2 years of treatment, or until 
another treatment discontinuation criterion is met (see Section  8.1). 
19 Administer pembrolizumab as a single IV infusion over 30 ( ±5) minutes . See Section 7.[ADDRESS_919692] 
occur within 3 days  of the scheduled infusion (every 3 weeks ±2 days ) day unless a delay in dosing is required to allow for the resolution of AEs as outlined in 
Section  7.6. The interval between each pembrolizumab dose should not be  less than 2 weeks without Sponsor approval . Treatment will continue every 3 weeks (±2 
days)  for approximately the first year from the first dose on this study . Thereafte r, the PI [INVESTIGATOR_679696] Q3W or change to Q6W schedule until the 
completion of 2 years of treatment  on this study (see footnote 21) , or until another treatment discontinuation criterion is met (see Section  8.1). 
[ADDRESS_919693] 
30 minutes b efore the start of each ADXS -503 infusion.  
21 Administer ADXS -503 as a single IV infusion over 60 ( ±10) minutes, every 3 weeks starting at Week 1 (±2 days) until a treatment  discontinuation criterion is met.  See 
Section  7.[ADDRESS_919694] occur within 3 days  of the scheduled infusion day (every 3 weeks  ±2 days ) unless 
a delay in dosing is req uired to allow for the resolution of AEs as outlined in Section  7.6. The interval between each ADXS -503 dose should not be less than 2 weeks 
without Sponsor approval.  Upon Investigator assessment  and discretion , the treatment schedule of ADXS -503 (1x108 CFU ) + [ADDRESS_919695] dose of antibiotics will be administered 
approximately 48 hours after the ADXS -503 infusion. After the final dose of ADXS -503, a 3 -week course of oral antibiotics will be administered to ensure the clearance 
of Lm (the first dose administered approximately 48 hours after the final ADXS -503 infusion) . See Section [IP_ADDRESS]  for the antibiotic regimen.  
23 Safety follow -up phone call/ visit to be made 30 days ( ±5 days) after final dose of study treatment to confirm resolution of any new or ongoing AEs, ESI or SAEs.  
24 Following treatment discontinuation, all subjects will enter a 1 -year survival/treatment Follow -up Period.  
• Survival status will be confirmed remotely with the subject, their physician , or their legally authorized representative every 3 months (±2 weeks) for up to 1 
year.  
• Any subsequent anti -cancer treatment received by [CONTACT_679775] 1 -year period will  be recorded.  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
24 • During the Lm surveillance Follow -up Period, subjects will also be contact[CONTACT_679776] 3 months (± 2 week)  for [ADDRESS_919696] 
experienced for several days, the following symptoms that could potentially be associated  with delayed listeremia: fever or chills, headache, nausea, 
confusion or changes in alertness (for over 72 hours). As part of EOT  procedures, upon completing the Lm Surveillance period, site staff should instruct 
subjects to contact [CONTACT_679781], as applicable . See Section  [IP_ADDRESS] . 
25 HBsAg and HCV screening is required for subjects with a history of active hepatitis B or hepatitis C infection.  
26 PT/INR and aPTT must be measured during Screening  only if clinically indicated.  
[ADDRESS_919697] will be required.  Note: a pregnancy test will not be required prior to the first dose of 
pembrolizumab at Week 2 (it will be required prior to the first ADXS -503 dose at Week 1).  
[ADDRESS_919698] 
recently acquired archived tumor biopsy sample may be used for analysis (date of biopsy within 3 years of Screening). The baseline biopsy must be from a location that 
has not been ra diated. (see Section  9.4.1  and Section 9.5). Sufficient tumor samples should be acquired to allow biomarker testing (eg, at least 12 -15 unstained slides). 
Tumor tissue and m atching b lood samples collected during Screening will be used  for sequencing analysis .  
[ADDRESS_919699] provide documentation of tumor PD-L1 expression and EGFR  mutation and/or ALK translocation status as evaluated by [CONTACT_8415] -approved tests  in all 
patients from Part B and Part C . If the site is unable to provide this source documentation , PD-L1 expression and/or  EGFR /ALK testing should be performed per 
institutional standard of care (see Section  9.5). Only  subjects whose tumors express PD -L1 [Tumor Proportion Score (TPS) ] ≥1% as determined by [CONTACT_13247] -approved 
test will be eligible for enrollment in Part C (see Section 9.4.1  and Section  9.5). 
32 Blood samples for exploratory immune correlative studies (eg, RNAseq,  cfDNA , flow cytometry  and ELISPOT analysis ) may be collected in up to 25 total  patients  
from Part B and Part C during Screening,  at Week 1  (ie, right before the first infusion) , and 7 days ( ±2 days)  after the end of each of the first 3 ADXS -503 infusions 
(Weeks 2, 5, and 8)  and EOT . Samples for cfDNA are only collected  at week 1 if samples are not colle cted during screening.  To monitor the durability of T cell 
responses, subsequent blood samples for PBMCs may be taken at Week 25 (±1 week) and/or at end of treatment.  
33 7 days (±3 days) after the completion of the [ADDRESS_919700] should receive treatment as outlined in Section  [IP_ADDRESS] .    
1 .
CONFIDENTIAL    
Protocol ADXS -503-101 
25 3. Introduction  
3.1. Background  on Non -Small Cell Lung Cancer  
Lung cancer is the leading cause of cancer death in the [LOCATION_002], with 154,000 deaths 
estimated in 2018. Lung cancer is also the second -leading cancer diagnosed in the [LOCATION_002] 
with 234,000 new cases estimated in 2018. Globally, lung cancer is both the leading cause of 
cancer diagnoses (1.8 million) a nd cancer deaths (1.6 million) annually  (American Cancer Society, 
2019 ; Ferlay, 2015 ). 
Lung cancers can be broadly divided into two histological groups: non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC). Non -small cell lung cancer accounts for 
approximately 84% of lung cancers and can be subclassified according to squamous and non -
squamous (including adenocarcinoma and large cell carcino ma) histological types  (Luo, 2013 ). 
Patients diagnosed with ear ly-stage NSCLC may be cured with surgery and/or radiotherapy. 
However, more than  50% of patients are diagnosed with advanced or metastatic disease, for which 
systemic treatment is the standard of care  (Ferlay, 2015 ; Luo 2013 ). 
 
Traditionally, cytotoxic chemotherapy has been the mainstay of front -line treatment for patients 
with metastatic NSCLC.  Multiple randomized clinical trials established platinum -based doublets 
as the most active regimens, because of a demonstrated improvem ent in overall survival (OS), 
when compared with best supportive care  (Schiller, 2002 ). However, chemotherapy yields only a 
modest clinical benefit and is limited by [CONTACT_679782]. Only 15 -32% 
of patients treated with platinum -based chemotherapy achieve an objective tumor response, and 
most patients experience disease progression within 3-6 months  (Kelly, 2001 ; Scagliotti, 2002 ; 
Scagliotti, 2008 ; Schiller 2002 ). 
Over the past decade and a half, progress in characterizing the molecular biology of NSCLC, has 
provided the opportunity for a targeted therapeutic approach that has advanced the treatment 
landscape at a rapid pace  (Luo 2013 ). Three  key therapeutic milestones were the approval in 2003 
and 2004 of the tyrosine kinase inhibitor s (TKI s), gefitinib and erlotinib, and the approval in 2006 
of the angiogenesis inhibitor, bevacizumab, in combination with platinum -based chemotherapy  
(Nguyen -Ngoc, 2017 ; Sandler, 2006 ; Shepherd, 2005 ; Stinchcombe, 2007 ). Multiple TKIs were 
developed over the next decade for the limited subset of patients with activating mutations in the 
epi[INVESTIGATOR_3506] (EGFR) and other mutated proteins that play key roles in cell 
growth and survival. TKIs are now an established option for front -line management of patients 
with NSCLC that harbor these mutations  (Nguyen -Ngoc 2017 ; Zappa, 2016 ). 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919701] 
now been approved for the front -line and later management of NSCLC, firmly establishing 
immunotherapy as a valid treatment strategy for this malignancy  (Malhotra, 2017 ; Nguyen -Ngoc 
2017 ; Zappa 2016 ). 
A variety of treatment options are available for patients with NSCLC, based on factors that include 
histology (squamous or non -squamous),  the presence of specific biomarkers, and the ability to 
tolerate treatment with regimens that incorporate bevacizumab  (Malhotra 2017 ; Zappa 2016 ). 
However, despi[INVESTIGATOR_679697], outcomes remain poor for patients with advanced 
NSCLC. The estimated 5 -year survival for all stages of NSCLC combined is approximately 18%, 
and for patients with metastatic d isease, the 5 -year survival estimate is less than 5%  (American 
Cancer Society, 2019 ; Ferlay, 2015 ). 
3.1.1.  Mutational Burden in Non-Small Cell Lung Cancer  
Genomic  sequencing  reveals  that NSCLC,  like other  forms  of cancer , develops  as a consequence  
of accumulated  mutations .  These  mutations  trigger malignant transformation that results in cancer 
over the course of 2 to 3 decades  (Massion, 2003 ). The concept of mutational burden has been 
introduced as a way to capture the number of mutations in the genome of a tumor  (Alexandrov, 
2013 ). Most  mutations  in NSCLC  are somatically  acquired  as errors  in DNA  replication  or as DNA  
damage  caused  by [CONTACT_679783]  (Liu, 2012 ). 
Some mutations, termed driver mutations, play a key role in oncogenesis and malignant 
progression.  Up to 60% of lung adenocarcinomas and up to 80% of lung squamous cell carcinomas 
harbor at least one known dri ver mutation.  The remaining tumor  mutational burden consists of 
passenger mutations, which develop  as a consequence of the genetic instability that develops in 
parallel with malignant progression  (Alamgeer, 201 3; Chan, 2015 ; Nguyen -Ngoc 2017 ; Savas, 
2013 ). 
Mutations in driver oncogenes or tumor suppressor genes encode for proteins (typi[INVESTIGATOR_679698]) with altered activity (gain -of-function/ loss -of-function) that  
stimulate a complex cascade of signaling pathways, such as RAS -RAF -MEK -ERK, PI3K -AKT -
mTOR or JAK -STAT, ultimately leading to uncontrolled cell proliferation, evasion of apoptosis, 
and other oncogenic alterations  (Chan 2015 ). 
A notable aspect of mutational burden for most cancers, including NSCLC, is that several  
mutations occur in a limited set of genes, known as mutation hotspots. Hotspot mutations in 
NSCLC consist of  certain  driver mutations that appear with high frequency amongst patients with 
NSCLC and represent common or shared somatic mutations  (Chang, 2016 ). For example, driver 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919702] recently been documented (eg, ERBB2 , MET , HRAS  and NRAS : Figure 2A) 
(TCGA, 2014 ). In squamous cell NSCLC, driver mutations in TP53 , CDKN 2A, PIK3CA , PTEN , 
MLL2  and NOTCH  genes are common (Figure 2B) (TCGA, 2012 ). 
 
                                
                    
Figure 2. Driver mutations in non-small cell lung cancer.  
(A) New candidate driver oncogenes (blue: 13% cases) and known somatically activated driver events (red:  63%) that 
activate the (RTK )/RAS/RAF pathway in 230 lung adenocarcinomas  (TCGA, 2014 ); (B) Significant mutated genes 
in squamous cell NSCLC  (TCGA, 2012 ). 
In addition to accumulating mutations, tumor cells may abnormally express or overexpress non -
mutated genes. Examples of these types of tumor -associated antigens  (TAAs)  are proteins 
normally expressed only during embryonic development (oncofetal antigens; OFAs) or cancer 
testis antigens (CTAs), which are proteins whose normal expression is restricted to male germ  
cells in the immune -privileged testis. Aberrant expression of OFA s (eg, CEACAM) or CTA s 
(eg, MAGE, NY -ESO -1) occurs  in most patients with NSCLC  (Reche, 2005 ). 

CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919703] been developed to target certain driver mutations found in NSCLC. 
These targeted therapi[INVESTIGATOR_679699] -tumor activity by [CONTACT_679784], resulting in cancer cell death  (Chan 2015 ; Hirsh, 2018 ; 
National Comprehensive Cancer Network (NCCN), 2018 ; Zappa 2016 ). 
Unfortunately, currently approved TKIs  are limited to the subset of patients (~20-25%) that harbor  
aberrations  in EGFR , ALK, ROS1  and BRAF  genes. Other known driver  mutation s remain  
unactionable , most notably in squamous cell carcinoma  (Chan 2015 ; NCCN, 2018 ). 
Furthermore, despi[INVESTIGATOR_679700] 80%, the long -term 
effectiveness of TKI treatment is limited by [CONTACT_679785], or 
the presence of resistant subsets of cancer cells from the time of treatment initiation. M ost patients 
treated with currently approved TKIs ultimately experience disease progression within 10 -19 
months  (Chan 2015 ; Hirsh 2018 ; Soria, 2018 ; Zappa 2016 ).  
Therefore, existing targeted approaches with TKI agents are suboptimal , and new treatment 
strategies are needed.  
3.3. Immunotherapy in Metastatic Non-Small Cell Lung Cancer  
The recognition that NSCLC tumors harbor a high number of somatic mutations suggests the 
possibility of u tilizing  the power of the immune system to attack cancer cells by [CONTACT_679786] -
specific mutated proteins  as antigens . An important  advantage of th is strategy  over TKI therapy , 
is that the immune system can target mutat ed proteins  regardless of their role in driving 
malignancy. This means that the mutations that limit the duration of sensitivity to TKIs , will not 
limit the immune system. Furthermore,  the immune system can elicit anti -tumor immunity by 
[CONTACT_679787] 
(eg, KRAS, TP53,  and others).  
In addition, the immune system can target TAAs (such as OFAs and CTAs), that are aberrantly 
expressed in NSCLC tumors, further extending the therapeutic potential of immunotherapy 
strategies.  
Cancer immunotherapy rests on the premise that malignant cells  can be recognized as foreign 
rather than as self and, as such, can be attacked by [CONTACT_27639]. An effective immune 
response in this setting relies on immune surveillance, where antigens  expressed on cancer cells 
(such as somatic mutation -derived antig ens or TAAs) are recognized by [CONTACT_27639], 
resulting in  an anti-tumor immu ne response and, ultimately, cancer cell death  (Chen, 2013 ; Dunn, 
2002 ; Zitvogel, 2006 ). However, tumor cells can employ multiple mechanisms to evade immune 
CONFIDENTIAL    
Protocol ADXS -503-101 
29 detection.  Programmed cell death protein 1 (PD -1) is a cell surface receptor expressed on activated 
T cells, and when bound to its ligand (PD -L1 or PD -L2) on tumor cells, functions as a c heckpoint 
to halt or limit  the anti-cancer T cell response. Aberrant expression of PD -L1 or PD -L2 has been 
observed in multiple tumor types ; clear evidence of how tumors can exploit and co -opt this 
pathway  to avoid immune -mediated eradication of cancerous cells (Carter, 2002 ; Freeman, 2000 ; 
Keir, 2008 ; Latchman, 2001 ). Alternatively, tumors may evade immune detection via tumor -
mediated recruitment of immunosuppressive cells (including regulatory T cells [Tregs] and 
myeloid -derived suppressor cells [MDSCs]), which suppress the function of effector T cells  (Chen 
2013 ). 
One ap proach to assist the immune system in overcoming these tactics is through the use of 
immune checkpoint inhibitors. Immune c heckpoint inhibitors are a type of immunotherapy that 
release the brakes on the immune system , thereby [CONTACT_679788] -specific T cells 
to function  (Pardoll, 2012 ). The first immune checkpoint inhibitor, ipi[INVESTIGATOR_222055] (targeting cytotoxic 
T-lymphocyte -associated protein 4 [CTLA -4 ]), was approved for advanced melanoma in 2011  
(Hodi, 2010 ). It is worth not ing that melanoma and NSCL C have of the highest mutational burden 
amongst cancers; a consequence of continual exposure to ultraviolet radiation from the sun , in the 
case of melanoma, and in large part to the numerous mutagens in cigarette smoke, in the case of 
NSCLC  (Alexandrov 2013 ). Checkpoint inhibitors have now been successfully developed to treat 
patients with NSCLC.  
To date, the immune checkpoint inhibitors pembrolizumab, nivolumab and atezolizumab have 
been approved to treat both squamous and non -squamous metastatic NSCLC  (Borghaei, 2015 ; 
Brahmer, 2015 ; Herbst, 2016 ; Langer, 2016 ; Reck, 2016 ; Rittmeyer, 2017 ). These 
immunotherapi[INVESTIGATOR_679701] -existing T cells by [CONTACT_133607] -
1:PD -L1/PD -L2 checkpoint axis, which normally halts or limits a T cell response. All three 
checkpoint inhibitors (pembrolizumab, nivolumab and atezolizumab) have demonstrated 
meaningful clinical benefit over docetaxel as monotherapy in the second -line setting and are 
currently approved  (Borghaei, 2015 ; Brahmer, 2015 ; Herbst, 2016 ; Rittmeyer, 2017 ). In the first -
line setting, pembrolizumab has also been approved as monotherapy and in combination with 
chemotherapy  (Brahmer, 2017 ; Langer 2016 ; Reck 2016 ). Additional studies are under evaluation 
with pembrolizumab, nivolumab , and atezolizumab in the first -line setting, as described below.  
3.3.1.  Immune Checkpoint Inhibitors in First -Line Me tastatic Non -
Small Cell Lung Cancer  
Pembrolizumab is approved as monotherapy in the first -line setting, in patients with squamous or 
non-squamous metastatic NSCLC, with high PD -L1 expression (≥50%) and without an EGFR  or 
ALK mutation. Pembrolizumab receive d approval in this setting based on the results from the 
Keynote 024 study, which evaluated pembrolizumab monotherapy compared with platinum -based 
CONFIDENTIAL    
Protocol ADXS -503-101 
30 chemotherapy. Updated data with a median follow -up of 2 years, show ed an improvement in OS 
(median of 30 mont hs vs. 14.2 months; hazard ratio [ HR]=0.63), progression -free survival ( PFS) 
(median of 10.3 vs. 6 months; HR=0.50) and objective response rate ( ORR ) (45.5% vs. 29.8%) in 
favor of pembrolizumab  (Brahmer 2017 ; Reck 2016 ). 
Pembrolizumab has also received accelerated approval in the first -line setting in combination with 
pemetrexed and carboplatin  chemotherapy , in patients with non -squamous metastatic NSCLC a nd 
without an EGFR  or ALK mutation (irrespective of PD -L1 expression). Accelerated approval in 
this setting was based on the results from the Keynote 021 study. Updated data with a median 
follow -up of 23.9 months, show ed a 14.7-month median increase in PFS (median of 24 months vs. 
9.3 months; HR=0.5 3) and an improvement in ORR (57% vs. 30%) for the combination of 
pembrolizumab with pemetrexed -carboplatin compared with pemetrexed -carboplatin alone . The 
HR for OS was 0.56 in favor  of the pembrolizumab combination  (OS data are immature)  (Gentzler, 
2018 ; Langer 2016 ). 
The confirmatory trial (Keynote 189) in subjects with treatment -naïve non -squamous metastatic 
NSCLC and without an EGFR  or ALK mutation is ongoing. In this trial, subjects are randomized 
in a 2:1 ratio to receive pemetrexed -platinum chemotherapy in combination with pembrolizumab 
or placebo for 4 cycles, followed by [CONTACT_679789] 35 cycles with 
pemetrexed main tenance.  Preliminary data , with a median follow -up of 10.5 months, show ed a 
3.9-month median increase in PFS (8.8 months vs. 4.9 months; HR=0.52), and a 12 -month OS rate 
benefit (69.2% vs. 49.4%; HR=0.49) for the combination of pembrolizumab and chemothera py 
compared with placebo and chemotherapy.  The benefit in PFS and 12 -month OS rate was observed 
irrespective of PD -L1 expression.  The ORR and duration of response for each arm was 47.6% v s. 
18.9% and 11.2 months vs. 7.8 months, respectively  (Gandhi, 2018 ). 
In subject s with metastatic squamous cell NSCLC, pembrolizumab has been evaluated  in the first -
line setting  in combination with carboplatin -paclitaxel/nab -paclitaxel v s. placebo and carboplatin -
paclitaxel/nab -paclitaxel (Keynote 407 ). In this trial, subjects are randomized in a 1:1 ratio to 
receive chemotherapy with pembrolizumab or placebo for 4 cycles, followed by [CONTACT_679790] 35 cycles. Preliminary data , with a median follow -up of 7.7 months , show ed 
a 4.6-month improvement in median OS ( median of 15.9 vs. 11.3 months; HR=0.64)  with 
pembrolizumab in combination with chemotherapy compared with placebo and chemotherapy. 
The benefit in OS was observed irrespective of PD -L1 status. Progression -free survival ( median 
of 6.4 months vs. 4.8 months;  HR=0.56) and ORR (58.4% v s. 35%) also favored the combination 
of pembrolizumab with chemotherapy  (Paz-Ares, 2018 ). Pembrolizumab in combination with 
chemotherapy in this setting, is yet to be approved.  
Progression -free survival and OS have also been evaluated in the first -line setting with nivolumab 
in combination with ipi[INVESTIGATOR_125] v s. chemotherapy, in subjects with metastatic squamous  or non -
CONFIDENTIAL    
Protocol ADXS -503-101 
31 squamous  NSCLC, without EGFR  or ALK mutations, and with a high tumor mutational burden 
(≥10 muta tions per megabase). In this study (CheckMate 227), the PFS amongst subjects with high 
tumor mutational burden was improved with  nivolumab + ipi[INVESTIGATOR_103964]. The 12 -month PFS rate was 42.6% with nivolumab + ipi[INVESTIGATOR_125] v s. 13.2% with 
chemotherapy, and the median PFS was 7.2 vs. 5.5 months (HR=0.58). The ORR was 45.3% for 
nivolumab + ipi[INVESTIGATOR_164] 26.9% with chemotherapy. The combination of nivolumab + 
ipi[INVESTIGATOR_679702] , is yet to be approved  (Hellmann, 2018 ). 
Furthermore, atezolizumab has been evaluated in the first -line setting in combination with 
platinum -based chemotherapy and bevacizumab in subjects with metastatic non-squamous 
NSCLC  (IMpower 150) . Subjects were enrolled in this trial irrespective of PD -L1 expression, and 
without regard to EGFR  or ALK mutation status.  Updated data with a median follow -up of 
approximately 15 months, show ed a 1.5 -month median increase in PFS (median of 8.3 months vs. 
6.8 months; HR=0.617) for the combination of atezolizumab with chemotherapy -bevacizumab 
compared with chemotherapy -bevacizumab alone. The improvement in PFS was observed across 
all PD -L1 subgrou ps (Socinski, 2018 ). Additionally, i n subjects with metastatic squamous cell 
NSCLC, the combination of atezolizumab with carboplatin -paclitaxel or carboplatin -nab-
paclitaxel vs. carboplatin -nab-paclitaxel is under evaluation in the IMpower 131 trial. Preliminary 
data, with a median follow -up of 17.1 months , show ed a median PFS benefit of 0.7 months for 
atezolizumab in combination with carboplatin -nab-paclitaxel vs. ca rboplatin -nab-paclitaxel (6.3 
months vs. 5.6 months; HR= 0.715). The PFS benefit was observed across all PD -L1 subgroups. 
The ORR was 49% and 41% for each group, respectively  (Jotte, 2018 ). 
3.3.2.  The Unmet Need for New Immunotherapi[INVESTIGATOR_679703] -Small Cell Lung Cancer  
While PD -1/ PD -L1 checkpoint inhibitors have improved the treatment paradigm for metastatic 
NSCLC, the data described above show s that only approximately one -half of patients achieve an 
objective tumor response. Moreover, the PFS data in Keynote 189, Keynote 407, IMpower  150, 
IMpower 131 and CheckMate 227 show that approximately 50-60% of  patients experience dis ease 
progression within one year of combination therapy with PD -1/ PD -L1 checkpoint inhibitors, 
regardless of the agents used ( eg, VEGF inhibitor, ipi[INVESTIGATOR_164]/or chemotherapy). This 
suggests that in metastatic NSCLC, the efficacy of immune checkpoint in hibitors requires the 
presence of another element of the immune response; a missing element . 
Several  insights suggest ways  to optimize the  anti-cancer activity  of immune checkpoint inhibitors . 
The first insight is that pre -existing anti -cancer immunity is a pre -requisite for the activity of 
checkpoint inhibitors  (Dammeijer, 2017 ). Secondly , the mutational burden , and thus number of 
mutation -derived tumor antigens , is an important determinant of the activity of checkpoint 
CONFIDENTIAL    
Protocol ADXS -503-101 
32 inhibitors  (Goodman, 2017 ; Rizvi, 2015 ). Furthermore,  immunosuppressive factors (such as Tregs 
and MDSCs) in the tumor microenvironment (TME) are a ble to establish or maintain immune 
tolerance despi[INVESTIGATOR_679704]  (Weber, 2018 ). 
These observations suggest that  an immunotherapeutic option that could directly 1) activate innate 
immunity  to create an environment that supports anti-cancer immune system activation ;  
2) increase the number and breadth  of T cells specific for NSCLC -associated tumor antigens and 
3) reduc e the  immunosuppressive actions of MDSCs and Tregs within the TME, would be a 
promising approach to improve treatment outcomes . 
3.4. Overview of ADXS -[ADDRESS_919704] step of effective immunotherapy is to alert the immune system to the presence of cancer 
by [CONTACT_679791] -specific antigens to antigen -presenting cells (APCs).  Since the immune 
system’s raison d'être  is to detect and eliminate infection, an infection or an apparent infection is 
the best method to engage the immune system.  
ADXS -503 is a live attenuat ed Listeria monocytogenes (Lm) -based immunotherapy entering  
clinical development for the treatment of squamous and non -squamous NSCLC. ADXS -503 is 
bioengineered to secrete an antigen -adjuvant fusion protein consisting of a truncated nonhemolytic 
fragment o f listeriolysin O (tLLO)  fused to a total of [ADDRESS_919705] of peptides derived from tumor -specific somatic mutations that commonly occur in 
NSCLC patients (‘hotspot mutation peptide antigens’), and [ADDRESS_919706] of sequence -optimized 
peptide antigens derived from commonly occurring tumor -associated antigens (‘sequence -
optimized TAA peptide antigens’), which include OFAs and CTAs.  The Lm component of ADXS -
503 serves as a delivery system for these tumor antigens, which  are present in intra -bacterial 
plasmid constructs, the other component of ADXS -503. The proposed mechanism of action of 
ADXS -503 is to stimulate both the innate and adaptive immune systems to initiate a coordinated 
anti-tumor response culminating in the de novo  generation of tumor antigen -specific T cells that 
are capable of infiltrating and destroying NSCLC tumors  that express the targeted antigens . 
ADXS -503 was designed so that 42% of patients with NSCLC will express at least one of the 
targeted hotspot mutation peptide antigens and that >90% will express at least one of the TAAs 
targeted by [CONTACT_679792] -optimized TAA peptide antigens. By c ombining these shared, commonly 
expressed  antigen  targets into a single Lm-based immunotherapy, ADXS -503 provides the  
potential for a potent, disease -specific approach to treating patients with NSCLC . 
In addition to the generation of antigen -specific T cell responses , treatment with Lm-based 
immunotherapi[INVESTIGATOR_679705], by [CONTACT_679793] , and upregulating PD -L1 expression 
(see Section 3.4.2 ). 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919707] of care agents in 
NSCLC, such as immune checkpoint inhibitors. In combination with immune checkpoint 
blockade, ADXS -503 has the potential to optimize immunotherapy, and even produce synergistic 
clinical activ ity, given complementary mechanisms of immune stimulation and reversal of immune 
tolerance (see Section 3.4.5  for clinical and nonclinical data supporting this approach).  
Based on these properties, ADXS -503 is a promising cancer immunotherapy  for treating patients 
with metastatic squamous or non -squamous NSCLC. Please refer to  the ADXS -503 Investigator’s 
Brochure (IB)  for addition al details.  
3.4.1.  Description  of ADXS -[ADDRESS_919708]  
ADXS -503 consists of LmddA, a highly attenuated strain of Lm bacteria, stably transformed with 
a DNA plasmid that expresses tLLO , an adjuvant  (refer to  Section 3.4.2 ), fused to  [ADDRESS_919709] were selecte d based on their 
binding affinity to 4 common HLA alleles , which  cover  >90% of patients  with NSCLC in North 
America and Western Europe.  
The [ADDRESS_919710] frequent 
somatic alterations in a proprietary mutational database from over 600 patients with NSCLC. 
These hotspot mutations occur in oncogenic driver genes, such as KRAS  and PIK3CA , and in tumor 
suppressor genes such as TP53 . Approximately 42% of patients with squamous or non -squamous 
NSCLC have at least one hotspot mutation that is targeted by [CONTACT_679794] -503. 
The [ADDRESS_919711] . 
3.4.2.  Mechanism of Action  
As a live attenuated bacterium, the Lm-based vector is rapi[INVESTIGATOR_679706]. The uptake of the Lm-based vector  results  in the activation and maturation 
of not only the APC  but also other innate immune cells  through their recognition of Lm-specific 
PAMPs (pathogen -associated molecular patterns) and DAMPs (damage -associated molecular 
patterns). Once inside the APC, ADXS -[ADDRESS_919712] . The presentation of ADXS -503-derived peptides by [CONTACT_79906] I and class II molecules 
on the surface of activated APCs stimulates the generation  of hotspot mutation - and 
TAA -specific CD4+ and CD8+ T cells  and culminates in T cell  infiltration and destruction of 
tumors expressing one or more of these antigens  (Wood, 2014 ). 
In addition to the generation of antigen -specific T cell responses, treatment with Lm-based 
immunotherapi[INVESTIGATOR_212086] s been shown to reprogram the TME . First, administration of a n Lm-based 
immunotherapy  trigge rs the expression of chemokines and chemokine receptors that recruit 
effector T cells  from tumor -draining lymph nodes into the core of the tumor  (Guirnalda, 2013 ). 
Second, administration of an Lm-based immunotherapy  reduces the relative number and 
suppressive function of intratumoral Tregs and MDSCs  (Wallecha, 2013 ). Overcoming the 
immunosuppressive TME that often characterizes solid tumors in patients with advanced cancers , 
such as metastatic NSCLC,  is critical to enabling an effective immunologic response to the cancer. 
An increase in the ratio of CD8+ tumor -infiltrating leukocytes to Tregs, as a result of the 
administration of  an Lm-based immunotherapy , has been observed in a variety of mouse tumor 
models  (Chang, 2014 ). Finally , in preclinical studies, Lm-based immunotherapi[INVESTIGATOR_679707] -L1 on both tumor cells and tumor -infilt rating macrophages in a  HPV+ murine 
tumor model that  normally does not express PD -L1 ( Figure 3). Therefore, Lm-based 
immunotherapi[INVESTIGATOR_679708] a nonimmunogenic 
“cold” tumor to an immunogenic “hot tumor ”. This supports the combination of Lm-based 
immunotherapi[INVESTIGATOR_679709] , as described in  Section [IP_ADDRESS] . 
CONFIDENTIAL    
Protocol ADXS -503-101 
35  
Figure 3. Lm-based immunotherapi[INVESTIGATOR_679694] -L1 on tumor cells and tumor -infiltrating 
macrophages in a HPV+ murine tumor model.  
C57BL/6 mice were implanted with 1x105 HPV+ TC-[ADDRESS_919713] -tumor implantation with phosphate buffered saline ( PBS) or ADXS11 -001 ( Lm vector 
expressing the full length E7 protein of HPV 16) and at [ADDRESS_919714] PD -L1 (red) and the macrophage marker F4/80 (green) for immunofluorescence microscopy. A) PD -L1 (red) 
expression is detected in tumors of ADXS11 -001-treated mic e but not in tumors of PBS -treated mice. B) In the tumors 
of ADXS11 -001 treated mice, PD -L1 expression is detected on both TC -1 tumor cells (examples highlighted with red 
arrows) and tumor -infiltrating macrophages (examples highlighted with yellow arrows).  
Please refer to the ADXS -503 IB for additional details  on the mechanisms of action of Advaxis’ 
Lm-based immunotherapi[INVESTIGATOR_014] . 
3.4.3.  Nonclinical Studies with ADXS -503 
The ability of ADXS -503 to inhibit tumor growth was  evaluated in the CT26 mouse tumor model , 
which expresses the G12D hotspot mutation in Kras . Eight-week -old female BALB/c mice (n=40) 
were injected subcutaneously with 3x105 CT26 tumor cells in the hind flank on  Day 0 . Mice (n=10 
per group)  subsequently received [ADDRESS_919715]-tumor 
implantation : 
• Phosphate buffered saline (PBS; vehicle control);  
• 1x108 colony forming units ( CFU ) of LmddA -274, a non -TAA  expressing Lm vector ; 
• 1x108 CFU of ADXS -503; 
• 1x108 CFU of ADXS -Kras G12D, an Lm vector expressing only the Kras  G12D 
mutation, as a [ADDRESS_919716].   
Tumor growth was monitored by [CONTACT_679795] 24 days after tumor 
implantation . See  Figure 4A for the experimental design . 
DAPI
F4/80
PD-L1
PBS
ADXS1 1-001
DAPI
F4/80
PD-L1PD-L1+Tumor cell
PD-L1+Macrophage (F4/80+)ADXS1 1-001-treatedA B
CONFIDENTIAL    
Protocol ADXS -503-101 
36   
Figure 4. Both ADXS -503 and ADXS -Kras G12D, an Lm-based vector targeting a single Kras hotspot mutation, 
significantly inhibit the growth of CT26 tumors .    
A) BALB/c mice were implanted with 3x105 CT26 tumor cells in the hind flank. Tumor -bearing mice were then 
treated on Day [ADDRESS_919717] -tumor implantation with PBS, LmddA -274 (empty Lm vector control), ADXS -503 or 
ADXS -Kras G12D ( Lm vector expressing the Kras G12D mutation as a 21mer) and at 7 -day intervals thereafter for 
a total of 3 doses. Tumor volume was measured twi ce a week. B) tumor growth curves for all treatment groups.  
****P< .0001. Data are representative of 2 independent experiments.  
As shown in Figure 4B, ADXS -503 significantly delayed tumor growth compared with control 
groups (PBS and LmddA -274), demonstrating the potential for ADXS -[ADDRESS_919718].   In addition, the anti -tumor activity of ADXS -Kras G12D was  equivalent  to 
that of ADXS -503, indicating  that a peptide antigen derived from a single hotspot mutation and 
expressed by [CONTACT_679796]-based vector can inhibit tumor growth . 
Please refer to the ADXS -503 IB for additional details on the anti -tumor activity of ADXS -503 in 
the CT26  tumor model experiments. The IB also describes other nonclinical studies with Lm-based 
immunotherapi[INVESTIGATOR_679710] -503 in humans.  
3.4.4.  Clinical Experience  with ADXS -503 
[IP_ADDRESS].  Clinical Safety with ADXS -[ADDRESS_919719] study of ADXS -503 in the clinic where humans  were dosed , and therefore, clinical 
data are limited.  However, because Advaxis  Lm-based immunotherapi[INVESTIGATOR_679711] a common platform 
and are bioengineered and manufactured in a similar manner, the clinical safety profile of 

CONFIDENTIAL    
Protocol ADXS -503-101 
37 ADXS -503 is expected to be similar to that of other Lm-based immunotherapi[INVESTIGATOR_014]. Therefore, the 
following clinical safety  data across the Advaxis Lm immunotherapy platform is presented.  
As of November 2020 , clinical safety data are available for 540 subjects enrolled in 1 4 clinical 
studies with Advaxis Lm-based immunotherapi[INVESTIGATOR_679712] -HPV (ADXS11 -001), 
ADXS -PSA (ADXS31 -142), and ADXS -NEO . These agents have been evaluated in subjects with 
human papi[INVESTIGATOR_28597] (HPV) -associated cancers, prostate cancer, metastatic solid tumors , and in 
person alized Lm-based cancer immunotherapy , respectively. A total of over 1,[ADDRESS_919720] tissue . In other words, since the antigenic peptides expressed by 
[CONTACT_679794] -503 are derived from  hotspot mutations or OFAs/CTAs present in NSCLC cells, 
ADXS -503 is not expected to induce  reactivity with normal tissue.  
From clinical  experience  with Lm-based immunotherapi[INVESTIGATOR_014] , a clear pattern of  treatment -related AEs 
(TRAEs ) has emerged, which is consistent with immune cell activation.  The AEs typi[INVESTIGATOR_679713] 1 -2 (mild -moderate) AEs such as  chills, pyrexia, nausea, vomiting, fatigue, 
headache , tachycardia  and hypotension, and appear during or shortly after treatment  infusion. 
Grade [ADDRESS_919721] that occurs in ~7% of 
subjects treated with Lm-based immunotherapy. The symptoms usually resolve within [ADDRESS_919722] clinical experience with Lm-based immunotherapi[INVESTIGATOR_679714] 478 subjects treated with 
ADXS11 -001, alone or in combination with other agents . Treatment -related AEs  with 
ADXS1 1-001 monotherapy  in Advaxis Sponsored clinical trials, are shown in Table 1. Refer to 
the ADXS -503 IB for safety data across the Advaxis Lm-based immunotherapy platform.  
CONFIDENTIAL    
Protocol ADXS -503-101 
38 Table 1: Treatment -Related Adverse Events Reported ≥5% with ADXS11 -001 Monotherapy  
in Advaxis Sponsored Trials  
 n (%) Adverse Events  
(N=192)a 
System Organ Class  
 Preferred Term  All Grades  Grade 3 or 4  
Cardiac disorders    
 Tachycardia  15 (7.8%)  0 
Gastrointestinal disorders    
 Diarrhoea  10 (5.2%)  1 (0.5%)  
 Nausea  54 (28.1%)  0 
 Vomiting  48 (25.0%)  1 (0.5%)  
General disorders and administration site 
conditions    
 Chills  91 (47.4%)  0 
 Influenza like illness  11 (5.7%)  0 
 Pain 10 (5.2%)  0 
 Pyrexia  70 (36.5%)  3 (1.6%)  
Immune system disorders    
 Cytokine release syndrome  15 (7.8%)  7 (3.6%)  
Investigations    
 Aspartate aminotransferase increased  13 (6.8%)  0 
 Blood alkaline phosphatase increased  11 (5.7%)  2 (1.0%)  
 Gamma -glutamyltransferase increased  15 (7.8%)  3 (1.6%)  
Metabolism and nutrition disorders    
 Decreased appetite  10 (5.2%)  0 
Musculoskeletal and connective tissue disorders    
 Back pain  12 (6.3%)  0 
 Myalgia  12 (6.3%)  0 
Nervous system disorders    
 Dizziness  14 (7.3%)  0 
 Headache  41 (21.4%)  0 
Vascular disorders    
 Hypotension  46 (24.0%)  12 (6.3%)  
a Subjects who were dosed on or before 22 Dec 2017, including 24 subjects from study ADXS001 -02 which had a 
2:1 randomization between ADXS11 -001 and placebo.  
Note: Adverse events with onset on or before 22 Dec 2017 are included.  
 
The Phase 1 study of ADXS -NEO  (ADXS -NEO -02), a fully personalized Lm-based 
immunotherapy that expresses  somatic mutation -derived  neoantigens specific to each subject’s 
tumor , is completed . Data  are available for 2 subjects  treated during the dose -escalation portion of 
the study  at dose level 1 (1x109 CFU) . Of these [ADDRESS_919723] 24 hours , while both cases of  Grade 3 hypoxia were  more persistent , 
resolving in a few days. Prior  medications and comorbidities were confounding factors in the 
genesis of hypoxia.  Subsequently, 3 subjects completed ADXS -NEO therapy at 1×108 CFU dosing 
level; this dose was well -tolerated for subjects with advanced or metastatic solid tumors.  
High-grade  (≥ Grade 3 ) hypotension and/or hypoxia are considered Events of Special Interest  with 
Lm-based immunotherapy treatment . An updated algorithm for the management of high -grade, 
acute toxicities during or after treatment infusion (including hypotension,  hypoxia, 
encephalopathy , and organ toxicity)  can be found in Appendix [ADDRESS_919724] been two (2) reported cases of listeremia , in which attenuated Lm was 
found to be growing on implanted medical devices after the  completion of study treatment. As a 
key safety measure with  Lm-based immunotherap ies, a 7-day course of post-infusion antibiotics 
are administered to ensure the clearance of Lm. Additionally, following the final dose of treatment, 
a 3-week course of antibiotics is administered to ensure the clearance of Lm (see Section [IP_ADDRESS]  
for additional details). Furthermore, c linical trials with Lm-based immunotherapi[INVESTIGATOR_679715] s with implantable medical devices that can serve as a nidus of infection, 
further mitigating the risk of listeremia . 
In the Phase 1 study for ADXS11 -001 (n=15 subjects) , Lm was not detected in the blood of any 
subject beyond [ADDRESS_919725] dose level tested 
(1x1010 CFU)  (Maciag, 2009 ). ADXS -[ADDRESS_919726].  
Preliminary data from the ongoing ADXS -503-101study shows that ADXS -503 either alone (Part 
A) or in combination with Pembrolizumab (Part B -DL1 and Part C) appears to be safe and 
tolerable. Transient Grade 1 –2 adverse events like fever, chills , and nausea were common after the 
infusion of ADXS -503. In 16 patients so far evaluated in the ongoing study, 7 treated with ADXS -
monotherapy (1x108 and 5x108 CFU) and 9 in combination with ADXS -503 (1x108 CFU) with 
pembrolizumab, there have been no dose-limiting toxicity events or events of high grade (eg, 
hypotension or hypoxia ) as observed in the past at higher doses with other Lm constructs ( Table  2). 
CONFIDENTIAL    
Protocol ADXS -503-101 
40 Table  2: Treatment -Related Adverse Events , All Treated  
  Part A  
Part A  
DL1 + DL2  
(N=7)  Part B  
Dose Level 1  
(N= 7)  Part C  
Dose Level 1  
 (N=2)  DL  1 
(N=4)  D L  2 
(N=3)  
≥ Grade 3 events  
Infusion related reaction  0 1 (33.33)  1 (14.28)  0 0 
Grade 1 & 2  
Pyrexia  0 1 (33.33)  1 (14.28)  2 (28.57)  0 
Chills  0 1 (33.33)  1 (14.28)  2 (28.57)  0 
Influenza like illness  0 1 (33.33)  1 (14.28)  0 0 
Nausea  0 1 (33.33)  1 (14.28)  0 0 
Back pain  0 1 (33.33)  1 (14.28)  0 0 
Neck pain  0 1 (33.33)  1 (14.28)  0 0 
Rash  0   1 (14.28)  0 
Acute kidney injury  0 1 (33.33)  1 (14.28)  0 0 
Alanine aminotransferase 
increased  0 1 (33.33)  1 (14.28)  0 0 
Aspartate aminotransferase 
increased  0 1 (33.33)  1 (14.28)  0 0 
DL = Dose Level e. Comment about “ Acut e Kidney  Injury” and elevation of liver enzymes were transient and in 
different patients and in all cases , patients recovered  after brief hospi[INVESTIGATOR_059]?  
 
Please refer to the ADXS -503 I B for additional details  on the clinical experience with Lm-based 
immunothera pi[INVESTIGATOR_014]. 
[IP_ADDRESS].  Clinical Efficacy  with ADXS -503 
ADXS -503 has not previously been administered to humans, and therefore, clinical efficacy data 
is not yet available . 
CONFIDENTIAL    
Protocol ADXS -503-101 
41 3.4.5.  Combination of  Lm-Based  Immunotherapy with an Immune 
Checkpoint Inhibitor  
[IP_ADDRESS].  Rationale for Combining Lm-Based Immunotherapy with an 
Immune Checkpoint Inhibitor  
ADXS -[ADDRESS_919727] complementary mechanisms of immune 
activation a nd reversal of immune tolerance  (see Section 3.3 and Section 3.4). ADXS -503 induces 
the generation  of tumor -specific T cells, whereas pembrolizumab  inhibits the PD-1/PD -L1 
checkpoint, allowing  the T cells to engage in a more sustained attack against the tu mor. Therefore, 
combining both  agents in a dual -treatment approach , has the potential to provide synergistic anti -
cancer activity . 
As described in Section 3.4.2 , Lm-based immunotherapi[INVESTIGATOR_679716], generate 
antigen -specific T cell responses  and reprogram  the TME. Specifically, Lm-based 
immunotherapi[INVESTIGATOR_014] 1) trigger the expression of chemoki nes and chemokine receptors that recruit 
effector T cells  from tumor -draining lymph nodes into the tumor core; 2) reduce the frequenc ies 
and function of immunosuppressive Tregs and MDSCs in the TME ; and 3) induce the expression  
of PD -L1 in the TME  (Chang 2014 ; Guirnalda 2013 ; Wallecha 2013 ). These are hallmark 
characteristics  of an immunogenic or “hot” tumor and provide support for the combina tion of  
ADXS -503 with  PD-1/PD -L1 checkpoint inhibitors  (Sharma, 2015 ). 
In a non-randomized clinical trial, the combination of ADXS -PSA with pembrolizumab in subjects 
with metastatic cast rate-resistant prostate cancer (mCRPC)  produced a 56.8% rate of disease 
control, whereas ADXS -PSA produced a 38.5% rate of disease control  (Stein, 2018 ). These 
findings included stabilization of disease in subjects who presented with non -measurable disease 
(either soft tissue disease , bony disease, or both). Notably, PDCD1  (PD-1) and CD274 (PD-L1) 
expression were upregulated in PBMCs following a single dose of ADXS -PSA in this trial  
(Advaxis Internal Data ). These results suggest that the upregulation of PD -L1 expression may be 
a key mechanism through which Lm-based immunotherapi[INVESTIGATOR_679717] -1/PD -L1 checkpoint  inhibitors. Furthermore, an optimal 
combination strategy may be to prime T cell immunity and induce the upregulation of PD -L1 
expression before administering the first dose of a PD -1/ PD -L1 checkpoint inhibitor.  
Please refer to the ADXS -503 IB for additio nal details.  
[IP_ADDRESS].  Safety  of Lm-Based Immunotherapy with an Immune 
Checkpoint Inhibitor  
The known toxicity profile of Lm-based immunotherapi[INVESTIGATOR_679718] -overlappi[INVESTIGATOR_679719]. In clinical trials combining Lm-based immunothe rapi[INVESTIGATOR_679720], treatment has been generally well -tolerated. The toxicities observed 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919728] s with mCRPC, the 
observed TRAEs were as expected relevant to each agent’s individual safety profile, but no 
additive toxicities  were observed as a result of the combination (Table  3). In this trial, ADXS -PSA 
was administered as monotherapy in Part A at escalating doses of 1x109 CFU, 5x109 CFU and 
1x1010 CFU every 3 weeks. In Part B, ADXS -503 was administered at 1x109 CFU in combination 
with 200 mg of pe mbrolizumab every 3 weeks  for 3 doses, followed 3 weeks later by 200 mg of 
pembrolizumab alone, in a 12 -week cycle . The 12 -week cycle repeated until treatment 
discontinuation.  
Table  3: Treatment -Related Adverse Events >10% with ADXS -PSA Alone (Part A) and in 
Combination with Pembrolizumab (Part B) in Metastatic Castrate -Resistant Prostate 
Cancer (mCRPC)  
Treatment Related Adverse 
Event (TRAE)  
 
System Organ Class  
Preferred Term  Grade 1 -2 Grade 3  
  Part A    
(N=13)  Part B 
(N=37)  Part A 
(N=13)  Part B 
(N=37)  
Subject s with ≥1  TRAE; n (%)  13 (100 %) 36 (97 %) 5 (38.5 %) 13 (35.1 %) 
TRAEs occurring in ≥10% of subject s (Part A + Part B)  
Chills  7 (53.8 %) 25 (67.6 %) 0  0  
Rigors  6 (46.2 %) 21 (56.8 %) 1 (7.7 %) 0  
Fever  8 (61.5 %) 19 (51.4 %) 0  1 (2.7 %) 
Nausea  5 (38.5 %) 14 (37.8 %) 0  0  
Fatigue  4 (30.8 %) 10 (27.0 %) 1 (7.7 %) 3 (8.1 %) 
Hypertension  0  5 (13.5 %) 2 (15.4 %) 7 (18.9 %) 
Hypotension  4 (30.8 %) 7 (18.9 %) 1 (7.7 %) 1 (2.7 %) 
Pain (all)  2 (15.4 %) 11 (29.7 %) 0  0  
Anemia  0  4 (10.8 %) 1 (7.7 %) 3 (8.1 %) 
Vomiting  2 (15.4 %) 4 (10.8 %) 0  0  
Sinus tachycardia  2 (15.4 %) 3 (8.1 %) 1 (7.7 %) 0  
CONFIDENTIAL    
Protocol ADXS -503-101 
43 Treatment Related Adverse 
Event (TRAE)  
 
System Organ Class  
Preferred Term  Grade 1 -2 Grade 3  
  Part A    
(N=13)  Part B 
(N=37)  Part A 
(N=13)  Part B 
(N=37)  
Subject s with ≥1  TRAE; n (%)  13 (100 %) 36 (97 %) 5 (38.5 %) 13 (35.1 %) 
TRAEs occurring in ≥10% of subject s (Part A + Part B)  
Dyspnea  1 (7.7 %) 4 (10.8 %) 0  1 (2.7 %) 
Diarrhea  1 (7.7 %) 3 (8.1 %) 0  1 (2.7 %) 
Headache  1 (7.7 %) 4 (10.8 %) 0  0  
Decreased appetite  0  5 (13.5 %) 0  0  
Hypothyroidism  0  5 (13.5 %) [ADDRESS_919729] had areas of dense pulmonary 
fibrosis, but it is unknown whether the presenc e of fibrosis in the lung contributed to the event. An 
updated algorithm for the management of high -grade , acute toxicities  during or after treatment 
infusion ( including hypotension, hypoxia, encephalopathy , and organ toxicity) , has been 
developed as a res ult of this event (see Appendix 7 ). Furthermore, the subject ID card provided to 
study subjects during Screening must specify that the subject is enrolled in a clinical trial of an 
experiment al agent that may be associated with immune -mediated toxicity , induced by [CONTACT_679773]. 
Please refer to the ADXS -[ADDRESS_919730] been 
approved to treat patients with metastatic NSCLC, improving the overall therapeutic 
armamentarium (see  Section 3.2 and Section 3.3). Unfortunately, the majority of known driver 
mutations  are not targets for approved TKIs , and even in the subset of patients harboring an 
CONFIDENTIAL    
Protocol ADXS -503-101 
44 actionable mutation, drug resistance ultimately deve lops, leading to disease progression in 
approximately 10 -19 months  Chan 2015 ; Hirsh 2018 ; NCCN, 2018 ; Soria, 2018 ; Zappa 2016 ).  
Furthermore, fewer than 20% of patients treated with immune checkpoint inhibitors derive long -
term clinical benefit . For example, in patients with high PD -L1 expression who receive 
pembrolizumab as monotherapy in the first -line setting, the ORR is less than 50% and most 
patients experience disea se progression in approximately 10-12 months  (Brahmer 2017 ; Reck 
2016 ). Furthermore, data from Keynote 189, Keynote 407, IMpower  150, IMpower [ADDRESS_919731] -line setting show that approximately 50-60% of patients 
experience disease progression within one year of combination therapy with PD -1/ PD -L1 
checkpoint inhibitors, regardless of the agents used ( eg, VEGF in hibitor, ipi[INVESTIGATOR_164]/or 
chemotherapy)  (Gandhi 2018 ; Hellmann 2018 ; Jotte 2018 ; Paz-Ares 2018 ; Socinski 2018 ). 
Therefore, a clear unmet need remains for new treatment strategies for patients with metastatic 
NSCLC.  
An important aspect of treatment with checkpoint inhibitors such as pembrolizumab, is the option 
to confirm apparent disease progression by [CONTACT_679797] [ADDRESS_919732] evidence of progression  is expanded based o n 
input from treating physicians . This is based on the observation that response patterns may be 
atypi[INVESTIGATOR_679721]. Apparent disease progression may not be confirmed 
after a subseque nt assessment; therefore, it is appropriate to continue therapy while awaiting 
confirmation of disease progression. Stable subjects may be treated beyond confirmed progression 
in situations where the investigator determines that the subject is deriving cli nical benefit. The 
iRECIST guidelines also provide a method for making treatment decisions in the context of 
confirmation of PD assessment.  
This approach to managing checkpoint inhibitor treatment means that the introduction of a new 
treatment intervention  may be able to delay the process of disease progression.  The time interval 
prior to PD confirmation provides an opportunity to evaluate an investigational agent prior to the 
development of confirmed disease progression  and allows the treating physician t o independently 
assess the clinical status of the patient for possible benefit with treatment  under this study . 
ADXS -[ADDRESS_919733]  22 tumor antigens that include 1) 11 peptide  antigens derived from frequently occurring 
and commonly shared hotspot mutations in patients with squamous and non -squamous NSCLC 
and 2) 11 peptide antigens derived from  sequence -optimized TAAs  that are differentially 
expressed or over expressed in NSCLC tumors  (see Section 3.4.1  and Section  3.4.2 ). ADXS -[ADDRESS_919734] set 
of effector  T cells  for tumor control. Similar to other Lm-based immunotherapi[INVESTIGATOR_014], ADXS -503 has 
the potential to reduce immunosuppressive Treg and MDSC frequencies and function within the 
CONFIDENTIAL    
Protocol ADXS -503-101 
45 TME and has the potential for clinical synergy when used in combination with immune checkpoint 
inhibitors  (see Section 3.4.2  and Section  3.4.5 ). Furthermore, ADXS -503, which includes the 
KRA S G12D hotspot mutation peptide antigen, has demonstrated activity in a mouse Kras G12D 
tumor model (see Section  3.4.3 ). The multi -target ADXS -[ADDRESS_919735] -in-human c linical study is to evaluate the safety, tolerability and 
clinical/immunological activity of ADXS -[ADDRESS_919736] 1 prior line of approved targeted therapy  
to be eligible for Part A. In this patient population, ADXS -503 monotherapy has the potential to 
provide clinical benefit when compared to salvage treatments such as single -agent docetaxel or 
pemetrexed.  
Part B  will enroll subjects with metastatic NSCLC w ho meet the following criteria:  
• Are undergoing treatment with pembrolizumab monotherapy  or combination therapy with 
pembrolizumab + platinum -based chemotherapy or are receiving pembrolizumab + 
pemetrexed as maintenance therapy , as last treatment  for metast atic NSCLC  
• The subject’s most recent tumor assessment is consistent with PD according to RECIST v1.1  
• There is no evidence of rapid disease progression or clinical deterioration that would  
preclude continuation of pembrolizumab treatment for up to 12 weeks before ADXS -503 is 
added -on 
• Subjects must consent to allow the acquisition of  fresh or archival  formalin -fixed paraffin -
embedded (FFPE) tumor tissue, either a block or unstained slides along with matching blood at 
CONFIDENTIAL    
Protocol ADXS -503-101 
46 baseline for performance of sequencing analysis.    
• In Part B, s ubjects must receive the first dose of ADXS -503 within 12 weeks  of the initial 
tumor assessment showing PD (while on last treatment with pembrolizumab monotherapy  or 
pembrolizumab + platinum -based chemotherapy or pembrolizumab + pemetrexed  as 
maintenance therapy ). ADXS -503 will be administered as add -on treatment to the ongoing 
pembrolizumab therapy . 
• Subjects who are receiving pembrolizumab in combinatio n with platinum -based 
chemotherapy or pembrolizumab with pemetrexed as maintenance therapy, will continue on 
pembrolizumab monotherapy every 3 weeks per schedule while other drugs are washed -out 
for 3 weeks.  
Efficacy Phase  
In the efficacy phase (Part B) , expansion of the Part B -dose level 1 cohort will enroll subjects 
with metastatic squamous or non -squamous NSCLC who meet the same criteria as Part B dose 
escalation mentioned above. Based on Stage I of Simon’s Two -stage design, 18 patients will be 
accrued  in this study arm. Sponsor may decide to accrue additional 25 subjects for a total of 43 
patients in Stage II. Accrual of patients to Part B dose level 2 (ADXS -503 at 5x108 CFU in 
combination with 200  mg pembrolizumab) is pending Sponsor decision to commence . 
In the efficacy phase  (Part C ), ADXS -[ADDRESS_919737] provide documentation of tumor PD -L1 
expression and EGFR  mutation and/or ALK translocation status as evaluated by [CONTACT_8415] -approved 
tests in all patients in Part C.  Baseline tumor sampl es must express  PD-L1 [Tumor Proportion 
Score (TPS)  ≥1% as determined by [CONTACT_13247] -approved test ], with no EGFR or ALK genomic tumor 
aberrations  for subjects to be eligible for Part C. The rationale for enrolling subjects in a first -line 
setting in Part C, is based on the principle of cancer immunotherapy that tr eatment may be less 
effective as a patient receives more lines of therapy. This would  make detection of an efficacy 
signal more difficult. An earlier line of treatment makes sense because it provides  an improved 
setting for detecting clinical activity.  
Study objectives are described in Section  4. See Section 5.1 for a full  description of the study 
design.  
CONFIDENTIAL    
Protocol ADXS -503-101 
47 3.6. Overall B enefit/  Risk Assessment  
3.6.1.  Potential Benefits  
ADXS -503 expresses a total of 22 NSCLC -associated tumor antigens , whose selection ensure s 
that 42% of patients with NSCLC will express at least one of the targeted hotspot mutation peptide 
antigens and that >90% will express at least one of the TAAs targeted by [CONTACT_679792] -optimized 
TAA peptide antigens. The delivery of multi ple tumor antigens increase s the likelihood of immune 
recognition of tumor cells, leading to potential  clinical efficacy. In addition to stimulating an anti-
tumor immune response, Advaxis’ Lm based immunotherapi[INVESTIGATOR_679722] , and upregulate the expression of 
PD-L1 (Advaxis Internal Data ; Chang 2014 ; Guirnalda 2013 ; Wallecha 2013 ). This 
reprogramming of the TME increases the susceptibility of the tumor to immune attack  and 
provides the potential for synergistic activity when ADXS -503 is used in combination with 
PD-1/PD -L1 immune checkpoint inhibitors .  Based on these properties , ADXS -503 represents a 
new trea tment approach for patients with metastatic NSCLC, with the potential for clinical benefit 
when used alone or in combination with an immune checkpoint inhibitor such as pembrolizumab . 
3.6.2.  Potential Risks  
[IP_ADDRESS].  Potential Risks with ADXS -503 
[IP_ADDRESS].1.    Risks  Associated with  Treatment Infusion  
The clinical safety profile of ADXS -503 is expected to  be similar to that of other Lm-based 
immunotherapi[INVESTIGATOR_014] , as described in Section  3.4.4 . The safety profile o f these agents primarily  
consists of Grade 1 -2 “flu-like” symptoms (eg, chills, pyrexia, nausea, vomiting, fatigue, headache , 
tachycardia  and hypotension ) that last [ADDRESS_919738] 4 hrs.  
In some instances  (<7%) , Grade [ADDRESS_919739] demonstrated good results in 
treating IL-6-induced hypotension , and is therefore recommend ed for cases of severe hypotension 
refractory to supportive care ( eg, fluids and/or pressors)  early in the course of the event  (Actemra®, 
2020 ; Grupp, 2013 ; Herceptin®, 2020 ; Lee, 2014 ; Winkler, 1999 ). 
Investigators will use their best judgement to appropriately code and treat individual AEs that 
occur during or after infusion, rather than groupi[INVESTIGATOR_679723], such a s “infusion 
reaction”  or “cytokine release syndrome”, so that specific management strategies can be applied, 
as appropriate. For example, a clinically suspected high -grade infusion reaction may only be 
related to anaphylaxis with hives and angioedema which  can be treated with diphenhydramine/ 
steroids, while a high -grade hypotension may require tocilizumab ± steroids after failing to be 
controlled with saline boluses.  Hypersensitivity/ anaphylactic events during or after the infusion, 
should be managed acco rding to the guidelines provided in Appendix 6 . An updated algorithm for 
the management of other acute  AEs, including hypotension, hypoxia, encephalopathy, organ 
toxicity , fever and constitutional symptoms is provided in Appendix 7 . 
As described in Section [IP_ADDRESS] , a subject with NSCLC experienced Grade [ADDRESS_919740] al cancer experienced Grade 3 hypotension and Grade 3 hypoxia following the second 
dose of ADXS -NEO  (dose of 1x109 CFU). Furthermore, as described in Section  [IP_ADDRESS] , a Grade 
[ADDRESS_919741] , includ ing Grade 3 or 4 
hypotension, hypoxia, encephalopathy and organ toxicity  (see Section  9.1.5 ). Furthermore, the 
subject ID card provided to study subjects  during Screening must specify that the subject is 
enrolled in a clinical trial of an experiment al agent that may be associated with immune -mediated 
toxicity  induced by [CONTACT_679773]. 
As of April 2021, nineteen subjects have been treated with ADXS 503 in the ongoing ADXS_503 -
101 study: seven as monotherapy and 12 in combination with pembrolizumab  or with ADXS -503 
alone . The ADXS -503 in combination continues to be safe and tolerable without inducing high 
grade toxicity of added doses being administered. See Table  3.  
[IP_ADDRESS].2.    Risks Associated with Immune -Related Adverse Events  
While the ho tspot mutation peptide antigens and TAAs expressed by [CONTACT_679798], the potential for sub-acute or late - 
occurring immune -related AEs exists. Therefore, immune -related AEs will be closely m onitored 
for in this study, with ADXS -503 as a single agent, and in combination with pembrolizumab . 
General guidance for treating immune -related AEs considered by [CONTACT_679799] -503, is provided in Appendix 8 . 
CONFIDENTIAL    
Protocol ADXS -503-101 
49 [IP_ADDRESS].3.    Risks Associated with Listeremia  
ADXS -[ADDRESS_919742] 
previously received heavy doses of  radiation and chemotherapy . In preclinical studies, attenuated 
Lm strains from Advaxis were cleared within 48 hours in immunocompromised mouse models, 
such as SCID mice and IFNγ -deficient mice, in the absence of antibiotic treatment  (Gunn, 2001 ). 
As described in Section  3.4.4 , listeremia , although rare, has been reported in two subjects  with 
implanted medical devices , who were treated with Lm-based immunotherap y. The risk of Lm 
biofilm formation will be mitigated in this study through the prohibition of the enrollment of 
subjects with implanted devices with such a risk and which cannot be removed easily. 
Additionally, t he risk of the persistence of Lm will be mitigated through the use of a 7-day course 
of prophylactic antibiotics after each ADXS -503 infusion. Following the final dose of ADXS -503, 
a 3-week course of oral antibiotics will be administered to ensure the clearance of Lm (see 
Section  [IP_ADDRESS]  for additional details).  
Listeriosis (as opposed to listeremia  with attenuated Lm) is a systemic organ infection caused by 
[CONTACT_433915], invasive Lm and is highly unlikely to occur during study treatment , because the  method 
of attenuation used in the Advaxis  Lm platform  results in a greater than 4 log reduction in virulence 
compared to wild type Lm. 
Lm-based immunotherapy is rapi[INVESTIGATOR_679724]. In the Phase 1 study for ADXS11 -001 (n=15 subjects) , Lm was not detected in the blood 
of any subject beyond [ADDRESS_919743] dose level tested 
(1x1010 CFU)  (Maciag 2009 ). Importantly, to date, no person -to-person transmission with Lm-
based  immunotherapi[INVESTIGATOR_679725].  
[IP_ADDRESS].4.    Other Risks  
Although  ADXS -503 is attenuated and nonpathogenic, all Lm strains are classified as biosafety 
level 2 (BSL -2) because the Centers for Disease Control and Prevention (CDC) do not provide 
differential classification for attenuated and wild -type bacterial agents . With proper PPE and 
hazardous waste disposal measures , nursing and pharmacy staff at over [ADDRESS_919744]  may initiate or resume 
study treatment 2 weeks afte r minor surgery (ie, surgery involving little risk to the life of the 
subject ; specifically, an operation on the superficial structures of the body or a manipulative 
procedure  that does not involve a serious risk) if the wound has completely healed and the re are 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919745]  who has wound healing complications following minor  
surgery, received major surgery or requires new implants and/or devices (permitted by [CONTACT_93865]) 
during the course of the study, must wait a minimum of [ADDRESS_919746]  recovered ( eg, 
return to baseline or Grade ≤1) from any toxicity and/or complication before the  next dose of study 
treatment. Sponsor consultation is required prior to resuming study  treatment for these subjects . If 
study treatment is  delayed beyond [ADDRESS_919747]  may be 
discontinued from study treatment . 
As noted , ADXS -503 administration is safe, however, there may also be potential unknown risks 
and additional information about the known and expected risks of ADXS -503 can be found in the 
IB. Please refer to Section 9.2 for clinical safety management and supportive care guidelines for 
ADX S-503 treatment.  
[IP_ADDRESS].  Potential Risks with Pembrolizumab  
Please refer to the approved pembrolizumab Product Label for the known and expected risks of 
treatment with pembrolizumab.  
A pattern of immune -related AEs has been defined  for pembrolizumab , for which ma nagement  
guidelines have been developed. These immune -related AEs include: pneumonitis , 
diarrhea/colitis , Type 1 diabetes mellitus (T1DM) , hypophysitis , hyperthyroidism or 
hypothyroidism , primary adrenal insufficiency, hepatic AEs , renal failure/ nephritis, skin 
reactions, infusion reactions , hemophagocytic lymphohistiocytosis , complications of 
allogeneic hematopoietic stem cell transplant (HSCT) , and hematological toxicity in patients 
with chronic Hodgkin lymphoma (cHL) . Immune -mediated adverse re actions reported in less 
that 1% of patients treated with pembrolizumab include uveitis, myositis, Guillain -Barre 
syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis and 
myocarditis. Guidelines for the management of common immune -related AEs are provided in 
Appendix 9 . Refer to Appendix 6  for guidelines to manage infusion reactions associated with 
pembrolizumab.  
CONFIDENTIAL    
Protocol ADXS -503-101 
51 4. Study Objective s and Endpoints  
The objectives and endp oints for this study are outlined in the Table below.  
This study will enroll subjects with metastatic squamous or non -squamous NSCLC in a safety 
phase  (Part A and Part B)  and an efficacy phase  (Part C) . See Section 5.1 for details  of the study 
design . 
• Safety phase  (Part A and Part B) : 
o Part A: ADXS -503 monotherapy  at 2 escalating dose levels ; Refractory setting . 
o Part B: ADXS -503 at 2 escalating dose levels + pembrolizumab ; Enroll subjects 
undergoing treatment with pembrolizumab monotherapy who have an initial 
assessment of  PD per RECIST v1.[ADDRESS_919748] recent tumor scan, and are awaiting 
a confirmatory scan 4 -8 weeks later . ADXS -503 administered as add -on therapy  to 
pembrolizumab . 
• Efficacy phase  
o Part B expansion: ADXS -503 at 1 x108 CFU+ pembrolizumab; Enroll subjects 
undergoing treatment with pembr olizumab monotherapy or receiving combination 
therapy with pembrolizumab + platinum -based chemotherapy or pembrolizumab + 
pemetrexed as maintenance therapy, as their last treatment in metastatic setting, and 
who have an initial assessment of PD per RECIST v1.[ADDRESS_919749] recent tumor 
scan. ADXS -503 administered as addon therapy to pembrolizumab. The 
administration of pembrolizumab is per the approved label and in the second year 
treating physicians can change dosing from Q3W to Q6W for both drugs.  
o Part C: ADXS -503 + pembrolizumab ; Enroll subjects per the approved Product 
Label for pembrolizumab monotherapy in the first -line setting  and in the second 
year treating physicians can change dosing from Q3W to Q6W  for both drugs . 
 
See Section 3.[ADDRESS_919750] population s in Parts A, B , and C . 
Objectives  Endpoints  
Primary  
1. To evaluate the safety and tolerability of 
ADXS -503, administered as monotherapy  in 
Part A  and in combination with 
pembrolizumab  in Part B , and to determine 
the maximum tolerated dose (MTD) or 
maximum administered dose (MAD) .   
1. Adverse events (AEs); dose -limiting toxicities 
(DLTs); physical examination findings; 
clinical laboratory values; vital sign 
measurements; and performance status 
monitoring.  
2. To characterize the preliminary anti-tumor 
activity  of ADXS -503, administered in 
combination with pembrolizumab in Part B  
dose-expansion and Part C, per RECIST v1.1.  
 2. Tumor response per RECIST v1.1 , including:  
• Best overall response (BOR)  
• Objective response rate (ORR)  
• Disease control rate (DCR)  
• Duration of objective  response (DOR ) 
 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919751] v1.1 , as 
described above.  
 
2. To determine the  progression -free survival 
(PFS)  and PFS rate at [ADDRESS_919752] 
v1.1. 
 
 
 
 
3. To determine  overall survival (OS) and 6 - and 
12-month milestone OS rates for subjects  
treated with ADXS -503 monotherapy  in Part 
A and ADXS -503 in combination with 
pembrolizumab  in Part B  and Part C . 3. OS; and 6- and 12-month milestone OS rates.  
4. To evaluate the safety and tolerability of 
ADXS -[ADDRESS_919753].  
3. To characterize  the immunological activity of 
ADXS -503, administered as monotherapy  in 
Part A  and in combination with 
pembrolizumab  in Part B ; and to characterize 
the genomic profiles of study subjects . 
 3. Immunological activity will be evaluated as 
follows:  
• In pre- and on -treatment  blood samples:  
o Evaluate the changes in the states of 
activation and differentiation in various 
immune cells by [CONTACT_4133] , whole 
exome sequencing  and profiling of 
gene expression.  
 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919754] -specific somatic 
mutations and neoantigens , 
microsatellite instability, tumor 
mutational burden, TCR analysis and 
haplotype . 
4. To characterize  changes in circulating free 
DNA (cfDNA)  in Part A , Part B , and Part C . 4. Quantitate changes in cfDNA levels pre - and 
on treatment  
5. Investigational Plan  
5.1. Study Design  
This is a  Phase 1/2, open -label , multi -center  study  of ADXS -[ADDRESS_919755] population for Part A and Part B is as follows:  
• Part A  will enroll  subjects  with metastatic NSCLC who have become refractory or 
intolerant to standard therapy. To be eligible for Part A, subjects must have previously 
received, and then progressed or been intolerant to up to [ADDRESS_919756] 1 prior line of approved targeted therapy to be eligible for Part A.  
• Part B  will enroll subjects with metastatic NSCLC who meet the following criteria:  
o Are undergoing last treatment with pembrolizumab monotherapy  for metastatic 
NSCLC  or receiving  combination therapy with pembrolizumab + platinum -based 
chemotherapy or pembrolizumab + pemetrexed as maintenance therapy in the 
metastatic setting . 
o The subject’s most recent tumor  assessment is consistent with PD according to 
RECIST v1.[ADDRESS_919757] dose of ADXS -503 within  12 weeks  of the initial 
tumor assessment showing PD (while on treatment with pembrolizumab monotherapy  or 
while receiving combination therapy with pembrolizumab + platinum -based chemotherapy 
or pembrolizumab +  pemetrexed  as maintenance therapy ). 
Efficacy Phase  
In the efficacy phase Part B dose -expansion, subjects  will be enrolled with metastatic squamous 
or non -squamous NSCLC who meet the same criteria as Part B dose -escalation mentioned above . 
In the efficacy phase  (Part C ), ADXS -[ADDRESS_919758] pro vide documentation of tumor PD -L1 expression and EGFR  
mutation and/or ALK translocation status as evaluated by [CONTACT_8415] -approved tests in all patients. 
Baseline tumor samples must express  PD-L1 (TPS  ≥1%) as determined by [CONTACT_13247] -approved test,  
with no EGFR or AL K genomic tumor aberrations  for subjects to be eligible for Part C . Subject 
must consent to allow the acquisition of fresh or archival FFPE tumor tissue, either a block or 
unstained slides along with matching blood at baseline, for performance of sequencing analysis  
(up to first 10 patients  enrolled ).  
CONFIDENTIAL    
Protocol ADXS -503-101 
55  
Figure  1 provides a schematic of the study design. Details of the study design are described  in 
Section 5.1.1  (safety phase)  and Section 5.1.2  (efficacy phase ). 
Additional cohorts or study par ts may be added to the protocol based on emerging study data or 
the evolving treatment landscape. In this situation, the protocol will be amended accordingly.  
      
           
             
                               
                                                      
                                 
                     
              
                               
                         
              
          
                        
                                         
                                                  
         
                                                 
                          
                                    
                                             
                                                                                      
                                                                
                                                      
                                                                  
                                                                    
                                                  
                                                                    
                                                               
               
               
                            
                           
                   
                                         
                         
                            
                                              
                         
              
                            
                                               
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919759] etion of DL1 in Part B, Dose -expansion of DL1 in Part B will occur in parallel with accrual in Part C. (Accrual in Part B Dose Level 2 may occur upon Spon sor’s decision).  Upon 
Investigators’ assessment and decision, treatment schedule with 1x108 CFU of ADX S-503 + [ADDRESS_919760] year 
of study therapy.  
c. If treatment is not safe/tolerable at DL1 in Part A or Part B  dose-escalation , a lower dose level (DL -1; 0.5x108 CFU of ADXS -503) will be evaluated before proceeding with Part B and Part C, 
respectively.  
d. Upon completion of dose escalation in Part A, ADXS -503 monotherapy may be evaluated in an expansion cohort.  
      
           
             
                               
                                                      
                                 
                     
              
                               
                         
              
          
                        
                                         
                                                  
         
                                                 
                          
                                    
                                             
                                                                                      
                                                                
                                                      
                                                                  
                                                                    
                                                  
                                                                    
                                                               
               
               
                            
                           
                   
                                         
                         
                            
                                              
                         
              
                            
                                               
CONFIDENTIAL    
Protocol ADXS -503-101 
57 5.1.1.  Safety Phase  
Up to approximately 24 subjects  with metastatic NSCLC will be enrolled in the safety phase  
(subject  population described in Section  5.1 above ; see Section 6 for full eligibility criteria) . The 
purpose of the safety phase is to evaluate the safety  and tolerability  of ADXS -503, administered 
as monothera py and in combination with pembrolizumab, and to determine the  MTD  or MAD . 
The preliminary  clinical and immunological activity of ADXS -503 alone and in combination with 
pembrolizumab , will also be characterized  in the safety phase  (see Section 4 for study objectives ). 
The safety phase will include  2 Parts (Part s A and B  dose-escalation ). In Part A, ADXS -503 will 
be administered as monothe rapy at 2 planned escalating dose levels. In Part B, ADXS -503 will be 
administered at 2 planned escalating dose levels in combination with pembrolizumab. Treatment 
in Part A and Part B will be administered as follows:  
• Part A  (ADXS -503 monotherapy  dose escalation ) 
o Dose level 1 (DL1): 1x108 CFU of ADXS -503 administered every 3 weeks (±2 
days) until disease progression, unacceptable toxicity or another treatment 
discontinuation criterion is met (see Section  8.1). 
o Dose level 2 (DL2): 5x108 CFU of ADXS -503 administered every 3 weeks (±2 
days) until disease progression, unacceptable toxicity or another treatment 
discontinuatio n criterion is met  (see Section 8.1). 
• Part B (ADXS -503 + pembrolizumab  dose escalation ) 
o Dose level 1 (DL1): 1x108 CFU of ADXS -503 + 200 mg of pembrolizumab  
administered every 3 weeks (±2 days) for up to 2 years  or until disease progression, 
unacceptable toxicity or another treatment discontinuation criterion is met  (see 
Section 8.1). 
o Dose level 2 (DL2)  (To proceed upon Sponsor’s decision ): 5x108 CFU of ADXS -
503 +  200 mg of pembrolizumab administered every 3 weeks (±2 days) for up to 2 
years  or until disease progression, unacceptable toxicity or another treatment 
discontinuation criterion is met  (see Section 8.1).  
Note  for Part B :  
▪ The dose of pembrolizumab will be fixed at 200 mg for both dose le vels. 
▪ ADXS -503 and pembrolizumab will be administered on the same day, every 3 
weeks  (±2 days) , starting at Week 1  (±2 days) . Upon Investigator assessment 
and d iscre tion, the schedule of therapy with 1x108 CFU of ADXS -503 + [ADDRESS_919761] year of study treatment.  
See Section 7 for treatment  administration instructions . 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
58 Part A (ADXS -503 Monotherapy  Dose Escalation ) 
In Part A, a 3+3 dose escalation design will be used  (rules described below) . The first [ADDRESS_919762] 14 days apart.  Dose -limiting toxicity (DLT) will be evaluated over the first 
28 days  of treatment for dose escalation purposes  in Part A  (see Section 9.1.6  for DLT cri teria). 
If ADXS -503 is safe and tolerab le at DL1 (based on DLT criteria ), escalation to DL2 will proceed 
in parallel with accrual at DL1 in Part B  (see below for description of Part B) . 
If based on DLT criteria, ADXS -503 monotherapy is not safe /tolerable at DL1 in Part A, a lower 
dose level (DL -1; 0.5x108 CFU  of ADXS -503) will be evaluated before proceeding with Part B.  
Upon completion of dose escalation in Part A, ADXS -503 monotherapy may be evaluated in a n 
expansion  cohort . This expansion coho rt may be enrolled  following consultation and agreement 
between study Investigators and the Sponsor. This expansion cohort may be restricted to the tumor 
type(s) found to be responsive to ADXS -503 monotherapy. The dose of ADXS -503 selected for 
the monother apy expansion will not exceed the MTD established in Part A . However, the dose 
may be intermediate to those tested in Part A if recommended by [CONTACT_58439]. 
Up to approximately 25 subjects will be enrolled in this expansion cohort.  
Part B (ADXS -503 + Pembrolizumab Dose Escalation ) 
In Part B, a 3+3 dose escalation design will also be used  (rules provided  below) . As described 
above, accrual at DL1 in Part B will proceed in parallel with escalation to DL2 in Part A (in 
accordance with dose escalation rules) . The first [ADDRESS_919763] 28 days  of treatment for dose 
escalatio n purposes  in Part B  (see Section 9.1.6  for DLT criteria ). If ADXS -503 + pembrolizumab 
is safe and tolerab le at DL1 in Part B  (based on DLT criteria ), DL 1 will be expanded  in parallel 
with accrual will occur in the efficacy phase ( Part B -expansion and Part C ). Part B -DL2 may occur 
upon Sponsor’s decision.  
If ADXS -503 + pembrolizumab is not safe/tolerable at DL1 in Part B, a lower dose level (DL -1; 
0.5x108 CFU  of ADXS -503) will be evaluated before proceeding with Part C. The dose of 
pembrolizumab will remain fixed at 200 mg.  
Note: Available safety data from DL2 in Part A will also be considered for escalation to DL2 in 
Part B.  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919764] 28 days  of treatment in Part A and Part B  
(see Section 9.1.6  for DLT criteria) . Note: The DLT window will end [ADDRESS_919765] may be replaced  for DLT assessment purposes.  
Dose escalation in Part A and Part B will proceed as follows : 
• An initial cohort of 3 subjects is enrolled.  
• If 0 of 3 subjects develop DLT, escalation to the next dose level will occur.  
• If 1 of 3 subjects develops DLT:  
o Another 3 subjects will be enrolled at this dose level.  
▪ If 0 of the 3 new subjects develops DLT (for a total of 1/6 subjects with DLT 
at this dose level) , escalation to the next dose level will occur.  
▪ If ≥1 of the 3 new subjects develops DLT (for a total of ≥2/6 subjects with DLT 
at this dose level), dose escalation will stop and the dose directly below the 
current dose will be considered the MTD if <2/6 s ubjects experience DLT at 
this lower dose.  
• If ≥2/3 subjects develop DLT, dose escalation will stop and the dose directly below the 
current dose will be considered the MTD if <2/6 subjects experience a DLT at this lower 
dose level . 
Note : DL -1; 0.5x108 CFU  of ADXS -503 will be evaluated  if DL1 is not safe and tolerable . 
Prior to declaring the MTD in Part A or Part B, and in consultation with the study Investigators, 
the Sponsor has the option to expand any dose level(s) previously established to be safe , or to 
evaluate intermediate dose levels. In addition, i f the MTD is not established, a higher dose level 
may be evaluated  with agreement between the Investigators and the Sponsor. Dose escalation rules 
(cohort size, DLT evaluation interval, etc.) will apply t o the expanded or additional cohorts.  
No within -subject dose escalation will be permitted  in Part A or Part B . If a dose level is found to 
exceed the MTD,  subjects enrolled in that dose level may be treated at a lower dose level following 
consultation and agreement between the Investigator and the Sponsor. The dose of pembrolizumab 
in all cases will be fixed at 200 mg.  
  
CONFIDENTIAL    
Protocol ADXS -503-101 
60 5.1.2.  Efficacy Phase  
Part B Dose Expansion (ADXS -503 + Pembrolizumab)  
• Part B at Dose L evel 1 (DL1): 1x108 CFU of ADXS -503 + 200 mg of pembrolizu mab 
administered every 3 weeks (±2 days) will be expanded using a Simon ’s Two-stage design 
prior to escalating to dose level 2 . 
• Upon Investigator assessment  and discretion , the schedule of therapy with 1x108 CFU of 
ADXS -503 + [ADDRESS_919766] year of study treatment.  
In the Part B expansion cohort (at DL1), up to 43 subjects will be enrolled using a Simon ’s Two-
stage design prior to e scalating to DL2. In stage I, a total of 18 subjects will be accrued. If there 
are 2 or fewer responses among the 18 subjects, the study will be stopped early. Otherwise, an 
additional 25 subjects will be accrued in stage II, resulting in a total sample si ze of 43 subjects.  
The purpose of Part B - dose expansion is to gather additional safety, tolerability, efficacy and 
pharmacodynamic information regarding the combination of ADXS -503 and pembrolizumab. The 
population in the dose expansion cohort will be re stricted to the same population evaluated in Part 
B. Continuous evaluation of toxicity events in the dose -expansion cohort will be performed 
throughout enrollment. If, at any time, the aggregate rate of treatment -related toxicities meeting 
DLT criteria exc eeds 33% across all subjects treated in the dose -expansion cohort, the finding will 
be discussed, and further enrollment may be interrupted. Depending on the nature and grade of 
toxicity and after assessing the risk:benefit ratio, a new lower dose may be i nitiated following 
consultation and agreement between the Investigators and the Sponsor.  
If stage II completes enrollment of the 43 subjects, and the true response rate is  ≥ 0.25, the cohort 
may be expanded up to 140 subjects to further evaluate efficacy, following consultation and 
agreement between the Investigators and the Sponsor.  
 
Part C (ADXS -503 + Pembrolizumab ) 
In the efficacy phase ( Part C), approximately [ADDRESS_919767] 
received no prior systemic treatment in the metastat ic setting , and whose tumors express PD -L1 
(TPS ≥1%) as determined by [CONTACT_13247] -approved test , with no EGFR or ALK genomic tumor 
aberrations , will be enrolled  (see Section 6 for full eligibility criteria) . Note: Subjects who have 
received adjuvant /neoadjuvant therapy are eligible for Part C if the adjuvant/neoadjuvant therapy 
was completed at least 6 months prior  to the diagnosis of metastatic disease. The purpose of Part 
CONFIDENTIAL    
Protocol ADXS -503-101 
61 C is to evaluate the safety and preliminary  clinical efficacy  of ADXS -503 in combination with 
pembrolizumab in this patient population.  See Section 4 for study objectives.  
The planned dose of ADXS -503 to be used in combination with pembrolizumab  (200 mg)  in Part 
C is 1x108 CFU ( dose evaluated a t DL1 in Part B).  This dose may be adjusted but will not exceed 
the MTD established in Part B. ADXS -503 + pembrolizumab will be administered every 3 weeks 
(±2 days) for up to 2 years  or until disease progression, unacceptable toxicity or another treatment 
discontinuation criterion is met (see Section  8.1). Upon Investigator assessment  and discretion , 
therapy with 1x108 CFU of ADXS -503 + [ADDRESS_919768] year of study treatment.  
Note  for Part C : . Starting at Week 1, ADXS -503 and pembrolizumab will be administered on the 
same day, every 3 weeks  (±2 days) , as described above . See Section 7  for treatment administration 
instructions . 
In Part C, toxicities will be evaluated on an ongoing basis. If the aggregate rate of treatment -
related toxicities that meet the DLT  criteria  (see Section  9.1.6 ) exceed s 33% at any time (across 
all subjects in Part C ), the findings will be discussed  between the Sponsor and study 
Investigators , and further enrollment may be interrupted. Depending on the nature and grade of 
the toxicit ies and after asse ssing the risk / benefit, treatment may  be adjusted to a lower dose of 
ADXS -503 or a n alternative treatment schedule. In all cases , the dose of pembrolizumab will be 
fixed at 200 mg.  
Overall treatment and enrollment stoppi[INVESTIGATOR_679695] 8.1.2 . 
In total in the efficacy phase , up to approximately 165 subjects may be enrolled  in Part B . Up to 
43 subjects may be enrolled in Part B expansion of DL1  in the  Simon’s Two-stage study cohort 
(S1, n=18 and S2, n= 25) and up to a total of 140 thereafter. As described above, approximately  
up to 25 subjects may  be enrolled in Part C . 
5.1.3.  Summary of Study Procedur es/Assessments  
Refer to the SoA, Section 9, and the sections referenced below for detailed information on study 
procedures and assessments.  
• Subjects will be enrolled in this study according to the Inclusion / Exclusion criteria 
outline d in Section [ADDRESS_919769] provide documentation of tumor PD -L1 expression 
and EGFR mutation and/or ALK translocation status as evaluated by [CONTACT_8415] -approved tests 
in Part B and  Part C  patients. P articipation  in both parts will be dependent upon supplying 
tumor tissue  (from fresh biopsy or archival)  from a location that ha s not been radiated. 
Formalin -fixed specimens obtained either at the time of or after the diagnosis of  metastatic 
disease will be required for performance of sequencing analysis . In Part C, b iopsies 
CONFIDENTIAL    
Protocol ADXS -503-101 
62 obtained PRIOR to receipt of neoadjuvant/adjuvant chemotherapy are NOT permitted . 
Only subjects whose tumors express PD -L1 (TPS  ≥1%) as determined by [CONTACT_679800] -approved test , will be eligible for enrollment  in Part C . Furthermore, 
documentatio n of EGFR  mutation and/or ALK transl ocation status will be required for 
subjects with non -squamous NSCLC. If the clinical site is unable to provide this source 
documentation,  PD-L1 expression and  EGFR / ALK testing should be performed in all Part 
C patients per institutional standard of care  using  FDA -approved tests before enrollment .  
See Section 9.5. 
• Study treatment will be administered as described  in Section 7. 
• At least [ADDRESS_919770] s will receive a pre -
infusion prophylactic regimen of adequate hydration, NSAIDs, antihistamines and 
antiemetics to mitigate the potential for “flu -like” symptoms during or after  treatment 
infusion . Vital signs will be monitored  every 30 minutes (±5 minute s) starting  immediately 
prior to each ADXS -503 infusion, until 4 hours after the end of each ADXS -503 infusion. 
To ensure the clearance of Lm, subjec ts will receive a 7 -day course of oral antibiotics 
starting approximately 48 hours after each ADXS -503 infu sion. After the final dose of 
ADXS -503, a 3 -week course of oral antibiotics will be administered to ensure the clearance 
of Lm. A blood sample will also be collected at 7 days ( ±3 days) after the completion of 
the 3 -week  course of oral antibiotics to cultu re for Lm. See Section 7  and Section 9.2 for 
details . 
• Safety will be assessed throughout this study by [CONTACT_320113], physical examination 
findings, vital sign measurements, monitoring of performance status , and  clinical 
laboratory values . Adverse events will be graded in severity according CTCAE v4.03 (see 
Section 9.1). 
• Tumor imaging will be performed by [CONTACT_22242] -enhanced CT/M RI as follows:  
o Part A (ADXS -503 monotherapy): Screening (baseline), at Week 8 (± 8 days), at 
Week 16 (±7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) thereafter, until confirmed 
disease progression or treatment discontinuation, whichever occurs later.  
o Part B (ADXS -503 + pembrolizumab): Screening (baseline), which corresponds to 
the most recent tumor assessment that is consistent with PD (according to RECIST 
v1.1)  while on treatment with pembrolizumab monotherapy  as last treatment , or 
while  receiving com bination therapy with pembrolizumab + platinum -based 
chemotherapy or pembrolizumab + pemetrexed as maintenance therapy , as last  
treatment in the metastatic setting . As described above, the first dose of ADXS -503 
will be administered within 12 weeks  of the initial assessment of PD . Subsequent 
CONFIDENTIAL    
Protocol ADXS -503-101 
63 scans will be performed at Week 8 (±7 days), at Week 16 (± 7 days), and every 9 
weeks (±7 days) thereafter , until confirmed dise ase progression or treatment 
discontinuation, whichever occurs later.  
o Part C (ADXS -503 + pembrolizumab): Screening (baseline) , at Week 8 (±7 days), 
at Week 16 (± 7 days),  followed by [INVESTIGATOR_135] 9 weeks (±7 days) thereafter, until 
confirmed disease progression o r treatment discontinuation, whichever occurs later.  
See Section 9.4.1  for details on tumor imaging.  
• Tumor response will be evaluated by [CONTACT_737] (or designee) according to RECIST  
v1.1 as the basis for the primary analysis of tumor response -based endpoin ts. Exploratory 
analysis of tumor -response will be performed by [CONTACT_1034] (or designee) according to 
iRECIST  (see Section 9.4.1  for details) . 
o In Part A and Part C, s ubjec ts may receive study treatment beyond initial 
Investigator -assessed, RECIST  v1.1-defined disease progression, provided the 
criteria in Section 8.1.[ADDRESS_919771] treatment or 
while receiving combination therapy with pembroliz umab + platinum -based 
chemotherapy or receiving  pembrolizumab + pemetrexed as maintenance therapy , 
as last treatment in the metastatic setting  (if eligibility criteria are met) . 
o In Parts A, B and C, any apparent CR or PR must be confirmed ≥[ADDRESS_919772] subsequently discontinue 
treatment (see Section 8.1). 
o The following subjects may be eligible for re -treatment upon disease progression, 
with agreement between the Sponsor and Investigator (see Section 8.1): 
▪ Subjects who achieve a confirmed CR  during initial study t reatment (Parts 
A, B and C)  
▪ Subjects in Part B and Part C who stop trial therapy after 2 years of treatment 
for reasons other than disease progression or intolerability.  
Note: Tumor response data collected during the re -retreatment period will not 
be used for the primary analysis of tumor response endpoints . 
CONFIDENTIAL    
Protocol ADXS -503-101 
64 • In Part A , Part B  and Part C , peripheral b lood and tumor biopsy samples may be collected 
at baseline and /or during the treatment phase of this study to evaluate biomarkers and 
correlates of immune response . See Section 9.5. 
o Subject must consent to allow the acquisition of fresh or archival FFPE tumor 
tissue, either a block or unstained slides along with matching blood  at baseline , 
for performance of sequencing analysis . A fresh tumor biopsy sample must be 
collected within [ADDRESS_919773] dose of study treatment (baseline) in 
Parts A, B, and C , where feasible, in the opi[INVESTIGATOR_689]. If a fresh 
tumor biopsy sample cannot be obtained, the most recently acquired archived 
tumor biopsy sample may be used for analysis. The archived sample must have 
been biopsied within 3 years of Screening. For archived tumor biopsy samples, 
sufficient tumor samples should be acquired to allow biomarker testing (eg, at 
least unstained 12-15 slides). The baseline tumor biopsy sa mple (fresh or 
archived) must be from a location that has not been radiated.  
o Blood samples for exploratory immune correlative studies (eg, RNAseq, cfDNA,  
flow cytometry and ELISPOT analysis) may be collected in up to 25 total patients 
from Part B and Part C during Screening, at Week 1  (ie, right before the first 
infusion)  and 7 days (±2 days) after the end of each of the first 3 ADXS -503 
infusions (Weeks 2, 5, and 8)  and EOT . Samples for cfDNA are only collected at 
week 1 if samples are not collected duri ng screening.  To monitor the durability of 
T cell responses, subsequent blood samples for PBMCs may be taken at Week 25 
(±1 week) and/or at end of treatment  
• Following treatment discontinuation, all subject s will enter a 1-year survival/treatment and 
Lm surveillance ( LmS) Follow -up Period  (see Section  [IP_ADDRESS]  - Management of Listeria 
during Follow -Up).  
o Survival status will be confirmed remotely wi th the subject , their physician , or their 
legally authorized representative every 3 months (±2 weeks) for up to [ADDRESS_919774]  during this 1-year period 
will also be recorded.  
o During  the LmS Follow -up, subjects (or their legally authorized representative ) will 
be contact[CONTACT_679801] 3 months (± 2 week) for up to [ADDRESS_919775] experienced for several days, the following symptoms that could 
potentially be associated with delayed listeremia  and require prompt attention at the 
research site :  
▪ Fever or chills, headache, nausea, confusion or changes in alertness (for 
over 72 hours).  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919776] population.  
5.2.1.  Rationale for Starting Dose  
The starting dose of ADXS -503 in this study is 1x108 CFU , administered every 3 weeks. This dose 
is selected for three  key reasons: (1) the Lm-based construct and attenuated bacterial platform are 
comparable across the entire Advaxis Lm program; ( 2) clinical data from approximately [ADDRESS_919777] that a higher dose of 1x109 
CFU is safe and well-tolerated. The AEs  observed  at 1x109 CFU are primarily associated with 
infusion of the live attenuated Lm vector and are due to innate immune stimulation following 
phagocytosis of the bacteria by [CONTACT_85804]. The incidence and severity of infusion -related signs and 
symptoms exhibit a dose -dependent relationship with the total number of CFUs infused (dose 
range of 1x 109 to 1x1010 CFU). These AEs have been well managed with a pre-infusion  regimen 
of adequate hydration, NSAIDs, antihistamines and antiemetics ; (3) however, as described in 
Section [IP_ADDRESS] , [ADDRESS_919778] with colorectal 
cancer experienced Grade 3 hypotension and Grade 3 hypoxia  following the second dose of the 
neoa ntigen -based Lm immunotherapy ( ADXS -NEO ) at 1x109 CFU . Subsequently, 3 subjects 
completed ADXS -NEO therapy at 1 ×108 CFU dosing level; this dose was well -tolerated for 
subjects with advanced or metastatic solid tumors  similarly to what has been observed in this study 
with ADXS -503 at dose level -1 (1x108 CFU) . 
Based on these factors , the starting dose of 1x108 CFU of ADXS -[ADDRESS_919779] L abel for additional 
information.  
5.2.2.  Rationale for 3+3 Dose  Escalation/De -Escalation  and Dose -
Expansion  Design   
In this study, a  standard 3+3 design will be used for dose escalation/de -escalation purposes. The 
3+3 design is a widely used rule-based method  for dose  escalation /de-escalation  in Ph ase 1 
oncology clinical trials . This approach should allow  for a sufficient number of subjects to be 
enrolled at each dose level to evaluate study endpoints, while limiting the number of subjects 
exposed to potential toxicity . 
In Part B dose expansion, a Simon ’s Two-stage design will be used. The Simon ’s Two-stage design 
is one of the most common multi -stage designs used in Phase 2 oncology clinical trials. The 
Simon ’s Two-stage design is an exact design which allows flexibility regarding the null and 
alternative hypotheses , while also allowing stoppi[INVESTIGATOR_16589]  (Section  10.1). 
CONFIDENTIAL    
Protocol ADXS -503-101 
66 The rationale for combination of Lm-based immunotherapi[INVESTIGATOR_679726] -1/PD -L1 
checkpoint inhibitors i s described in Section 3.4.2  and Section [IP_ADDRESS] . 
 
5.3. Number of Subjects Enrolled  
In the safety phase, up to approx imately 24 subjects will be enrolled in either Part A ( up to 12 
subjects; ADXS -503 monotherapy; 2 planned dose levels) or Part B ( up to 12 subjects; ADXS -503 
+ pembrolizumab; 2 possible dose levels). The actual number of subjects enrolled in Part A and 
Part B will depend  upon potential toxicities observed during dose escalation according to the 3+3 
design.  
In the efficacy phase  (Part B -dose expansion and Part C combined) , up to approximately 165 
subjects may be enrolled . In Part B dose expansion, u p to 4 3 subjects  will be enrolled in the  
Simon ’s Two-stage study cohort and up to a total of 140 thereafter ; and a pproximately 25 subjects 
will be enrolled in the efficacy phase (Part C; ADXS -503 + pembrolizumab).  
Up to approximately [ADDRESS_919780] may be replaced for DLT assessment purposes . 
5.4. End of Study Definition  
The planned end of t he study is defined as the scheduled date when the survival /treatment  
follow -up period ends for the final subject  enrolled in this study . 
6. Study Population  
Prospective approval of protocol deviations  to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  Subjec ts are eligible for this  study only if all 
the following criteria apply:  
6.1. Inclusion Criteria  
1. Subjec t and/or thei r legally authorized representative  must be capable of understanding the 
investigational nature, potential risks, and benefits of the study. The subjec t and/or their 
legally authorized representative  must sign a written informed consent;  
CONFIDENTIAL    
Protocol ADXS -503-101 
67 2. Subjec t is ≥ 18 years of age upon si gning the Informed Consent Form;  
3. Subjec t has histologically or cytologically confirmed stage IV (metastatic ) squamous or 
non-squamous  NSCLC  
o For Parts A and B:  
▪ During Screening, a fresh tumor biopsy must be obtained if clinically 
feasible, in the opi[INVESTIGATOR_679727]. If a fresh 
biopsy cannot be obtained during Screening, the most recently acquired 
archived tumor biopsy sample may be used for analysis (date of biopsy 
within 3 years of Screening). For archived tumor biopsy samples, sufficient 
tumor samples should be acquired to allow biomarker testing (eg, at least 
unstained 12-15 slides). The baseline biopsy must be from a location that 
has not been radiated.  
o Part A only : 
▪ Subject has received, and then progressed or been intolerant to  up to [ADDRESS_919781] received >3 lines of prior therapy may be eligible for Part A, upon 
discussion with and approval by [CONTACT_1034].  
• Subjects will be eligible for Part A irrespective of PD -L1 
expression.  
• Subjects will be eligible for Part A irrespective of EGFR or ALK 
mutation status. However, subjects with an EGFR sensitizing 
mutation or ALK translocat ion must have received and then 
progressed or been intolerant to at least 1 prior line of approved 
targeted therapy to be eligible for Part A.  
Note: Subjects with tumors that harbour neuroendocrine or small cell 
components may be eligible for Part A upon d iscussion with and 
approval by [CONTACT_1034].  
o Part B only : 
▪ Subject is undergoing treatment with pembrolizumab monotherapy  for 
metastatic NSCLC  as last therapy  
OR 
▪ Subject is undergoing combination therapy with pembrolizumab + 
platinum -based chemotherapy as the last treatment  
OR 
▪ Subject is receiving pembrolizumab + pemetrexed as maintenance therapy 
after completing treatment with pembrolizumab plus platinum -based 
chemotherapy as the last therapy in the metastatic setting  
CONFIDENTIAL    
Protocol ADXS -503-101 
68 ▪ Subject’s  most recent tumor assessment is consistent with progressive 
disease ( PD) according to RECIST v1.1  
▪ There is no evidence of rapid disease progression or clinical deterioration 
in the subject that would preclude continuation of pembrolizumab treatment 
for up to 12 weeks before ADXS -503 is added -on. 
▪ Subjects who are receiving pembrolizumab in combination with platinum -
based chemotherapy or with pemetrexed, will continue on pembrolizumab 
monotherapy every 3 weeks per schedule while other drugs are washed -
out for 3 weeks  
▪ Subject must consent to allow the acquisi tion of fresh or archival FFPE 
tumor tissue, either a block or unstained slides  along with matching blood  
at baseline, for performance of sequencing analysis.  
Note: In Part B, s ubjects must receive the first dose of ADXS -503 within 12 weeks  
of the initial tumor assessment showing PD (while on treatment with 
pembrolizumab monotherapy  or the below  referenced combination therapi[INVESTIGATOR_679728] ). ADXS -503 will be administered as add -on treatment to the 
ongoing pembrolizumab therapy  (whether as monotherapy , or while receiving 
combination therapy with pembrolizumab + platinum -based chemotherapy or 
pembrolizumab + pemetrexed as maintenance therapy, as their last treatment in 
metastatic setting, where subjects  have had an initial assessment of PD per RECIST 
v1.[ADDRESS_919782] recent tumor scan ).  
o Part C  only: 
▪ Subject  has received no prior systemic treatment in the metastatic setting. 
Subjects previous ly treated with  adjuvant or neoadjuvant therapy are 
eligible if the adjuvant/neoadjuvant therapy was completed at least 6 
months prior to the diagnosis of metastatic disease.  
▪ Subject must consent to allow the acquisition of fresh or archival FFPE 
tumor tissue, either a block or unstained slides along with matching blood 
at baseline, for performance of sequencing analysis . 
▪ Subject has provided a formalin -fixed tumor sample from a biopsy of a 
tumor lesion either at the time of or after the diagnosis of metastatic disease 
AND from a site not previously irradiated , for correlative work . Biopsies 
obtained PRIOR to the administration of any systemic therapy to treat the 
subject’s tumor (such as neoadjuvant/adjuvant therapy) will not be 
permitted for analysis. The tissue sample must be received by [CONTACT_679802] . Fine needle 
aspi[INVESTIGATOR_4026], Endobronchial Ultrasound (EBUS) or cell blocks are not 
acceptable. Needle or excisional biopsies, or resected tissue is  required . If 
the tumor  specimen has not been evalua ted for PD -L1 expression , an 
additional tumor specimen must be submitted  to the local laboratory facility 
for assessment following an FDA -approved test.   
CONFIDENTIAL    
Protocol ADXS -503-101 
69 ▪ Subject ’s tumor has PD-L1 expression  (TPS ≥1%) as determined by [CONTACT_108076] -approved test .  
▪ Subject’s tumor has no EGFR or ALK genomic tumor aberrations . EGFR  
sensitizing mutations are mutations that are amenable to treatment with 
TKIs  (eg, erlotinib, gefitinib, afatanib , osimertinib) . ALK translocations are 
amendable to treatment with TKIs such as crizotinib, alectinib and ceritinib. 
Investigators must produce the source documentation of the EGFR  mutation 
and ALK translocation status in all subjects with non -squamous histolog y 
AND for subjects in whom testing  is clinically indicated . If either an EGFR  
sensitizing mutation or ALK translocation is detected, additional 
information regarding the mutation status of the other molecule is not 
required. If the clinical site is unable to provide the source documentatio n, 
EGFR  and ALK testing should be performed per institutional standard of 
care. 
• Subjects with non -squamous histolog y will not be eligible until the 
EGFR  mutation and/or  ALK translocation status is known . 
• EGFR and ALK testing will not be required for subjects with 
predominantly squamous histology, as this is not the standard of 
care. 
4. Subjec t has measurable disease for response assessment as defined by [CONTACT_393] v1.1  by [CONTACT_3786] ; 
5. Subjec t has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1  
(see Appendix 11); 
6. Subject has a life expectancy of at least 3 months;  
 
7. Subjec t has recovered to Grade ≤ 1 by [CONTACT_679803], Version 4.03 (NCI -CTCAE v4.03) of all clinically significant 
toxic effects of prior anti -cancer  chemotherapy, immunotherapy, radiotherapy or surgery 
before  entering this study , except for alopecia ; 
 
8. Subjec t has no major ex isting comorbidities or medical conditions that would preclude 
therapy in the opi[INVESTIGATOR_689];  
9. Subjec t has adequate organ function as described in Table 4 below . 
CONFIDENTIAL    
Protocol ADXS -503-101 
70 Table 4: Organ Function Requirements for Study Inclusion  
System  Laboratory Value  
Hematologic  
Absolute neutrophil count (ANC)  a ≥1 x 109/L (Parts A and B); ≥1.5 x 109/L (Part C)  
Platelets a ≥75 x 109/L (Parts A and B); ≥100 x 109/L (Part C)  
Hemoglobin  a ≥9 g/dL  or ≥5.6 mmol/L  
WBC  a ≥2000/ µL  
Renal  
Serum creatinine OR 
Measured or calculated creatinine clearance  
(CrCl). Note: GFR can also b e used in place of 
serum creatinine or  CrCl  ≤1.5 x upper limit of normal (ULN) OR 
 
≥50 mL/min  for subject s with serum creatinine levels >1.[ADDRESS_919783]  b 
Hepatic  
Serum total bilirubin  ≤1.[ADDRESS_919784] (except subject s with Gilbert Syndrome, who 
must have total bilirubin <[ADDRESS_919785] ) 
AST (SGOT) and ALT (SGPT)  <[ADDRESS_919786] (Parts A and B); <1.[ADDRESS_919787] (Part C)  
Endocrine  
Thyroid stimulating hormone (TSH)  Within normal limits (Parts B and C only). c 
aANC, platelets, hemoglobin , or WBC  requirement cannot be met by [CONTACT_679804], or growth factor 
support  (G-CSF, erythropoietin, etc.) within [ADDRESS_919788]  is eligible to participate if she is not pregnant (see Appendix 5 ), not 
breastfeeding, and at least one of the following conditions applies:  
a. Not a woman of childbearing potential (WOCBP) as defined in Appendix [ADDRESS_919789]  120 days  after t he final  dose of study treatment;  
11. A female subjec t of childbearing potential must  have a negative urine or serum pregnancy 
test within [ADDRESS_919790]  120 days  after the final dose of study treatment . 
6.2. Exclusion Criteria  
Subjec ts are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. Subjec t has an ongoing  different primary  malignancy. Exceptions include  treated  basal cell 
carcinoma of the skin or squamous cell carcinoma of the skin ; 
2. Subjec t has an active autoimmune disease requiring systemic treatment within the past 
[ADDRESS_919791] s with vitiligo , 
psoriasis, alopecia  or resolved childhood asthma/atopy not requiring systemic treatment would 
be an exception to this rule. Subjec ts with hypothyroidism who are stable on hor mone 
replacement  (>10 mg daily prednisone equivalent)  or Sj ögren’s syndrome will  not be excluded 
from the study;  
3. Subjec t has a d iagnosis of primary immunodeficiency, is dependent on or has received 
systemic cortico steroid therapy  (>10 mg daily prednisone equivalent)  or any other form of 
immunosuppressive therapy within [ADDRESS_919792] dose of study  treatment . Inhaled 
or topi[INVESTIGATOR_166501], and adrenal replacement corticosteroid doses >10 mg daily 
prednisone equivalent, are permitted in the absence of active autoimmune disease ; 
4. Subjec t has neuropathy (sensory or motor) ≥Grade 3 per CTCAE v4.03;  
5. Subject has had an allogeneic tissue/solid organ  transplant;  
 
6. Subject has known history (past 5 years) or any evidence of interstitial lung disease (ILD) 
OR active, non -infectious pneumonitis that has required oral or IV  steroids ; 
7. Subjec t has untreated central nervous system (CNS) metastases and/or  carcinomatous 
meningitis. Subject s with previously treated brain metastases may participate provided they 
are stable (no new or enlarging brain metastases) by [CONTACT_89181] [ADDRESS_919793] 14 days prior to the start of study  treatment ; 
8. Subjec t has a c oncurrent unstable or uncontrolled medical condition ( eg, active u ncontrolled 
systemic infection , unstable angina, congestive heart failure, uncontrolled diabetes) or other 
chronic disease, which in the opi[INVESTIGATOR_679729] t or the 
study;  
CONFIDENTIAL    
Protocol ADXS -503-101 
72 9. Subjec t has a k nown history of human immunodeficiency v irus (HIV) infection (HIV 1/2 
antibodies);  
10. Subjec t has a k nown active hepatitis B (eg, HBsAg reactive) or hepatitis C infection (eg, HCV  
RNA [qualitative] is detected)  or tuberculosis ; 
11. Subjec t has an a ctive infection requiring syste mic therapy or is dependent on or currently 
receiving antibiotics that cannot be discontinued before dosing.  (Note: Subject s who 
discontinue an antibiotic prior to dosing must wait at least [ADDRESS_919794] dose of 
antibiotic before receiving an y study treatment ); 
12. Subjec t has known psychiatric or substance abuse disorder(s) that would interfere with 
cooperation wit h the requirements of the study ; 
13. Subjec t has an i mplanted medical device that pose s a high risk for bacterial colonization and/or 
that cannot be easily removed ( eg, prosthetic joints, artificial heart valves, pacemakers, 
orthopedic screw s, bone graft s, or other critical exogenous implant s). NOTE:  More common 
devices and prosthetics that include arterial and venous  stents , hernia mesh, some metal plates,  
dental and breast implants and venous access devices ( eg, Port-a-Cath or Mediport) are 
permitted. Sponsor must be contact[CONTACT_679805] t who has a ny other device 
or implant;  
14. Subjec t is p regnant or  breastfeeding, or plans to become pregnant  or to father children , from 
the Screening visit through at least 120 days  after the final  dose of study  treatment;  
15. Subjec t has a c ontraindication ( eg, sensitivity/allergy) to trimethoprim/ sulfamethoxazole , 
ampic illin, and another antibiotic to which Lm is typi[INVESTIGATOR_679730] (eg, erythromycin , 
fluoroquinolones  – see Section [IP_ADDRESS].1.1 for further details ); 
16. Subjec t has a contraindication to non -steroidal anti -inflammatory drugs (NSAIDs);  
a. Subjec t has a k nown allergy to any component of the study formulation(s) ; 
17. Subjec t has a h istory of listeriosis ;  
18. Subjec t has a ny other serious or uncontrolled physical or mental condition/disease that, as 
judged by [CONTACT_737], could place the subjec t at higher risk derived from their 
participation in the study, could confound results of the study, or would be likely to prevent 
compliance with the requirements of the study ; 
Prior/Concomitant Therapy  
19. Subjec t has r eceived chemotherapy and/or radiation therapy (except palliative radiation  
therapy for disease -related pain) within [ADDRESS_919795] dose of study treatment ; 
20. Subjec t has received monoclonal antibody or other biologic therapy within [ADDRESS_919796] dose of study treatment , whichever is shorter . An e xception to this 
exclusion criterion will be pembrolizumab monotherapy for subjects enrolled in Part B ; 
CONFIDENTIAL    
Protocol ADXS -503-101 
73 21. Subjec t has received  prior treatment with an Lm-based immunotherapy ; 
a. Subjec t is receiving or plans to  receive future treatment with PI3K or TNFα inhibitors ; 
b. Subjec t has r eceived a live vaccine within [ADDRESS_919797] dose of study treatment ; 
c. Subjec t has not recovered to baseline  from AEs, with the exception of alopecia , due to 
previously adminis tered agent(s) ; 
22. Subjec t has had m ajor surgery within 6 weeks prior to the initiation of study treatment.  NOTE: 
All surgical  complications must have recovered to baseline or Grade ≤[ADDRESS_919798] a new artificial implant, and/or devices ; 
Prior/Concurrent Clinical Study Experience  
23. Subjec t is currently participating in or has participated in a study of an investigational agent(s) 
within [ADDRESS_919799] dose of study treatment ; 
24. Subject is or has an immediate family member (spouse or children) who , as investigational site 
or sponsor staff , is directly involved with this trial, unless prospective IRB approval (by [CONTACT_679806]) is given allowing exception to this criterion for a specific  subject ; 
Exclusion Criteria for Part C only  
25. In Part C, s ubject has received systemic therapy for the treatment of their metastatic NSCLC. 
Completio n of treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant 
therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of 
metastatic  disease ; 
26. In Part C, subject has an EGFR  sensitizing mutation and/or  an ALK translocation;  
27. In Part C, baseline tumor specimen is not evaluable for PD -L1 expression. If an additional 
tumor specimen is submitted AND evaluable for PD -L1 expression, the subject will be eligible 
to participate if the tumor express es PD-L1 (TPS ≥1%) as determined by [CONTACT_13247] -approved 
test with no EGFR or ALK genomic tumor aberrations ; 
28. In Part C, s ubject has received prior systemic chemotherapy, biological therapy, OR major 
surgery within [ADDRESS_919800] dose of study treatment; received thoracic radiation therapy 
of >[ADDRESS_919801] dose of study treatment;  
29. In Part C , subject ha s received prior therapy with an anti -PD-1, anti -PD-L1, anti -PD-L2, anti -
CD137, or anti -CTLA -4 antibody, or any other antibody or drug that specifically targets T  cell 
co-stimulation or immune checkpoint pathways .  
CONFIDENTIAL    
Protocol ADXS -503-101 
74 6.3. Lifestyle Restriction  
No lifestyle restri ctions are specified in this protocol. Subjects should maintain a normal diet 
unless modifications are required to manage an AE such as nausea, diarrhea or vomiting.  
6.4. Screen Failures  
Screen failures are defined as subjec ts who consent to undergo Screening f or the clinical study  but 
fail to meet the required entry criteria . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure subjec ts to meet the Consolidated Standards of 
Reporting Trials  (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any serious adverse event  (SAE) . 
A subjec t who has laboratory test results, vital signs, or other findings that do not satisfy the 
eligibility criteria may have the test(s) repeated. These tests may be repeated as soon as the 
Investigator believes the re -test result to likely be within the accept able range to satisfy the entry  
criteria but must be completed within the Screening period. The subjec t will not be required to 
sign another ICF, and the original subjec t identification number will be used. If the laboratory 
test(s) cannot be performed within the Screening period, if the re -test(s) do es not meet the entr y 
criteria or if the subjec t’s medical condition has changed sign ificantly during the Screening p eriod 
so that inclusion/exclusion criteria are no longer met, the n the  subjec t is considered a Screen 
failure.  
Individuals who d o not meet the criteria fo r participation in this study (S creen failure) may be re -
screened  after consultation with the Sponsor  and will require a new subjec t identification number.  
Part C: If the tumor spe cimen has not been evaluated for PD -L1 expression , it may be tested  at a 
local  laboratory  facility , so the subject can be eligible to participate if the tumor expresses PD-L1 
(TPS ≥1%) as determined by [CONTACT_13247] -approved test , with no EGFR or ALK genomic tumor 
aberrations . 
7. Treatment s 
The rationale for the starting dose of ADXS -503 (1x108 CFU) is described in Section 5.2.1 .  This 
study will use the approved dose of pembrolizumab for treating patients with metastatic NSCLC : 
[ADDRESS_919802] Label for 
additional information.  
CONFIDENTIAL    
Protocol ADXS -503-101 
75 7.1. Treatment s Administered  
7.1.1.  ADXS -503 Monotherapy (Part A)  
In Part A, ADXS -503 will be administered as monotherapy at 2 planned escalating dose levels 
(1x108 CFU and 5x108 CFU) . If treatment with ADXS -503 monotherapy at the starting dose of 
1x108 CFU (DL1) is not safe and tolerable  (based on DLT criteria) , a lower dose of 0.5x108 CFU 
(DL -1) will be evaluated. Treatment in Part A will be administered as outlin ed in Table 5 and as 
described below.   
Table 5: Treatment in Part A : ADXS -503 Monotherapy  
Treatment  Dose Level  
(DL)  Dose  
 Dose 
Frequency  Route of 
Administration  
 
 
ADXS -503  
 2 5x108 CFU  Q 3 weeks  Intravenous  
1 
(starting dose)  1x108 CFU  Q [ADDRESS_919803] will receive ADXS -503 monotherapy at their enrolled dose level,  every 3 
weeks  (±2 days)  until disease progression, unacceptable toxicity or another treatment 
discontinuation  criterion is met  (see Section 8.1). Treatment with ADXS -[ADDRESS_919804]-
infusion  procedures are required  for each ADXS -503 treatment infusion . 
Pre-infusion : A pre-infusion  regimen of adequate hydration, NSAIDs, antihistamines and 
antiemetics as a prophylaxis for “flu -like” symptoms will be completed at least 30 minutes prior 
to each ADXS -503 infusion  (see Section [IP_ADDRESS] ). Vital signs will be monitored  every 30 minutes 
(±5 minutes)  starting  immediately prior to each ADXS -503 infusion , until 4 hours after the end of 
each ADXS -503 infusion (see Section [IP_ADDRESS] ). 
Infusio n: Administer ADXS -503 as a single IV infusion over 60 ( ±10) minutes through a 
dedicated  infusion line. ADXS -[ADDRESS_919805] ’s first post -infusion  dose of oral antibiotics is administered . Refer to the 
Pharmacy Manual  for treatment preparation and additional treatment administration instructions . 
Vital si gns will continue to be monitored every 30 minu tes (±5 minutes) during each ADXS -[ADDRESS_919806]-infusion :  Following each infusion of ADXS -503, vital signs will continue to be monitored 
every 30 minutes (±5 minutes) for [ADDRESS_919807] antibiotic dose will be administered at approximately 48 hours after the completion of 
each ADXS -503 infusion . See Section  [IP_ADDRESS]  for additional information.  
Refer to the Pharmacy Manual  for treatment preparation and detailed  treatment administration 
instructions . 
Refer to Section 9.2.2  for supportive care guidelines for ADXS -503 treatment. Guidelines for the 
management of infusion reactions can be found in Appendix 6. Guidelines for the management of 
other acute events, including hypotension, hypoxia , encephalopathy, organ toxicity, fever and 
constitutional symptoms  can be found in Appendix 7. 
7.1.2.  ADXS -503 + Pembrolizumab (Part B Dose -Escalation and Dose -
Expansion ) 
In Part B  dose escalation , ADXS -503 will be administered at 2 planned escalating dose levels 
(1x108 CFU and 5x108 CFU) in combination with a fixed dose of pembrolizumab (200 mg).  If 
treatment with ADXS -503 + pembrolizumab is not safe and tolerable at the starting dose of 1x108 
CFU (DL1) (based on DLT criteria), a lower dose of 0.5x108 CFU (DL -1) will be evaluated. 
Treatment in Part B dose expansion , ADXS -503 will be administered at DL1 (1x108 CFU ) in 
combination with a fixed dose of pembrolizumab (200 mg)  as outlined in Table 6 and as described 
below . 
CONFIDENTIAL    
Protocol ADXS -503-101 
77 Table 6: Treatment in Part B : ADXS -503 + Pembrolizumab  
Treatment  Dose Level  
(DL)  Dose  
 Dose  
Frequency  a Route of 
Administration  
 
 
ADXS -503  2  5x108 CFU  Q 3 weeks  Intravenous  
1  
(starting /expansion  
dose)  1x108 CFU  Q 3 weeks  Intravenous  
-1  0.5x108 CFU  Q 3 weeks  Intravenous  
PLUS  
Pembrolizumab  N/A 200 mg  Q 3 weeks  Intravenous  
a: At each dose level in Part B, ADXS -503 and pembrolizumab will be administered on the same day, every 3 
weeks, starting at Week 1  (±2 days ). 
 
In Part B, e ach subject will receive ADXS -503 at their enrolled dose level  in combination with 
200 mg of pembrolizumab , every 3 weeks  (±2 days) until disease progression, unacceptable 
toxicity , the completion of 2 years of study treatment  or another treatment discontinuation criterion 
is met (see Section 8.1). Upon Investigator assessment  and discretion , the schedule of therapy with 
ADXS -503 +  [ADDRESS_919808] year of study treatment. Treatment with ADXS -503 and pembrolizumab will start at 
Week 1  (±2 days) . Treatme nt with ADXS -[ADDRESS_919809] occur within 3 days of 
the scheduled infusion day unless a delay in dosing is required to allow for the resolution of AEs 
as outlined in Section 7.6. The interval between each subsequent dose of ADXS -503 and each 
subsequent dose of pembrolizumab should not be less than 2 weeks without Sponsor approval.  
Week 1 (±2 days) onwards : On each treatment day, pembrolizumab will be infused first over 30 
(±5) minutes , followed approximately 60 ( ±15) minutes after the end of the pembrolizumab 
infusion by [CONTACT_679780] -503 infusion. Treatment will be administered as follows:  
1. Pembrolizumab Inf usion:  Administer pembrolizumab as a single IV infusion over 30 ( ±5) 
minutes through a dedicated infusion line  containing a sterile, non -pyrogenic, low -protein binding 
0.[ADDRESS_919810] Label and 
Pharmacy Manual  for treatment preparation and detailed  treatment administration instructions.  
2. ADXS -503 Infusion : Following the administration of pembrolizumab and before the 
administration of ADXS -503, the Investigator must confirm that the subject  is in a stable medi cal 
condition and any ongoing AEs, if present, would not preclude the administration of ADXS -503. 
If ongoing AEs do preclude the administration of ADXS -503, ADXS -[ADDRESS_919811]-infusion  procedures are required for each  ADXS -
503 treatment infusion.  
Pre-infusion:  A pre-infusion  regimen of adequate hydration, NSAIDs, antihistamines and 
antiemetics as a prophylaxis for “flu -like” symptoms will be completed at least 30 minutes prior 
to each ADXS -503 infusion  (see Section [IP_ADDRESS] ). Vital signs w ill be monitored  every 30 minutes 
(±5 minutes)  starting  immediately prior to each ADXS -503 infusion, until 4 hours after the end of 
each ADXS -503 infusion (see Section [IP_ADDRESS] ). 
Infusion:  Administer ADXS -503 as a single IV infusion over 60 ( ±10) minutes through a 
dedicated infusion line , or through the same one used for pembrolizumab administration, if needed 
for subjects with vein access difficulties . Where one infusion line is used  for the administration of 
both drugs , it must be flushed after each infusion , ie, after the pembrolizumab  infusion  and pre- 
and post -infusion of ADXS -503 infusion  regimen ( Section  7.1.1 .). In addition, if the infusion line 
is the same, the  in-line filter used for the infusion of pembrolizumab must be removed before 
infusing ADXS -503. ADXS -[ADDRESS_919812] not be administered  via an existing  or newly placed central venous catheter or 
infusion port that is planned t o be used for another purpose. On the other hand , an existing  central 
venous catheter or infusion port may be used  to withdraw blood samples for correlative analysis  
in this trial . Refer to the Pharmacy Manual  for treatment preparation and detailed  treatment 
administration instructions . 
Vital signs will continue to be monitored every 30 minutes (±5 minutes) during each ADXS -[ADDRESS_919813]-infusion:   Following each  infusion of ADXS -503, vital signs will continue to be monitored 
every 30 minutes (±5 minutes) for [ADDRESS_919814] antibiotic dose will be administered at approximately 48 hours after the completion of 
each ADXS -503 infusion. See Section [IP_ADDRESS]  for additional information.  
CONFIDENTIAL    
Protocol ADXS -503-101 
79 Refer to Section 9.2.2  for clinical safety management and supportive care guidelines for ADXS -
503 and pembrolizumab treatment. Guidelines for the management of infusion reactions can be 
found in Appendix 6 . Guidelines for the management of other acute events, including hypotension,  
hypoxia , encephalopathy, organ toxicity, fever and constitutional symptoms can be found in 
Appendix 7 . 
Note:  If any toxicity results in the discontinuation of either ADXS -503 or pembrolizumab but not 
both, treatment with the non -discontinued study drug may continue as monotherapy  in Part B , 
unless the nature of the toxicity precludes administration of any treatm ent (see Section 7.6). In 
such cases, the treatment administration instruction s for the individual study drug 
administered as monotherapy are to be followed until treatment discontinuation . 
7.1.3.  ADXS -503 + Pembrolizumab (Part C)  
In Part C, ADXS -503 will be administered at a planned dose of 1x108 CFU in combination with a 
fixed dose of pembrolizumab (200 mg). Treatment in Part C will be administered as outl ined in 
Table 7, and as described below.  
Table 7: Treatment in Part C : ADXS -503 + Pembrolizumab  
Treatment  Dose  
 Dose 
Frequency  a Route of 
Administration  
ADXS -503  1x108 CFU  Q 3 weeks  Intravenous  
PLUS  
Pembrolizumab  200 mg  Q 3 weeks  Intravenous  
a: In Part C, ADXS -503 and Pembrolizumab will be administered on the same day , every 3 weeks  starting on Week 
1 (±2 days) . However, after first year of treatment, the dosing  schedule could be changed to every 6 weeks, upon 
investigator assessment and discretion.  
In Part C , starting at Week 1 (±2 days) , ADXS -503 and pembrolizumab will be administered on 
the same day, every 3 weeks  (±2 days)  until disease progression, unaccepta ble toxicity , the 
completion of 2 years of study treatment,  or another treatment discontinuation criterion is met (see 
Section 8.1). Upon Investigat or assessment and discretion, the schedule of therapy with ADXS -
503 + [ADDRESS_919815] occur within 3 
days o f the scheduled infusion day unless a delay in dosing is required to allow for the resolution 
of AEs as outlined in Section 7.6. The interval between each subsequent dose of ADXS -503 and 
each subsequent dose of pembrolizumab  should not be less than 2 weeks without Sponsor 
approval.  
CONFIDENTIAL    
Protocol ADXS -503-101 
80 Follow the treatment administration instructions outlined below for each respective agent.  
1. Pembrolizumab Infusion:  Administer pembrolizumab as a single IV infusion over 30 ( ±5) 
minutes through a dedicated infusion line  containing a sterile, non -pyrogenic, low -protein binding 
0.[ADDRESS_919816] -ADXS -503 infusion regimen ( Section  
7.1.1. ). If the infusion line is the same, the in -line filter used for the infusion of pembrolizumab 
must be remove d before infusing ADXS -503. See the approved pembrolizumab Product Label 
and Phar macy Manual  for treatment preparation and detailed treatment administration  
instructions . 
2. ADXS -503 Infusion : Following the administration of pembrolizumab and b efore the 
administration of ADXS -503, the Investigator must confirm that the subject  is in a stable medical 
condition and any ongoing AEs, if present, would not preclude the administration of ADXS -503. 
If ongoing AEs do preclude the administration of ADXS -503, ADXS -[ADDRESS_919817]-infusion  procedures are required for each  ADXS -
503 treatment infusion.  
Pre-infusion:  A pre-infusion  regimen of adequate hydration, NSAIDs, antihistamines and 
antiemetics as a prophylaxis for “flu -like” symptoms will be completed at least 30 minutes prior 
to each ADXS -503 infusion  (see Section [IP_ADDRESS] ). Vital signs will be monitored  every 30 minutes 
(±5 minutes)  starting  immediately prior to each ADXS -503 infusion, until 4 hours after the end of 
each ADXS -503 infusion (see Section [IP_ADDRESS] ). 
Infusion:  Administer ADXS -503 as a single IV infusion over 60 ( ±10) minutes through a 
dedicated infusion line  or through  the same one used for pembrolizumab administration, if needed 
for subjects with vein access difficulties. Where one infusion line is used  to administer both drugs , 
it must be flushed after each infusion , ie, after the pembrolizumab infusion, pre - and post -infusion 
of ADXS -503 regimen ( Section  7.1.1 ). In addition, if the infusion line is the same, the filter used 
for the infusion of pembrolizumab must be removed before infusing ADXS -503. ADXS -[ADDRESS_919818] not be administered  via an 
existing or newly placed central venous catheter or infusion port that is planned to be used for 
another purpo se. The central venous catheter or infusion port may be used to withdraw blood  
CONFIDENTIAL    
Protocol ADXS -503-101 
81 samples for correlative analysis . Refer to the Pharmacy Manual  for treatment preparation and 
detailed  treatment administration instructions . 
Vital signs will continue to be monitored every 30 minutes (±5 minutes) during each ADXS -[ADDRESS_919819]-infusion:   Following each infusion of ADXS -503, vital signs will continue to be monitored 
every 30 minutes (±5 minutes) for [ADDRESS_919820] antibiotic dose will be administered at approximately 48 hours after the completion of 
each ADXS -503 infusion. See Section [IP_ADDRESS]  for additional information.  
Refer to Section 9.2.2  for clinical safety management and supportive care guidelines for ADXS -
503 and pembrolizumab  treatment. Guidelines for the management of infusion reactions can be 
found in Appendix 6 . Guidelines for the management of other acute events, including hypotension, 
hypoxia , encephalopathy, organ toxicity, fever and constitutional symptoms can be found in 
Appendix 7 . 
Note:  If any toxicity results in the discontinuation of either ADXS -503 or pembrolizumab  but not 
both, treatment with the non -discontinued study drug may continue as monotherapy  in Part C , 
unless the nature of the toxicity precludes administration of any treatment  (see Section 7.6). In 
such cases, the treatment administration instruction s for the individual study drug 
administered as monotherapy are to be followed until t reatment discontinuation . 
7.2. Preparation/  Handling/  Storage/  Accountability  
1. ADXS -503 is shipped at minus  (-)80C with a temperature monitor included in the box 
that will be retrieved by [CONTACT_100677]. It is imperative that all ADXS -503 drug shipments be 
stored at minus  (-)80C (±10C) immediately after being removed from the shippi[INVESTIGATOR_34919].  Recommended safety measures for preparation and hand ling of ADXS -[ADDRESS_919821] be stored in a secure , 
environmentally controlled , and monitored (manual or automated) area in accordance with 
the labeled  storage conditi ons with access limi ted to the I nvestigator and authorized site 
staff. 
4. Upon completion or termination of the study, all unused and/or partially used 
investigational product will be destroyed at the site  or by a third party outside of the site,  
per institutional policy. It is the Investigator's responsibility to arrange for disposal of all 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919822] (including pembrolizumab) 
that is provided by [CONTACT_21655], subsidiary or designee, every attempt will be made to source 
these supplies from a single lot/batch numbe r. The trial site will be responsible for recording the 
lot number, manufacturer and expi[INVESTIGATOR_679731].  
The Investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriat e supply, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and any applicable laws and regulations.  
7.3. Treatment Compliance  
Treatment compliance is not applicable to this study because ADXS -[ADDRESS_919823] ’s study site.  
In Part A, ADXS -503 will be administered as monotherapy at 2 planned escalating dose levels. In 
Part B, ADXS -503 will be administered at 2 planned escalating dose levels in combination with a 
fixed dose of pembrolizumab (2 00 mg). T he dose of ADXS -503 administered to each subjec t will 
depend on the point at which the subjec t enrolls in the study during the dose escalation phase  for 
Part A and Part B . 
In Part C, all subjects will receive ADXS -503 + pembrolizumab. The planned dose of ADXS -503 
in Part C is 1x108 CFU in combination with a fixed dose of pembrolizumab (200 mg).  
See Section 5.1 for a description of the study design.  
7.5. Blinding  
This is an open -label study . Therefore,  the Sponsor, Investigator and subjec t will be aware of the 
treatment  and dose  administered.  
CONFIDENTIAL    
Protocol ADXS -503-101 
83 7.6. Treatment  Modification  and Discontinuation Guidelines  for Toxicity  
Treatment  will be  delayed , or treatment will be discontinued due to specific toxicities as outlined  
in Section 7.6.1  for ADXS -503 and Section 7.6.2  for pembrolizumab.  
For subjects treated with  ADXS -503 in combination with pembrolizumab  (Part B and Part C), the 
following guidance should be followed:  
• Treatment modifications and treatment discontinuation as a result of toxicity should be 
based on the causal agent. Toxicity that was assessed as being caus ed by [CONTACT_679794] -503 should 
be managed according to the criteria for dose delays and treatment discontinuation for 
ADXS -503 (see Section  7.6.1 ), whereas toxicity that was assessed as being caused by 
[CONTACT_679807]  (see Section  7.6.2 ). This means that when 
administration of one agent has been delayed for toxicity, the other agent may be 
administered as scheduled, unless the nature of the toxicity precludes administration of any 
treatment. Similarly, tre atment with either ADXS -503 or pembrolizumab  may be 
discontinued when either drug is considered to be the cause of the toxicity.  
• If any toxicity results in the discontinuation of either ADXS -503 or pembrolizumab  but not 
both, treatment with the non -discont inued study drug may continue as monotherapy, unless 
the nature of the toxicity precludes administration of any treatment.  
• On the day of dosing  (from Week 1 [± 2 days] onwards in Part B and Part C ), following 
the administration of pembrolizumab  and before the administration of ADXS -503, the 
Investigator must confirm that the subject  is in a stable medical condition and any ongoing 
AEs, if present, would not preclude the administration of ADXS -503. If ongoing AEs do 
preclude the administration of ADXS -503, ADXS -[ADDRESS_919824] be delayed until the 
resolution of the AEs.  
 
7.6.1.  ADXS -503: Treatment Modification and Discontinuation 
Guidelines  
Treatment modification and discontinuation guidelines for ADXS -503-related toxicities  are 
outlined in Table 8 below . 
CONFIDENTIAL    
Protocol ADXS -503-101 
84 Table 8: Treatment Modification s/Discontinuation  for ADXS -503-Related Toxicity  
Toxicity  Grade  Interrupt or Hold  
Treatment ? Timing for Restarting 
Treatment  Discontinue 
Treatment  
Hematologic  1, 2, 3 No  N/A N/A 
4 Yes Toxicity resolves to 
Grade  ≤ 1 or baseline  
within 12 weeks of 
previous dose of 
ADXS -503 Toxicity does not 
resolve to Grade  ≤ 1 
or baseline within 12 
weeks of previous 
dose of ADXS -503 
Non-
hematologic  
(excluding  
AEs 
described in 
footnote b ) b 1 No N/A N/A 
2-3 Yes Toxicity resolves to 
Grade  ≤ 1 or baseline  
within 12 weeks of 
previous dose of 
ADXS -503 a Toxicity does not 
resolve to Grade  ≤ 1 
or baseline within 12 
weeks of previous 
dose of ADXS -503 a 
4 N/A Permanently 
discontinue treatment  Permanently 
discontinue treatment  
a With Investigator and S ponsor agreement, subject s with a non -hematologic AE (eg, alopecia, vitiligo) still at G rade 2 after 12 
weeks, may continue treatment only if  asymptomatic and controlled.  
b Refer to Appendix 6 for recommended management guidelines for AEs associated with  infusion reactions ; Appendix 7 for 
recommended management guidelines for other acute events, including hypotension, hypoxia, encephalopathy, organ toxicity, 
fever and constitutional symptoms ; and Appendix [ADDRESS_919825] occur within 3 days of the scheduled infusion day (every 3 weeks  
±2 days ) unless a delay in dosing is required to allow for the resolution of AE s (see Table 8 above). 
Subject s who require a delay of ADXS -503 dosing should be re -evaluated weekly or more 
frequently if clinically indicated and resume ADXS -503 dosing when re -treatment criteria are met 
as outlined in Table 8 above. If treatment with ADXS -503 is delayed by > 12 weeks from the 
previous dose of ADXS -503 for toxicities as outlined in Table 8, treatment  should be discontinued 
after consultation  with the Sponsor . 
Dosing delays lasting > [ADDRESS_919826] be consulted. Periodic study visits to assess safety should 
also continue every 6  weeks or more frequently if clinically indicated during dosing delays  lasting 
>[ADDRESS_919827]  discontinues treatment at their enrolled dose level  due to toxicity , but is otherwise 
experiencing clinical benefit, he/she  may be eligi ble to receive ADXS -[ADDRESS_919828] . No other reason for dose reduction will be considered.  All 
study -related procedures will apply for subsequent doses at the reduced dose.  
CONFIDENTIAL    
Protocol ADXS -503-101 
85 7.6.2.  Pembrolizumab: Treatment Modification and Discontinuation 
Guidelines  
Treatment modification  and discontinuation guidelines  for pembrolizumab -related toxicit ies are 
outlined in Table 9 below . 
Table 9: Treatment Modification s/ Discontinuation  for Pembrolizumab -Related Toxicity  
Toxicity  Hold 
Treatment 
For Grade  Timing for Restarting 
Treatment  Discontin ue Subject  d 
Diarrhea/Colitis  2-[ADDRESS_919829] dose.  
3-4 Permanently discontinue  
(see exception below) . a Permanently discontinue . 
Type 1 diabetes 
mellitus (T1DM) 
(if new onset) or 
Hyperglycemia  T1DM or   
3-[ADDRESS_919830] dose or inability to reduce 
corticosteroid to 10 mg or less of prednisone 
or equivalent per day within 12 weeks.  
4 Permanently discontinue . Permanently discontinue . 
Note:  Permanently discontinue for any severe or Grade 3 (Grade 2 for pneumonitis)  drug-related AE that recurs 
or any life -threatening event . 
a For subjects with liver metastasis who begin treatment with Grade [ADDRESS_919831] or ALT increases by [CONTACT_216729] 50% relative to baseline and lasts for at least 1 week then subjects should be discontinued.  
b If symptoms resolve within o ne hour of stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the  original infusion 
rate (eg, from 100 mL/hr to 50 mL/hr). Otherwise , dosing will be held until symptoms resolve and the subject should be 
premedicated for the next scheduled dose . See Appendix [ADDRESS_919832] dose.  
d With Investigator and S ponsor agreement, subjects  with certain  non-hematologic AE s (eg, alopecia, vitiligo) still at G rade [ADDRESS_919833] occur within 3 day s of the scheduled infusion day (every 3 
weeks  ±2 days ) unless a delay in dosing is required to allow for the resolution of AEs (see Table 
9 above). Subjects who require a delay of pembrolizumab dosing should be re -evaluated weekly 
or more frequently if clinically indicated and resume pembrolizumab dosing when re -treatment 
criteria are met as outlined in Table 8 above. If treatment with pembro lizumab is delayed by >12 
weeks from the previous dose of pembrolizumab for toxicities as outlined in Table 8 , treatment 
should be discontinued after consultation with the Sponsor . 
Dosing delays lasting > [ADDRESS_919834] be consulted. Periodic study visits to assess safety should 
also continue every 6  weeks or more frequently if  clinically indicated during dosing delays  lasting 
>[ADDRESS_919835]’s welfare may be 
administered at the discretion of the Investigator in keepi[INVESTIGATOR_12983]. All concomitant prescription and nonprescription medication s or vaccines  received  
by [CONTACT_70579] t from 30 days prior to screening until 30 days after the final  dose of study treatment, 
will be recorded in the  electronic case report form  (eCRF ) along with : 
• generic name [CONTACT_11889]  
• reason for use  
• dates of admini stration including start and end dates  
• dosage informati on including dose and frequency  
Any addition, deletion, or change in the dose of these medi cations will also be recorded.  
If a subjec t develops intolerance or an AE to ampi[INVESTIGATOR_679732]/or trimethoprim/s ulfamethoxazole on 
study for Lm prophylaxis, another antibiotic to which Lm is typi[INVESTIGATOR_679733]  (eg, erythromycin  or fluoro quinolone ). 
In addition, any anti-cancer treatment received by [CONTACT_70579] t for 1 year following the final dose 
of study treatment  (duri ng the survival/treatment follow -up period), will  be recorded in the eCRF, 
along with the information listed above.  
Medications specifically prohibited in the exclusion criteria  (Section 6.2) and Section 7.7.2  are 
not all owed during the ongoing study. If there is a clinical indication for a med ication  specifically 
prohibited during the trial, discontinuation from study treatment may be required.  
Palliative and supportive care is permitted during the course of the trial for underlying medical 
conditions and management of symptoms. Surgery or radi otherapy for tumor control is not 
permitted during the study; however, radiotherapy or procedures for symptom management is 
allowed.  
The Medical Monitor should be contact[CONTACT_10964] . 
CONFIDENTIAL    
Protocol ADXS -503-101 
88 7.7.2.  Prohibited Medications / Therapy  
Subject s are prohibited from receiving the following therapi[INVESTIGATOR_679734]:  
• Anti-cancer systemic chemotherapy , immunotherapy , targeted therapy (eg , tyrosine kinase 
inhibitor s), or other biological therapy ( eg, anti -VEGF agents)  not specified as study 
treatment in this protocol . Note: Ongoing pembrolizumab therapy  will be permitted for 
subjects enrolled in Part B . 
• Surgical treatmen t as per consultation with the S ponsor . 
• Immunosuppressive agents  (except as stated in Section 6.2). 
• Immunosuppressive doses of systemic corticosteroids  (ie, >10 mg daily prednisone 
equivalent) , except as stated in Section 6.2. 
• PI3K and TNF α inhibitors . 
• Any Investigational agent(s)  other than that/those to be administered to the subjec t per 
protocol in this study . 
• Radiati on therapy (except palliative radiation therapy for disease -related pain with a 
consult with the Sponsor's Medical M onitor) . 
• Live vaccines within [ADDRESS_919836] dose of study  treatment and whi le 
participating in the study . Examples of live vacc ines include, but are not limited to the 
following:  measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid 
(oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines 
and are allowed; however, intran asal influenza vaccines ( eg, Flu -Mist®) are live 
attenuated vaccines and are not allowed . 
• Acetaminophen cannot be substituted for NSAIDs  as pre -medication for ADXS -503. 
Subjec ts who, in the Investigator ’s judgement , require the use of any of the aforementioned 
treatments for clinical management , should be discontinued from  study  treatment . Subject s may 
receive other medications that the Investigator deems to be medically necessary.  
In addition, please note the following : 
• Anti-infectives  should be avoide d. However, subjec ts with a documented infectious 
complication should receive oral or IV antibiotics or other anti -infective agents as 
considered appropriate by [CONTACT_679808] a given infectious condition, 
according to standard institu tional practice . 
• Medications described in Appendix 6, Appendix 7, or Appendix 8 , Appendix 9 for the 
management of infusion reactions ; acute hypotension, hypoxia , encephalopathy, organ 
toxicity, fever and constitutional symptoms; and  immune -related AEs, respectively,  
should be administered as described in these guidelines.  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919837] been conducted. However, 
based on the mechanism of action  of ADXS -503, it is not expected that administration of the agent  
would complicate wound healing. Therefore, a  subjec t may initiate or resume study treatment  2 
weeks after minor surgery (ie, surgery involving little risk to the life of the subjec t; specifically, 
an operation on the superficial structures of the body or a manipulative procedure  that does not 
involve a seri ous risk) if the wound has completely healed and there are no wound  healing 
complications. A subjec t who has wound healing complications following minor  surgery, received 
major surgery or requires new implants and/or devices (permitted by [CONTACT_93865]) dur ing the 
course of the study, must wait a minimum of [ADDRESS_919838]  recovered (eg, return to 
baseline or Grade ≤1) from any toxicity and/or complication before the  next dose of study 
treatment. Sponsor consultation is required prior to resuming study  treatment for these subjec ts. If 
study treatment is delayed beyond [ADDRESS_919839]  may be 
discontinued from study treatment . 
7.8. Treatment after the End of the Study  
There is no mandated  treatment following the end of the stud y. 
8. Discontinuation/  Withdrawal Criteria  
8.1. Discontinuation of Study Treatment  
Each subjec t will receive study treatment until a treatment discontinuation criterion is met . 
Treatment d iscontinuation criteria include:  
• Documented d isease  progression (radiographical per RECIST v1.1 or clinical , as 
determined by [CONTACT_737] ). 
• Unacceptable toxicity . See Section 7.6. 
• Intercurrent illness that prevents the further administration of study treatment.  
• Physician determines that it is in the subjec t’s best interest . 
• Noncompliance with study treatment or procedure requirements.  
• Subjec t requires treatment with prohibited medic ation(s)/ therapy (see Section 7.7.2 ). 
• Pregnancy  or breastfeeding  (see Appendix 5 ). 
• Withdrawal of consent . 
• Death . 
CONFIDENTIAL    
Protocol ADXS -503-101 
90 • Sponsor’s decision to terminate treatment or the study . 
• Part B and Part C: subject completes 2 years of treatment with ADXS -503 + 
pembrolizumab. Note: [ADDRESS_919840] dose of 
pembrolizumab.  
• Subject achieves a confirm ed CR, as described below.  
If a subjec t achieves a confirmed Investigator -assessed , REC IST v1.[ADDRESS_919841] 
subsequently discontinue treatment . Conf irmation of CR should be performed ≥4 weeks  after 
initial CR assessment.  
Subjects who achieve a confirmed CR  (Parts A, B and C) , as well as those subjects in Part B or 
Part C who stop trial therapy after 2 years of treatment for reasons other than disease progression 
or intolerability, may be eligible for re -treatment  upon disease progression ( with discussion and 
agreement between the Investigator and Sponsor) . 
Section 8.1.[ADDRESS_919842] s may continue  to receive  study treatment provided the following criteria  are 
met: 
• No deteriora tion in ECOG performance status  
• Absence of signs and symptoms (includi ng worsening of laboratory values)  indicating 
disease progression  
• Absence of rapid progression of disease  
• Absence of progressive tumor at critical anatomical sites (eg, spi[INVESTIGATOR_13377]) 
requiring urgent a lternative medical intervention  
• The subject  is tolerating treatment  
• Continued treatment is in the best interest of the subject , in the opi[INVESTIGATOR_679735] -503-[ADDRESS_919843] be repeated ≥[ADDRESS_919844] ’s clinical condition warrants . If repeat imaging  does not 
confirm PD , then treatment may continue or resume. If repeat imaging confirms initially 
documented  PD and shows further  progression of disease, the subjec t should  be discontinued from 
study treatment, unless the basis for the PD assessment is enlarged tumor -draining lymph nodes in 
the presence of a target tumor reduction. In determining whether tumor burden h as increased or 
decreased, Investigators should consider all target lesions as well as non -target lesions. If the repeat 
imaging confirms initially documented  PD but shows no evidence of further tumor progression, 
the subject  should be discontinued from st udy treatment , unless t he Investigator considers the 
subject  to be deriving clinical benefit , the Investigator considers continued treatment to be in  the 
best interest of the subject , and the other criteria listed above are met . In this situation, treatment 
may continue  after consultation with the Sponsor . 
Additional information , including iRECIST  assessments may be provided to the Investigator to 
assist in treatment -related decisions at  the time of RECIST v1.1-defined progression.  
8.1.2.  Treatm ent/ Enrollment  Stoppi[INVESTIGATOR_679736]. The purpose of the medical 
oversight is to identify potential safety signals that indicate continued treatment and/or further 
study enrollment may present a risk t o study subjects. Observed safety signals will be discussed 
between the Sponsor and study Investigators during scheduled teleconferences.  
Treatment and/or study enrollment may be stopped based on the nature, frequency, or reversibility 
of observed toxicity . The following are examples of safety events that may require stoppi[INVESTIGATOR_679737]/or study enrollment for further Investigation by [CONTACT_1034]:  
• A rate of dose -limiting toxicity at dose level 1 in Part A or Part B that exceeds 33%  
• Evidence of inva sive infection with study treatment  
• Delayed listeremia in subjects without risk factors such as implanted medical devices or 
hardware  
• A rate of toxicity or type of toxicity that is unanticipated based on prior experience with 
Lm-based immunotherapy and or/  pembrolizumab  
Study treatment and/or study enrollment may resume if deemed appropriate by [CONTACT_679809], based on the review of cumulative study data and an evaluation of risk/ benefit.  
In dose-escalation Part A and Part B, safety da ta, including dose -limiting toxicities (see Section 
9.1.6 ) will be discussed between the Sponsor and study Investigators for dose escalation/ de -
escalation purposes during scheduled meetings. In Part B dose -expansion and Part C, toxicities 
CONFIDENTIAL    
Protocol ADXS -503-101 
92 will be evaluated on an ongoing basis. If the aggregate rate of treatment -related toxicities that meet 
the DLT  criteria  (see Section 9.1.6 ) exceed s 33% at any time ( across all subjects in Part B dose -
expansion and Part C ), the findings will be discussed  between the Sponsor and study Investigators , 
and further enrollment may be interrupted. Depend ing on the nature and grade of the toxicit ies and 
after assessing the risk /benefit, treatment may  be adjusted to a lower dose of ADXS -[ADDRESS_919845]  may be discontinued from the study  for any of the following reasons:  
• A subjec t may withdraw from the study at any time at the subject ’s own request or that of 
the subject ’s legally authorized representative  or may be withdrawn at any time at the 
discretion of the Investigator for safety, b ehavioral, or administrative reasons . 
o If a subject  is withdrawn from the study, the Investigator will complete and report 
the observations as thoroughly as possible up to the date of withdrawal including 
the date of last treatment and the reason for withdr awal . 
o Refer to the SoA for procedures to be completed at the time of study  
discontinuation and follow -up and for any further evaluations that need to  be 
completed . 
• Eligibility  (subjec t doesn’t meet key eligibility  criteria) . 
• Study closure or termination . 
• Death . 
• Lost to follow -up. 
8.2.1.  Withdrawal from the Study  
In accordance with the Declaration of Helsinki and other applicable regulations, a subjec t has the 
right to withdraw consent from study participation at any time and for any reason without 
prejudice to his/her future medical care by [CONTACT_679810].  
Only subject s who refuse all of  the following methods of follow -up will be considered to have 
withdrawn consent  from study participation:  
• Attendance at study visits per prot ocol. 
• Study personnel contact[CONTACT_679811] t by [CONTACT_756] . 
• Study personnel contact[CONTACT_152830] (eg, family member, spouse, partner, 
legal representative, physician, or other healthcare provider) . 
CONFIDENTIAL    
Protocol ADXS -503-101 
93 • Trial personnel accessing and reviewing the subjec t’s medical information from 
alternative sources (eg, doctor’s notes, hospi[INVESTIGATOR_1097]).  
If the subject  and/or their legally authorized representative  refuses all of the a bove methods of 
follow -up, the I nvestigator should personally speak to the subjec t and/or their legally authorized 
representative  to ensure the subject  and/or thei r legally authorized representative  understand s all 
of the potential methods of follow -up.  If the subjec t and/or their legally authorized 
representative  continues to refuse all poten tial methods of follow -up, the I nvestigator will 
document this as a withdrawal of consent in the medical record and in the eCRF . 
For a subjec t and/or their legally authorized representative  who withdra ws consent as define d 
above, study personnel may use local, regional, and national public records (in accordance with 
local law) to monitor vital status.  
8.2.2.  Lost to Follow -Up 
A subjec t will be considered lost to follow -up if he/she repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a subjec t fails to return to  the clinic for a required study 
visit:  
• The site must attempt to contact [CONTACT_70579] t and reschedule the m issed visit as soon as 
possible and counsel the subjec t on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subjec t wishes to and/or should continue in t he 
study.  
• In cases in which the subjec t is deemed lost to follow -up, the Investigator or designee 
must make every effort to regain contact [CONTACT_286679] t (where possible, [ADDRESS_919846] ’s last known mailing address or 
local equivalent methods). These contact [CONTACT_679812] t’s 
medical record . 
• Should the subjec t continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primar y reason of lost to follow -up. 
9. Study Assessments and Procedures  
• Study procedures and their timing are summarized in the  SoA. 
• As protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns , these should be discussed with the S ponsor immediately upon occurrence or 
awareness  to determine if the subjec t should continue or discontinue study treatment . 
CONFIDENTIAL    
Protocol ADXS -503-101 
94 • Adherence to the study design requirements, including those specified in th e SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all subjec ts screen ed and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the subjec t’s routine clinical management and obtained 
before signing the Informed Consent Form, may be utilized for Screening or baseline  
purposes provided the procedure meets the protocol -specified criteria . 
• Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples . 
9.1. Safety  Assessments   
Planned time points for all safety assessments are provided in the SoA (Section  2). Safety 
assessments may be perform ed more frequently than the timepoints specified in the SoA, as 
clinically i ndicated. An “Unscheduled Visit”  form will be used to record this additional 
information in the eCRF.  
9.1.1.  Physical Exam ination s 
A complete physical examination will include, at a minimum, assessment of the body systems. 
Height will be measured at S creening only. Weight will be measured at all physical examination 
timepoints.  
A clinically significa nt finding or a worsening in a phys ical examination  finding from the previous 
visit in the opi[INVESTIGATOR_679738].  
9.1.2.  Vital Sign  Measurements  
Vital signs will be measured in a semi -supi[INVESTIGATOR_55848] [ADDRESS_919847] and will include 
temperature, systolic and diastolic blood pressure , pulse , oxygen saturation, and respi[INVESTIGATOR_697].  
In Part A, vital signs w ill be monitored  every 30 minutes (±5 minutes)  starting  immediately prior 
to each ADXS -[ADDRESS_919848] of care until the administration of ADXS -503. Vital 
sign monitoring for ADXS -503 will then occur every 30 minutes (±5 minutes)  starting  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919849] of care.  
9.1.3.  Performance Status  Monitoring  
The Eastern Cooperati ve Oncology Group (ECOG) Performance Scale will be used to monitor  
performance status. Refer to Appendix 11  for a description  of the ECOG scale.  
9.1.4.  Clinical Safety Laboratory Assessments  
• All protocol -required laboratory assessments, as defined in  Appendix [ADDRESS_919850] be  conducted 
in accordance with th e Laboratory M anual and the  SoA. 
• The volume of blood to be collected at each timepoint for clinical safety laboratory 
assessments, can be found in the Laboratory M anual.  
• The I nvestigator must review the laboratory report, document this review, and record a ny 
clinically relevant changes occurring during the study in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying d isease, unless 
judged by [CONTACT_941] I nvestigator to be more severe than expected for the subjec t's condition.  
• All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline. 
If such values do not return to normal/baseline within a period of time judged reasonable 
by [CONTACT_941] I nvestigator, the etiology should be identified and the Sponsor  notified.  
• If laboratory values from non -protocol specified  laboratory assessments performed at the 
institution’s local laboratory require a change in the subject’s clinical  management or are 
considered  clinically significant by [CONTACT_941] I nvestigator (eg, SAE  or AE or treatment  
modification), then the resul ts must be r ecorded in the eCRF.  
• A pregnancy test will be performed for all WOCBP . All WOCBP  must have a negative 
pregnancy test within 72 hours prior to receiving each dose of ADXS -503 in Part A, or 
each dose of ADXS -503 or pembrolizumab in Parts B and C. Note: the o nly exception will 
be Week [ADDRESS_919851] 
pembrolizumab dose  (pregnancy test performed prior to the first ADXS -503 dose at Week 
1). A positive urine pregnancy test must be confirmed by a serum pregnancy test (minimum 
sensitivity  of 25 IU/L or equivalent units of βHCG) .  If the pregnancy test is positive, the 
subjec t must not receive study treatment and must  not be enrolled in the study.  
9.1.5.  Assessment and Reporting of Adverse Event s 
The definition  of an AE , Event  of Special  Interest  (ESI), and  SAE can be found in Appendix 4 . 
CONFIDENTIAL    
Protocol ADXS -503-101 
96 AEs will be reported by [CONTACT_70579] t (or, when appropriate, by a caregiver, surrogate, or the subjec t’s 
legally authorized  representative).  
The Investigator and any designees are responsible for detecting, documenting, and recording  
events that meet the definition of an AE , ESI, or SAE and remain responsible for follow -up of AEs 
that are serious, considered related to the stu dy treatment or study  procedures , or that caused the 
subjec t to discontin ue the study treatment or the study (see Section 8). 
[IP_ADDRESS].  Time Period and Frequ ency for Collecting AE and SAE 
Information  
All AEs and SAEs will be collected from the signing of the ICF  until [ADDRESS_919852] dose of study treatment . In Part A and Part 
B, ESI will be reviewed as they are reported and will be discussed at the time of the dose escalation 
meetings, an d periodically afterwards . In Part C, ESI will be reviewed and discussed on an ongoing 
basis.  
Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the Medical History/Current Medical Co nditions section of the eCRF , 
not the AE section . 
All SAEs  and ESI will be recorded and reported to the S ponsor or designee within [ADDRESS_919853]  has been 
discharged from the study, and he/she considers the event to be reasonably related to the study 
treatme nt or study participation, the I nvestigator must promptly notify the Sponsor  (ie, within 24 
hours) . Furthermore, if the I nvestigator becomes aware of any instances (eg, blood tests performed 
at another medical facility) in which a subject has Lm isolated from a blood culture or develops an 
illness consistent with an Lm infection, the Sponsor must be notified within 24 hours of the 
Investigator becoming aware of the event.  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in  Appendix 4 . 
Adverse reactions will be reported to FDA according to 21 CFR 312.32.  
Toxicity will be graded according to the National Cancer Institute  Common Terminology 
Criteria for Adverse Events (CTCAE) v4.03 . 
CONFIDENTIAL    
Protocol ADXS -503-101 
97 [IP_ADDRESS].  Method of Detecting AEs, ESIs, and SAEs  
Care will be taken not to introduce bias when detecting AEs, ESIs, and/or SAEs. Open -ended and  
non-leading verbal questioning of the subject  is the preferred method to inquire about 
AE occurrence s. 
[IP_ADDRESS].  Follow -Up of AEs , ESI and SAEs  
After the initial AE/SAE report , the I nvestigator is required to follow each subject  at subsequent 
visits/contacts. All AEs, SAEs, and ESI (as defined in  Appendix 4 ), will be followed until 
resolution, stabiliz ation , the event is otherwise explained, or the subject  is lost to follow -up (as 
defined in  Section 8.2.2 ). See Appendix 4 for additional  information on follow -up procedures.  
[IP_ADDRESS].  Regulatory Reporting Requirements for SAEs  
• Prompt notification  (ie, within 24 hours) by [CONTACT_679813] s and the safety of a study treatment under clinical investigation are met.  
• The Sponsor has a legal responsibility to no tify both the local regulatory authority and 
other regulatory agencies about the safety of a study treatment under clinical 
investigation. The Sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent E thics Committee s (IEC ), and I nvestigators.  
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory requirements and Sponsor policy and 
forwarded to I nvestigators as necessary.  
• An Investigator who receives an I nvestigator safety report describing a n SAE or other 
specific safety information ( eg, summary or listing of SAE s) from the Sponsor will 
review the information and then file it along with the Investigator’s Brochure and will 
notify the IRB/IEC, if appropria te according to local requirements.  
[IP_ADDRESS].  Pregnancy and Breastfeeding  
• Prior to enrol lment , study candidates who are WOCBP  must be advised of the 
importance of avoiding pregnancy and lactation/breastfeeding during trial participation 
and the potential risk factor s for an unintentional pregnancy.  
• All WOCBP  must have a negative pregnancy test within 72 hours prior to receiving 
each dose of ADXS -503 in Part A, or each dose of ADXS -503 or pembrolizumab in 
Parts B and C. Note: the only exception will be Week [ADDRESS_919854] pembrolizumab dose  (pregnancy test 
performed prior to the first ADXS -503 dose at Week 1) . A positive urine pregnancy test 
must be confirmed by a serum pregnancy test (minimum sensitivity  of 25 IU/L or 
equivalent units of βHCG) .  If the pregnancy test is positive, the subject  must not 
receive study treatment and must  not be enrolled in the study.  
• A highly effective method of birth control must be used during study treatment and for  
at least  120 days  after the final dose of study treatment (see Appendix 5 ). 
• Details of all pregnancies and lactation/breastfeeding cases in female subjects  or female 
partners of male subjects , will be collected during the treat ment period and for at least 
120 days  after the final dose of study treatment.  
• If a pregnancy  or lactation/breastfeeding case is reported, the I nvestigator should inform 
Advaxis within 24 hours of learning of the pregnancy  or lactation/breastfeeding case  
and should follow the procedures outlined in  Appendix 5 . 
• Abnormal pregnancy outcomes ( eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE.  
• In the case of pregnancy  or a subject  breastfeeds while taking protocol -required therapy , 
study treatment will be discontinued . 
9.1.6.  Dose Limiting Toxicity Criteria  
Dose -limiting toxicity will be assessed over the initial 28 days  of treatment in Part A  and Part 
B for dose  escalation/de -escalation decisions. Note: t he DLT window will end 7 days after the 
second dose of ADXS -503 in Part A and 7 days after the second dose of ADXS -503 and 
pembrolizumab in Part B . Refer to Section 5.1 for the study design . 
The same DLT criteria will be used in both Part A and Part B. A DLT is defined as any of the 
following AEs that is judged by [CONTACT_110515], probably, o r definitely related to 
study treatment,  and occurs during the DLT  evaluation period described above  (according to 
CTCAE v4.03) . 
Grade 5 fatal adverse event  
Hematologic : 
1. Grade 4 neutropenia that lasts ≥72 hours  
2. Grade 4 febrile neutropenia  of any duration  
3. Grade 3 febrile neutropenia that lasts more than 48 hours  
CONFIDENTIAL    
Protocol ADXS -503-101 
99 4. Grade 4 thrombocytopenia  
5. Grade 3 thrombocytopenia associated with clinically significant bleeding  
6. Grade 3 hemolysis  
7. Grade 3 anemia that does not resolve to Grade ≤1 within 72 hours with supportive treatment, 
including transfusions  
Hepatic:  
1. ALT or AST >[ADDRESS_919855] >5 x and ≤[ADDRESS_919856], that fails to return to Grade ≤1 within 2 weeks despi[INVESTIGATOR_348874]  
3. Total bilirubin >[ADDRESS_919857] >[ADDRESS_919858] and c oncurrent total bilirubin >[ADDRESS_919859]  
Non-hematologic : 
1. Grade 4 anaphylaxis, hypotension, hypoxia, or acute respi[INVESTIGATOR_1506]  
2. Grade ≥3 non -hepatic or non -hematologic toxicity that cannot be controlled within 24 hours, 
with the exceptions below:  
The followi ng Grade 3 non -hematologic toxicities will not  be considered DLTs:  
a. Grade 3 nausea, vomiting and/or diarrhea lasting <3  days and reversible with medical 
intervention  
b. Grade 3 or 4  increase in amylase or lipase that persists <3 weeks and it is not 
associated  with clinical or radiographic evidence of pancreatitis  
c. Grade 3 electrolyte abnormality that lasts <72 hours, is not clinically complicated and 
resolves spontaneously or responds to conventional medical intervention  
d. Grade 3 fever that lasts <72 hours, and it is not associated with hemodynamic 
compromise (including hypotension, or clinical or laboratory evidence of end organ 
perfusion impairment)  
e. Grade 3 endocrinopathy that is well controlled by [CONTACT_108089]  
f. Grade 3 tumor flare (defined as pain, irrit ation, or rash that localizes to the sites of 
known or suspected tumor)  
g. Grade 3 fatigue for less than 7 days  
CONFIDENTIAL    
Protocol ADXS -503-101 
100 3. Delay of >12 weeks in treatment administration (ADXS -503 or pembrolizumab)  due to 
unresolved toxicities that are possibly, probably , or definitely related to study treatment  
The occurrence of toxicities that meet the criteria listed above but occur outside of the DLT 
evaluation period, will be assessed on a continual basis and may be taken into consideration for 
future dose  escalation/de -escalation decisions  in Part A and Part B . Subjects in Part A and Part B 
who discontinue prior to the end of the DLT evaluation period for any reason other than toxicity 
will be replaced.  Further more, if within the [ADDRESS_919860] may be replaced for DLT assessment purposes.  
In Part C, toxicities will be evaluated on an ongoing basis. If the aggregate rate of treatment -related 
toxicities that meet the DLT  criteria  listed above  exceed s 33% at any time ( across all subjects in 
Part C ), the findings will be discussed  between the S ponsor and study Investigators , and further 
enrollment may be interrupted . See Section 5.1. 
Treatment modifications for specific toxicities are desc ribed in Section 7.6. 
Overall treatment and enrollment stoppi[INVESTIGATOR_679695] 8.1.2 . 
9.2. Clinical Safety Management  
9.2.1.  ADXS -503 Treatment and Lm Management Guidelines  
[IP_ADDRESS].   ADXS -503 Pre-Infusion Prophylactic  Regimen  
From  the previous clinical experience with Lm-based immunotherapi[INVESTIGATOR_014], it is anticipated that mild 
to moderate “flu-like” symptoms (eg,  chills, pyrexia, nausea, vomiting, fatigue, headache , 
tachycardia  and hypotension ) may occur during or shortly after treatment  infusion. The symptoms 
usually resolve within [ADDRESS_919861] s should receive the following pre -infusion  regimen  prior to each 
ADXS -503 infusion : 
IV Fluid Hy dration:  
• Normal saline (eg, 500 mL over 30 minutes) . 
Pre-Medication Regimen:  
CONFIDENTIAL    
Protocol ADXS -503-101 
101 • Antihistamine – PO or IV (eg , diphenhydramine 25 mg or equivalent), once . 
• NSAIDs – PO (eg , naproxen 220 mg or ibuprofen  400 mg), once . 
• Antiemetic – PO or IV (eg, promethazine or ondansetron), once . 
• Histamine H2 -receptor antagonist – PO or IV (eg, famotidine 20 mg or equivalent), once . 
Pre-infusion treatment  should be administered  on the day of dosing and be completed at least 
[ADDRESS_919862] similar anti -inflammatory properties.  
[IP_ADDRESS].  ADXS -[ADDRESS_919863]-Infusion Monitoring  
 
Vital signs will be monitored  every 30 minutes (±5 minutes) starting immediately prior to each 
ADXS -[ADDRESS_919864] and will include temperature , systolic 
and diastolic blood pressure, pulse, oxygen saturation, and respi[INVESTIGATOR_697] (see Section 9.1.2 ). At 
[ADDRESS_919865] take action to provide 
appropriate medical care ( see Appendix 6 and Appendix 7). 
In Part B and Part C, ADXS -503 will be administered approximately 60 ( ±15) minutes after the 
end of the pembrolizumab infusion. Before administering ADXS -503, t he Investigator must 
confirm that the subject  is in a stable medical con dition and any ongoing AEs, if present, would 
not preclude the administration of ADXS -503. If ongoing AEs do preclude the administration of 
ADXS -503, ADXS -[ADDRESS_919866] be delayed until the resolution of the AEs . 
[IP_ADDRESS].  Mana gement of Listeria during Study Pa rticipation  
Following the completion of each ADXS -[ADDRESS_919867] s will receive a 7-day course of 
either oral 80 mg trimethoprim / 400 mg sulfamethoxazole  once daily  or 160 mg trimethoprim/ 
800 mg sulfamethoxazole (DS)  3 times  over the course of the 7 days , starting approximately 48 
hours after each ADXS -503 infusion. Subjects  with a known allergy to sulfa drugs  may receive 
ampi[INVESTIGATOR_10312] 500 mg  4 times daily  for 7 days starting  approximately 48 hours after  each ADXS -503 
infusion. Subjects with dual hypersensitivity to ampi[INVESTIGATOR_679739], after agreement between the Investigator and the medical 
monitor ( Section  [IP_ADDRESS].1.1 ). Post-infusion antibiotics  are administered to ensure the clearance of 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919868]  who experiences a fever (Grade 1 or greater) 24 hours following the completion of 
the ADXS -503 infusion sh ould be started on NSAIDs, hydration and other appropriate measures 
to treat the fever  (see Appendix 7 ). If the fever persists or worsens [ADDRESS_919869] ’s medical condition. If the fever remains unresponsive to oral/IV antibiotics [ADDRESS_919870] be sought. A microbial culture will be collected  to identify the agent of 
sepsis and antibiotic sensitivity testing should be performed to confirm susceptibility. An 
infectious disease consult should be obtained for further management of these events.  
As an additional precautionary measure  to ensure the clearance of Lm, a 3-week  course of oral 
antibiotics  (regimen as described above  but for 21 days rather than 7 days ) will be administered 
after the final  dose of ADXS -503. The first dose will be administered a t approximately 48 hours 
after the final dose of ADXS -503. 
Seven days ( ±3 days) after the completion of the [ADDRESS_919871] culture s positive for Lm, immediate and 
intensive IV antibiotic treatment (ampi[INVESTIGATOR_10312] +/ - gentamycin or other IV antibiotic regimen as 
indicated) is required. The Sponsor must be notified within [ADDRESS_919872] ’s case and at the discretion of the treating 
physician, the removal of any foreign medical object that has been present since the initiation of 
ADXS -503 treatment may be warranted.  
Furthermore, if the Investigator becomes aware of any instances (eg, blood tests performed at 
another medical facility) in which a subject has Lm isolated from a blood culture or develops an 
illness consistent with an Lm infection, the Sponsor must be notified within 24 hours of the 
Investigator becoming aware of the e vent.  
[IP_ADDRESS].1.1.  Listeremia  – Identification and Management  
ADXS -503 listeremia  is confirmed only after isolation of Lm from a normally sterile site, such as 
blood or spi[INVESTIGATOR_872] (in the setting of nervous system involvement ). Stool samples are of limited 
use as Advaxis Lm strains are not shed and Advaxis Lm-based immunotherapi[INVESTIGATOR_679740].  In additio n, genotypi[INVESTIGATOR_679741] -503. 
ADXS -[ADDRESS_919873] tested concentratio n of the following 
antimicrobial agents: ampi[INVESTIGATOR_10312], amoxicillin, ciprofloxacin, erythromycin, gentamicin, penicillin, 
CONFIDENTIAL    
Protocol ADXS -503-101 
103 tetracycline, trimethoprim/sulfamethoxazole , and vancomycin (IV). ADXS -503 is resistant to 
streptomycin  and nalidixic acid . 
[IP_ADDRESS].1.2.  Biofilm -Associated Listeremia  
Wild -type Lm is capable of forming and persisting within biofilms, including on medical device s, 
despi[INVESTIGATOR_133848].  Although rare, medical device -related infections such as ventriculo -
peritoneal  shunt infection, peritoneovenous shunt infection, and prosthetic joint infection have 
been reported after systemic listeriosis  (Charlier, 2012 ; Dominguez, 1994 ; Le Monnier, 2011 ; 
Winslow, 1984 ). ADXS -503 is expected to be highly sensitive to antibiotics such as 
trimethoprim/sulfamethoxazole , amoxicillin and ampi[INVESTIGATOR_10312] , erythromycin an d fluoroquinolones 
which can be effective treatment regimens for listeremia . 
Therefore, subjects  with implanted medical device(s) that pose a high risk for biofilm colonization 
and/or that cannot be easily removed , are excluded from this study. In addition , all subjects  will 
receive a [ADDRESS_919874]  suscept ibility to bacterial infections  (Smith, 2007 ). The absence 
of TNFα -mediated signaling may also enhance the potential virulence of attenuated Lm in subjects  
taking  PI3K or TNF α inhibitors  (Sonje, 2010 ).  
[IP_ADDRESS].1.3.  Antibiotic -Related Complic ations  
Subject s who develop complications during antibiotic administration, including but not limited to 
hypersensitivity reactions and Clostridium difficile -related diarrhea, may be appropriately 
managed with alternative antibiotics following discussion w ith the Sponsor.  
[IP_ADDRESS].  Management of Listeria During Follow -Up 
After completion of the treatment period that can last for 2 year, or discontinuation from study 
treatment, subjects enter the Follow -up Period. During Follow -up, subjects will be contact[CONTACT_679771] 3 months (± 2 week) for [ADDRESS_919875] experienced for 
several days the following symptoms tha t could potentially be associated with delayed listeremia  
and require prompt attention at the research site :  
• Fever or chills, headache, nausea, confusion or changes in alertness (for over 72 hours).  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919876] the site if they experience any o f these symptoms, as applicable.  
9.2.2.  Supportive Care Guidelines  for ADXS -503 and Pembrolizumab  
Immunotherapi[INVESTIGATOR_679742] . Early recognition and managemen t of AEs associated 
with immunotherapi[INVESTIGATOR_679743].  
Subjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_119557]. Suggested supportive care measures for the management of AEs associated wi th the 
administration of ADXS -503 or pembrolizumab are outlined below. Where appropriate, these 
measures include the use of oral or intravenous treatment with corticosteroids and additional anti -
inflammatory agents if symptoms do not improve with the admin istration of corticosteroids.  Note 
that several courses of steroid tapering may be necessary as symptoms may worsen when the 
steroid dose is decreased. For each AE, attempts should be made to rule out other causes, such as 
bacterial or viral infection, wh ich might require additional supportive care. The treatment 
guidelines are i ntended to be applied when the I nvestigator determines an AE  to be related to 
ADXS -503 or pembrolizumab . 
Note:  If after evaluation, the event is determined not to be related to a specific study treatment, 
the Investigator does not need to follow the treatment guidance (as outlined below).  
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event.  
[IP_ADDRESS].  Infusion Reactions  
Pembrolizumab and Lm-based immunotherapi[INVESTIGATOR_679744]  (see Section 3.6.2 ). ADXS -[ADDRESS_919877]. Infusion reaction signs/ symptoms typi[INVESTIGATOR_679745], or shortly thereafter . Signs/symptoms of infusion reactions 
may include: allergic reaction/hypersensitivity (including drug fever); arthralgia (joint pain); 
bronchospasm; cough; dizziness; dyspnea (shortness of breath); fatigue (asthenia, lethargy, 
malaise); headache; hypertension; hypotension; myalgia (m uscle pain); nausea; pruritic/itching; 
rash/ desquamation; rigors/chills; sweating (diaphoresis); tachycardia; tumor pain (onset or 
exacerbation of tumor pain due to treatment); urticaria (hives, welts, wheals); and vomiting.  
The management guidelines for subject s who experience infusion reaction s associated with the 
administration of ADXS -503 or pembrolizumab are provided  in Appendix 6. 
CONFIDENTIAL    
Protocol ADXS -503-101 
105 [IP_ADDRESS].  Acute , High -Grade Hypotension, Hypoxia, Encephalopathy  
and Organ Toxicity  
Guidelines for the management of acute, high -grade hypotension, hypoxia , encephalopathy, and 
organ toxicity , can be found in  Appendix 7. Additional information is provided in Section 
[IP_ADDRESS].1 . 
[IP_ADDRESS].  Management of Immune -Related Adverse Events  
[IP_ADDRESS].1.  ADXS -[ADDRESS_919878] are not 
expected to induce or exacerbate autoimmune toxicities, the potential for sub-acute or late -
occurring immune -related AEs exists. Therefore, immune -related AEs will be closely monitored 
for in this study, with ADXS -503 as a single agent, and in combination with pembrolizumab . 
General guidance for treating immune -related AEs considered by [CONTACT_679814] -503, is provided in Appendix 8 . 
[IP_ADDRESS].2.  Pembrolizumab  
A pattern of immune -related AEs has been defined  for pembrolizumab , for which management  
guidelines have been developed. These immune -related AEs include : pneumon itis, 
diarrhea/colitis , Type 1 diabetes mellitus (T1DM) , hypophysitis , hyperthyroidism or 
hypothyroidism , primary adrenal insufficiency, hepatic AEs , renal failure / nephritis , skin 
reactions, infusion reactions (as described above) , hemophagocytic lymphohistiocytosis , 
complications of allogeneic hematopoietic stem cell transplant ( HSCT ), and hematological 
toxicity in patients with chronic Hodgkin lymphoma ( cHL ). Immune -mediated adverse 
reactions reported in less that 1% of patients tr eated with pembrolizumab include uveitis, myositis, 
Guillain -Barre syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic 
syndrome/myasthenia gravis and myocarditis. Guidelines for the management of common 
immune -related AEs are provided in Appendix  9. Refer to Appendix 6  for guidelines to manage 
infusion reactions associated with pembrolizumab.  
[IP_ADDRESS].  Nausea  and Vomiting  
Nausea and vomiting should be treated aggressively. Following treatment, subject s should receive 
antiemetic therapy as needed, according to standard institutional practice . Subjects  should also be 
strongly encouraged to maintain liberal oral fluid intake.  
9.3. Treatment of Overdose  
For this study, any dose of ADXS -503 and/or pembrolizumab greater than the prescribed dose 
will be considered an overdose.  
CONFIDENTIAL    
Protocol ADXS -503-101 
106 In the event of an overdose , the Investigator  should:  
1. Contact [CONTACT_1034]’s Medical Monitor immediately  
2. Closely monitor the subject  
3. Document the quantity of the administered  dose as well as the duration of the dosing in 
the eCRF  
Appropriate supportive treatment should be provided if clinically indicated.  
9.4. Efficacy Assessments  
9.4.1.  Tumor Response -Based Assessments  
Tumor imaging will be performed by [CONTACT_22242] -enhanced CT/MRI. Baseline tumor imaging  will be 
performed within [ADDRESS_919879]/MRI of the 
chest,  abdomen, pelvis and any additional known sites  of disease . Subjects with known CNS 
metastases and subjects with signs or symptoms suggestive of brain metastasis should be evaluated 
with a CT/MRI of the brain at baseline. Subsequent tumor assessments should include CT/MRI of 
the head (for subjects with  known CNS metastases), chest, abdomen, pelvis and any additional 
known sites of disease using the same imaging method used for the baseline scan.  
In Part A  (ADXS -503 monotherapy) , tumor imaging will be performed during Screening 
(baseline), at Week 8  (±7 days) , at Week 1 6 (±7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) 
thereafter, until confirmed disease progression or treatment discontinuation, whichever occurs 
later.  
In Part B  dose-escalation and dose -expansion (ADXS -503 + pembrolizumab) , tumor imaging will 
be performed during Screening (baseline), which corresponds to the most recent tumor assessment 
that is consistent with PD (according to RECIST v1.1)  while on treatment with pembr olizumab 
monotherapy  or while receiving combination therapy with pembrolizumab + platinum -based 
chemotherapy or while receiving  pembrolizumab + pemetrexed as maintenance therapy, as the 
last therapy in the metastatic setting . As described above, the first dose of ADXS -503 will be 
administered within 12 weeks  of the initial assessment of PD . Subsequent  scans will be performed 
at Week 8 (± 7 days), at Week 16 (±7 days), every 9 weeks (±7 days) after  dosing with ADXS -503 
+ pembroli zumab  in all Part B subjects , until confirmed disease progression or treatment 
discontinuation, whichever occurs later.  
In Part C  (ADXS -503 + pembrolizumab), tumor imaging will be performed during Screening 
(baseline),  at Week 8 (± 7 days), at Week 16 (± 7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) 
CONFIDENTIAL    
Protocol ADXS -503-101 
107 thereafter, until confirmed disease progression or treatment discontinuation, whichever occurs 
later.  
Tumor imaging will occur a t the schedule above, independent of any adjustments to the 
treatment schedule.  
Tumor response will be evaluated by [CONTACT_737] (or designee) according to RECIST  v1.1 as 
the basis for the primary analysis of tumor response -based endpoints. Exploratory analysis of 
tumor -response will be performed by [CONTACT_1034] (or designee) according to iRECIST.  
• In Part A and Part C, s ubjec ts may receive study treatment beyond initial Investigator -
assessed, RECIST  v1.1-defined disease progression, provided the criteria in Section 8.1.[ADDRESS_919880] v1.1 -defined disease progression on treatment with 
pembrolizumab monotherapy  or while receiving combination therapy with pembrolizumab 
+ platinum -based chemotherapy or while receiving  pembrolizumab + pemetrexed as 
maintenance therapy, as the last therapy in the metastatic setting  (if eligibility criteria are 
met). 
• For all subjects  in Parts A, B and C, any apparent CR or PR must be confirm ed ≥4 weeks 
after radiological imaging indicating CR or PR.  
• Subjects who achieve a confirmed CR may receive up to [ADDRESS_919881] subsequently discontinue treatment (see 
Section 8.1). 
• Subjects who achieve a confirmed CR  (Parts A, B and C) , and subjects in Part B or Part C 
who stop trial therapy after 2 years of treatment for reasons other than disease progression 
or intolerability, may be eligible for re -treatment  upon disease progression (with agreement 
between the Investigator and Sponsor) [see Section 8.1]. Tumor response data collected 
during the re -retreatment period will not be used for the primary analysis of tumor resp onse 
endpoints . 
• All subjec ts who complete the first tumor scan after the first dose of study treatment,  will 
be considered evaluable for tumor response.  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919882] v1.1  (primary analysis)  and selectively, as deemed appropriat e 
by [CONTACT_19393]  (exploratory analysis)  (see Section 10.3 and Appendix 10): 
• Best overall response (BOR)  
• Objective response rate  (ORR)  
• Duration of objective response  (DOR ) 
• Disease control rate  (DCR)   
• Progression -free survival (PFS)  
• PFS rate at [ADDRESS_919883] , their physician , or their legally authorized representative 
every 3 months (±2 weeks) for up to 1 year . 
The following efficacy endpoints will be evaluated from the survival data  in Part A, Part B and 
Part C : 
• Overall survival  (OS)  
• 6- and 12-month  overall survival rate s 
Please refer to  Section  10.3 for the definition of survival endpoints and their analysis.  
9.5. Biomarker  Assessments  
• Blood and tumor tissue samples for biomarker research will be collected at the time  points 
specified in the SoA. 
• The volume of blood and tissue to be collected  for biomarker  analysis, and processing and 
shippi[INVESTIGATOR_3931], can be found in the Laboratory M anual.  
• Blood and  tumor  tissue samples may b e stored for a maximum of [ADDRESS_919884] 
subjec t’s last  study  visit at a facility selected by [CONTACT_941] S ponsor to enable further analysis of 
the samples . 
• Blood Sampling for Exploratory Correlates of Immune Response  in Part s A, B and C  
o In Part A , Part B  and Part C , peripheral blood may be collected at Screening and 
during the treatment phase of the study at the time  points specified in the SoA. 
CONFIDENTIAL    
Protocol ADXS -503-101 
109 Peripheral blood mononuclear cells ( PBMCs ) and sera will be prepared for the 
planned immune correlative analyses , as outlined in Section 9.5.1  below . 
• Tumor Biopsy Sampling  
o Exploratory Biomarker  Evaluation  in Part A , Part B  & Part C  
▪ Baseline biopsy sample:  All s ubject s must consent to allow the acquisition 
of fresh or archival FFPE tumor tissue, either a block or unstained slides  
along with matching blood at baseline, for pe rformance of sequencing 
analysis . A fresh tumor biopsy sample must be collected within 28 days (±2 
days) prior to the first dose of study treatment  (baseline)  in Part A and 
within [ADDRESS_919885] recently 
acquired archived tumor biopsy sample may be used for analysis. For 
archived tumor biopsy samples, sufficient tumor samples should be 
acquired to allo w sequencing analysis  (eg, at least unstained  12-15 slides) . 
The archived sample must have been biopsied within 3 years of Screening. 
The baseline tumor biopsy sample (fresh or archived) must be from a 
location that has not been radiated.  
▪ Baseline tumor bi opsy samples  and matching blood for sequencing analysis  
will be evaluated in all patients in the study as outlined in Section 9.5.1  
below.  
o Required Specimen Evaluation for Eligibility in Part C  
▪ Participation in Part C of t his trial will be dependent upon supplying tumor 
tissue from a location that ha s not been radiated. Subject must consent to 
allow the acquisition of fresh or archival FFPE t umor tissue, either a block 
or unstained slides along with matching blood at baseline, for performance 
of sequencing analysis . Biopsies obtained PRIOR to receipt of 
neoadjuvant/adjuvant chemotherapy are NOT permitted. The tumor tissue 
must have  been  previo usly evaluated for expression status of PD -L1 at a 
local laboratory facility using FDA -approved tests . Fine needle aspi[INVESTIGATOR_4026], 
Endobronchial Ultrasound (EBUS) or cell blocks are not acceptable. Needle 
or excisional biopsies, or resected tissue is  required . If the tumor spe cimen 
is not evaluable for PD -L1 expression , an additional tumor specimen must 
be submitted  to the local laboratory  facility for testing with FDA approved 
assays before enrolling . Only subjects whose tumors express PD -L1 (TPS 
CONFIDENTIAL    
Protocol ADXS -503-101 
110 ≥1%), as deter mined by [CONTACT_13247] -approved test  will be eligible for 
enrollment . 
▪ In Part C, d ocumentation of EGFR  mutation and/or ALK transl ocation status 
will be required for subjects with non -squamous NSCLC AND  if clinically 
indicated. If the site is unable to provide thi s source documentation, EGFR / 
ALK testing should be performed per institutional standard of care  using 
FDA -approved tests . 
9.5.1.  Biomarker Evaluation in Part A and Part B  
In Part A  and in up to a total of 25 patients from Part B and Part C, p eripheral blood will be 
collected at Screening and during the treatment phase of the study for correlative work at the time 
points specified in the SoA (Section 2). Peripheral blood mononuclear cells ( PBMCs ) and  sera 
will be prepared for the planned immune correlative analyses.  
Immune Cell Phenotype  
Flow cytometry will be performed on isolated PBMCs to examine the states of 
activation ,differentiation  and cytotoxicity of  various immune cells  in Patient s from Part A and in 
up to a total of 25 patients from Part B and/or Part C .  
Monitoring of T Cell Responses  
At baseline and d uring treatment in  in up to [ADDRESS_919886]’s tumor, to identify subject -specific mutation -
derived antigens , and to determine the subject’s  tumor mutational burden, microsatellite status, 
TCR repertoire, and haplotypes.   
9.6. Pharmacokinetic  Assessments  
Blood samples for pharmacokinetic analysis will not be taken in this study. Pharmacokinetic 
parameters will not be evaluated.  
CONFIDENTIAL    
Protocol ADXS -503-101 
111 9.7. Pharmacodynamic  Assessments  
Pharmacodynamic  parameters  other than biomarkers described in Section 9.5, will  not be 
evaluated in this study.  
9.8. Pharmacogenomic  Assessments  
Pharmaco genomic parameters will  not be evaluated in this study.  
9.9. Health Economic s OR Medical Resource Utilization and Health 
Economic  Assessments  
Health Economics/Medical Resource Utilization and Health Economics paramete rs are not 
evaluated in this study.  
10. Statistical Considerations  
10.1. Sample Size Determination  
Safety Phase  
Up to approximately 24 subjects will be enrolled in the safety phase  in either Part A or Part B  
dose-escalation . 
In Part A, up to approximately 12 subjects will receive treatment with ADXS -503 monotherapy at 
1 of 2 planned escalating dose levels . In Part B  dose-escalation , up to approximately 12 subjects 
will receive treatment with ADXS -503 at 1 of 2 planned escalating dose levels in combination 
with a fixed dose of pembrolizumab . A 3+3 design will be used for dose escalation/ de -escalation 
purposes in Part A and Part B.  
The sample size in Part A and Part B dose-escalation/de -escalation is not based on statistical 
considerations and will be determined by [CONTACT_679815].  
Upon completion of dose escalation in Part A,  ADXS -503 monotherapy may be evaluated in a n 
expansion  cohort . Up to approximately 25 subjects may be enrolled in this expansion cohort . 
Efficacy  Phase  
In the efficacy phase (Part B dose -expansion  and Part C ), up to approximately 165 subjects may 
be enrolled. Up to 43 subjects may be enrolled in Part B expansion of DL1  in the  Simon ’s Two -
stage study cohort and up to a total of 140 thereafter. In addition, a pproximately up to 25 subjects 
may be enrolled in Part C.  
CONFIDENTIAL    
Protocol ADXS -503-101 
112 The sample size in Part B dose -expansion at dose level 1 (DL -1) will use Simon's optimal Two -
stage design (Simon, 1989 ). The null hypothesis is that the true response rate is 0.1, and the 
alternative hypothesis is that the true response rate is 0.25. The Part B dose -expansion will be 
carried out in [ADDRESS_919887] the null hypothesis and claim that the treatment 
is promising. The design controls the type I error rate at 0.05 and yields a power of 0.8.  
 r1 n1 r n Type I error  Power  PET(p0)  EN(p0)  
Optimal  2 18 7 43 0.48 0.8003  0.7338  24.7 
Note: r1 = the first stage threshold to stop the trial for futility; n1 = number of accrual subjects for stage I; n  = total 
number of subjects; r = overall threshold to stop the trial for futility; EN(p0) = expected sample size for the cohort 
when the true response rate is p0; PET(p0) = probability of early termination when the true response rate is p0.  
In Part C, approximately [ADDRESS_919888] the 
sample size and relevant statistical analyses . 
10.2. Populations for Statistical Analyses  
For purposes  of statistical analysis, the following populations are defined  (see Table 10): 
Table 10: Populations for Statistical Analysis  
Population  Description  
All Enrolled Subjects  All subject s who sign the ICF , meet entry criteria and are allocated a 
slot in the study.  
All Treated Subjects  All subject s enrolled in the study who receive at least one dose of study 
treatment.   
Tumor  Response  Evaluable 
Subjects  All subject s in the All Treated Subjects population with at least one 
post-baseline evaluable tumor scan.  
CONFIDENTIAL    
Protocol ADXS -503-101 
113 10.3. Statistical Analyses  
The statistical analysis plan (SAP) will be developed and finalized before database lock to provide 
full details on the study population s, endpoint definitions, analyses and methods . 
Summary statistics for continuous variables will include mean, standard deviation, median and 
range. Categorical variables will be presented as frequency counts and percentages; and time -to-
event variables will be summarized by [CONTACT_5263] -Meier (KM) medians and survival plots. Data 
listings will be created to support tables and figures and to present data.  
Below is a summary of the planned statistical analyses to support the endpoints of this study.  
10.3.1.  Analysis of Safet y 
All safety analyses will be performed on All Treated Subjects and summarized by [CONTACT_679816].  
Adverse events will be summarized (incidence) and listed by [CONTACT_491286] (SOC), 
preferred term, toxicity/severity grade, and Investigator -assigned relationship  to study treatment .  
In addition, separate summaries of SAEs , ESIs  and Grade 3 and 4 AEs will be presented. 
Tabulations  will be limited to treatment emergent events – ie, those with onset anytime during 
study treatment through [ADDRESS_919889]; or if they were present prior to the 
first dose of study treatment and worsened during study treatment as specified above . 
Hematolog ical and chemistry laboratory parameters will be graded according to the CTCAE v.4.03, 
where applicable. Shifts from baseline in severity grade will be tabulated. Absolute values and 
changes from base line will be summarized . 
Vital sign measurements and the  corresponding changes from baseli ne will be summarized using 
descriptive statistics.  
Results of performance status  and physical examinations will be presented in the subject  data 
listings.  
10.3.2.  Analysis of Efficacy  
All efficacy  analyses will be performed on All Treated Subjects and summarized by [CONTACT_679817] .  
Efficacy endpoints will be descriptively summarized by [CONTACT_679818] . Tumor response 
will be summarized according to response category. Objective response rate ( ORR ) and disease 
control rate ( DCR ) will be summarized by [CONTACT_47898]. The KM method will be used to 
estimate progression -free survival ( PFS), PFS rate at 12 months,  overall survival ( OS) and 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919890] 
as stated below may not be conducted.  
[IP_ADDRESS].  Best Overall Response  
Best overall response ( BOR ) will be evaluated for  All Treated Subjects, and if warranted, for 
Tumor  Respon se Evaluable Subjects  according to  RECIST v1.[ADDRESS_919891]. For subjects without confirmed  disease 
progression or subsequent anti -cancer treatment, all available response designations will 
contribute to the BOR assessment.  
[IP_ADDRESS].  Objective Response Rate  
Objective res ponse rate  will be evaluated for All Treated Subjects, and if warranted, for Tumor  
Response Evaluable Subjects  according to  RECIST v1.[ADDRESS_919892]. Objective response rate  is 
defined as  the proportion of subjects who achieve a CR/iCR  or PR /iPR as BOR . 
CR or PR determinations included in the BOR assessment must be confirmed by a confirmatory  
scan ≥[ADDRESS_919893] met.  
[IP_ADDRESS].  Duration of Objective Response  
Duration o f objective response  will be evaluated for subjects  who have a BOR of CR or PR per 
RECIST v1.1, or a BOR of iCR or iPR per iRECIST. Duration of objective response  is defined as 
the time from the date when the criteria are first met for a CR /iCR  or PR /iPR to the first date that 
disease progression is objectively documented , or death  regardless of cause , whichever occurs 
first. 
For subjects who neither progress nor die, the duration of objective response will be censored at 
the same time  as the primary definition of PFS . 
[IP_ADDRESS].  Disease Control Rate  
Disease control rate  will be evaluated for All Treated Subjects, and if warranted, for Tumor  
Response Evaluable Subjects  according to  RECIST v1.[ADDRESS_919894]. Disease control rate  is 
defined as the propo rtion of subjects who achieve a CR /iCR , PR/iPR or SD /iSD ≥24 weeks as  
BOR  (as defined above) . 
CONFIDENTIAL    
Protocol ADXS -503-101 
115 [IP_ADDRESS].  Progression -Free Survival  
Progression -free survival  will be evaluated for All Treated  Subjects  according to  RECIST v1.[ADDRESS_919895] evaluable tumor assessment prior to initiation of 
the subsequent anti -cancer therapy.  
[IP_ADDRESS].  Progression -Free Survival Rate at [ADDRESS_919896]. Progression -free survival  rate at 12 months is defined as the KM 
probability of PFS at 12 months.  
[IP_ADDRESS].  Overall Survival  
Overall survival  will be evaluated for All Treated  Subjects . Overall survival  is defined as the time 
from the date of the first dose of study treatment  to the date of death , regardless of cause. If no 
death date is known for a subject , OS will be censored at the date the subject  is last confirmed to 
be alive . 
[IP_ADDRESS].  Milestone Overall Survival Rate at [ADDRESS_919897] dose of study treatment.  
10.3.3.  Biomarker  Analyses  
The analysis of biomarker  endpoints will be described in the SAP that is finalized before database 
lock. The results of biomarker data  may be presented separately from the main clinical study report 
(CSR).  
CONFIDENTIAL    
Protocol ADXS -503-101 
116 10.3.4.  Interim Analyses  
No formal interim analysis is planned for this study. Administrative interim analyses on safety 
and efficacy may be conducted prior to the completion of the study in order  to facilitate program 
decisions and to support study presentations or publications.  
CONFIDENTIAL    
Protocol ADXS -503-101 
117 11. Regulatory  
See Appendix 3  for information regarding regulatory and ethical considerations, including 
financial disclosure, informed consent pro cess, data protection, publication policy, dissemination 
of clinical study data, data quality assurance, source documents, and study and site closure.  
CONFIDENTIAL    
Protocol ADXS -503-101 
118 12. References  
Actemra®. (2020). (tocilizumab) [prescribing information]. South San Francis co, CA: 
Genentech, Inc.  
.  
Advaxis Internal Data.  
Alamgeer, M., Ganju, V., & Watkins, D. N. (2013). Novel therapeutic targets in non -small cell 
lung cancer. Curr Opin Pharmacol, 13 (3), 394 -401. doi:10.1016/j.coph.2013.03.010  
Alexandrov, L. B., Nik -Zainal,  S., Wedge, D. C., et al. (2013). Signatures of mutational 
processes in human cancer. Nature, 500 (7463), 415 -421. doi:10.1038/nature12477  
American Cancer Society. (2019). Cancer Facts & Figures.   Retrieved from 
https://www.cancer.org/content/dam/cancer -org/research/cancer -facts -and-
statistics/annual -cancer -facts -and-figures/2019/cancer -facts-and-figures -2019.pdf  
Borghaei, H., Paz -Ares, L., Horn, L., et al. (2015). Nivolumab versus Docetaxel in Advanced 
Nonsquamous Non -Small -Cell Lung Cancer. N Engl J Med, 373 (17), 1627 -1639. 
doi:10.1056/NEJMoa1507643  
Brahmer, J., Reckamp, K. L., Baas, P., et al. (2015). Nivolumab versus Docetaxel in Advanced 
Squamous -Cell Non -Small -Cell Lung Cancer. N Engl J Med, 373 (2), 123 -135. 
doi:10.1056/NEJMoa1504627  
Brahmer, J., Rodriguez, A., Robinson, A., et al. (2017). Updated  Analysis of KEYNOTE -024: 
Pembrolizumab vs Platinum -Based Chemotherapy for Advanced NSCLC With PD -L1 
TPS ≥50% . Paper presented at the IASLC 18th World Conference on Lung Cancer; 
October [ADDRESS_919898] OA 17.06 (ID 9582).  
Carter, L. , Fouser, L. A., Jussif, J., et al. (2002). PD -1:PD -L inhibitory pathway affects both 
CD4(+) and CD8(+) T cells and is overcome by [CONTACT_8668] -2. Eur J Immunol, 32 (3), 634 -643. 
doi:10.1002/1521 -4141(200203)32:3<634::AID -IMMU634>3.0.CO;2 -9 
Chan, B. A., & Hughes, B. G. (2015). Targeted therapy for non -small cell lung cancer: current 
standards and the promise of the future. Transl Lung Cancer Res, 4 (1), 36 -54. 
doi:10.3978/j.issn.2218 -6751.2014.05.01  
Chang, J. T., Wherry, E. J., & Goldrath, A. W. (2014). Molecular regulation of effector and 
memory T cell differentiation. Nat Immunol, 15 (12), 1104 -1115. doi:10.1038/ni.3031  
Chang, M. T., Asthana, S., Gao, S. P., et al. (2016). Identifying recurrent mutations in cancer 
reveals widespread lineage di versity and mutational specificity. Nat Biotechnol, 34 (2), 
155-163. doi:10.1038/nbt.[ADDRESS_919899], B., et al. (2012). Listeria monocytogenes -associated joint 
and bone infections: a study of [ADDRESS_919900] Dis,  54(2), 240 -248. 
doi:10.1093/cid/cir803  
Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: the cancer -immunity cycle. 
Immunity, 39 (1), 1 -10. doi:10.1016/j.immuni.2013.07.012  
Dammeijer, F., Lau, S. P., van Eijck, C. H. J., et al. (2017). Rational ly combining 
immunotherapi[INVESTIGATOR_679746]. 
Cytokine Growth Factor Rev, 36 , 5-15. doi:10.1016/j.cytogfr.2017.06.011  
Dominguez, E. A., Patil, A. A., & Johnson, W. M. (1994). Ventriculoperitoneal shunt infe ction 
due to Listeria monocytogenes. Clin Infect Dis, 19 (1), 223 -224.  
Dunn, G. P., Bruce, A. T., Ikeda, H., et al. (2002). Cancer immunoediting: from 
immunosurveillance to tumor escape. Nat Immunol, 3 (11), 991 -998. doi:10.1038/ni1102 -
991 
CONFIDENTIAL    
Protocol ADXS -503-101 
119 Eisenhauer, E. A. , Therasse, P., Bogaerts, J., et al. (2009). New response evaluation criteria in 
solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45 (2), 228 -247. 
doi:10.1016/j.ejca.2008.10.026  
Ferlay, J., et al. (2015). Cancer incidence and mortality w orldwide: Sources, methods and major 
patterns in GLOBOCAN 2012. Int J Cancer, 136 , E359 -E386.  
Freeman, G. J., Long, A. J., Iwai, Y., et al. (2000). Engagement of the PD -1 immunoinhibitory 
receptor by a novel B7 family member leads to negative regulation o f lymphocyte 
activation. J Exp Med, 192 (7), 1027 -1034. doi:10.1084/jem.192.7.1027  
Gandhi, L., Rodriguez -Abreu, D., Gadgeel, S., et al. (2018). Pembrolizumab plus Chemotherapy 
in Metastatic Non -Small -Cell Lung Cancer. N Engl J Med, 378 (22), 2078 -2092. 
doi:1 0.1056/NEJMoa1801005  
Gentzler, R. D., Langer, C. J., Borghaei, H., et al. (2018). 24 -month overall survival from 
KEYNOTE -021 cohort G: Pemetrexed -carboplatin plus pembrolizumab as first -line 
therapy for advanced nonsquamous NSCLC. Journal of Clinical Oncol ogy, 36 (15_suppl), 
9026 -9026. doi:10.1200/JCO.2018.36.15_suppl.9026  
Goodman, A. M., Kato, S., Bazhenova, L., et al. (2017). Tumor Mutational Burden as an 
Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer 
Ther, 16 (11), 2598 -2608. doi:10.1158/[ADDRESS_919901] -17-0386  
Grupp, S. A., Kalos, M., Barrett, D., et al. (2013). Chimeric antigen receptor -modified T cells for 
acute lymphoid leukemia. N Engl J Med, 368 (16), 1509 -1518. 
doi:10.1056/NEJMoa1215134  
Guirnalda, P., Wood, L., Goenka,  R., et al. (2013). Interferon gamma -induced intratumoral 
expression of CXCL9 alters the local distribution of T cells following immunotherapy 
with Listeria monocytogenes. Oncoimmunology, 2 (8), e25752. doi:10.4161/onci.[ZIP_CODE]  
Gunn, R. G. (2001). Recombinant  Listeria monocytogenes as a tumor therapeutic (Doctoral 
dissertation). Dissertations available from ProQuest (Paper), AAJ3O15316.  
Hellmann, M. D., Ciuleanu, T. E., Pluzanski, A., et al. (2018). Nivolumab plus Ipi[INVESTIGATOR_679747] a High Tumor Mu tational Burden. N Engl J Med, 378 (22), 2093 -2104. 
doi:10.1056/NEJMoa1801946  
Herbst, R. S., Baas, P., Kim, D. W., et al. (2016). Pembrolizumab versus docetaxel for 
previously treated, PD -L1-positive, advanced non -small -cell lung cancer (KEYNOTE -
010): a ran domised controlled trial. Lancet, 387 ([ZIP_CODE]), 1540 -1550. doi:10.1016/S0140 -
6736(15)[ZIP_CODE] -7 
Herceptin®. (2020). (trastuzumab) [prescribing information]. South San Francisco, CA. 
Genentech, Inc.  
Hirsh, V., & Melosky, B., eds. (2018). Update on the Treatment  of Metastatic Non -small Cell 
Lung Cancer (NSCLC) in New Era of Personalised Medicine : Lausanne: Frontiers 
Media.  
Hodi, F. S., O'Day, S. J., McDermott, D. F., et al. (2010). Improved survival with ipi[INVESTIGATOR_362]. N Engl J M ed, 363 (8), 711 -723. 
doi:10.1056/NEJMoa1003466  
Jotte, R. M., Cappuzzo, F., Vynnychenko, I., et al. (2018). IMpower131: Primary PFS and safety 
analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or 
nab-paclitaxel vs carboplat in + nab -paclitaxel as 1L therapy in advanced squamous 
NSCLC. Journal of Clinical Oncology, 36 (18_suppl), LBA9000 -LBA9000. 
doi:10.1200/JCO.2018.36.18_suppl.LBA9000  
CONFIDENTIAL    
Protocol ADXS -503-101 
120 Keir, M. E., Butte, M. J., Freeman, G. J., et al. (2008). PD -1 and its ligands in tolerance and 
immunity. Annu Rev Immunol, 26 , 677 -704. 
doi:10.1146/annurev.immunol.26.021607.090331  
Kelly, K., Crowley, J., Bunn, P. A., Jr., et al. (2001). Randomized phase III trial of paclitaxel 
plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with 
advanced non --small -cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol, 
19(13), 3210 -3218. doi:10.1200/JCO.2001.19.13.3210  
Keytruda®. (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: [COMPANY_006] & Co, 
Inc; 2020.  
Langer, C. J., Gadgeel, S. M., Borghaei, H., et al. (2016). Carboplatin and pemetrexed with or 
without pembrolizumab for advanced, non -squamous non -small -cell lung cancer: a 
randomised, phase 2 cohort of the open -label KEYNOTE -021 study. Lancet Oncol, 
17(11), 1497 -1508. doi:10.1016/S1470 -2045(16)[ZIP_CODE] -3 
Latchman, Y., Wood, C. R., Chernova, T., et al. (2001). PD -L2 is a second ligand for PD -1 and 
inhibits T cell activation. Nat Immunol, 2 (3), 261 -268. doi:10.1038/[ZIP_CODE]  
Le Monnier, A., Blanot, S., Abachin, E., et al. (2011). Listeria monocytogenes: a rare 
complication of ventriculoperitoneal shunt in children. J Clin Microbiol, 49 (11), 3924 -
3927. doi:10.1128/JCM.[ZIP_CODE] -11 
Lee, D. W., Gardner, R., Porter, D. L., et al. (201 4). Current concepts in the diagnosis and 
management of cytokine release syndrome. Blood, 124 (2), 188 -195. doi:10.1182/blood -
2014 -05-552729  
Liu, P., Morrison, C., Wang, L., et al. (2012). Identification of somatic mutations in non -small 
cell lung carcinoma s using whole -exome sequencing. Carcinogenesis, 33 (7), 1270 -1276. 
doi:10.1093/carcin/bgs148  
Luo, S. Y., & Lam, D. C. (2013). Oncogenic driver mutations in lung cancer. Transl Respir Med, 
1(1), 6. doi:10.1186/2213 -0802 -1-6 
Maciag, P. C., Radulovic, S., & Ro thman, J. (2009). The first clinical use of a live -attenuated 
Listeria monocytogenes vaccine: a Phase I safety study of Lm -LLO -E7 in patients with 
advanced carcinoma of the cervix. Vaccine, 27 (30), 3975 -3983. 
doi:10.1016/j.vaccine.2009.04.041  
Malhotra, J.,  Jabbour, S. K., & Aisner, J. (2017). Current state of immunotherapy for non -small 
cell lung cancer. Transl Lung Cancer Res, 6 (2), 196 -211. doi:10.[ZIP_CODE]/tlcr.2017.03.01  
Massion, P. P., & Carbone, D. P. (2003). The molecular basis of lung cancer: molecular 
abnormalities and therapeutic implications. Respir Res, 4 , 12. doi:10.1186/1465 -9921 -4-
12 
National Comprehensive Cancer Network (NCCN). (2018). Non -Small Cell Lung Cancer. 
Version 3.2008.   Retrieved from 
https://www.nccn.org/professionals/physician_gls/pdf/nscl  
Nguyen -Ngoc, T., Reck, M., Tan, D., et al. (2017). Immunotherapy and Targeted Therapi[INVESTIGATOR_679748] -small Cell Lung Cancer. European Oncology & Haematology . 
doi:https://doi.org/10.[ZIP_CODE]/EOH.2017.13.01.35  
Oken, M. M., Creech, R. H., Tormey, D. C., et al. (1982). Toxicity and response criteria of the 
Eastern Cooperative Oncology Group. Am J Clin Oncol, 5 (6), 64 9-655.  
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 
Cancer, 12 (4), 252 -264. doi:10.1038/nrc3239  
CONFIDENTIAL    
Protocol ADXS -503-101 
121 Paz-Ares, L. G., Luft, A., Tafreshi, A., et al. (2018). Phase 3 study of carboplatin -paclitaxel/nab -
paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with 
metastatic squamous (Sq) non -small cell lung cancer (NSCLC). Journal of Cl inical 
Oncology, 36 (15_suppl), 105 -105. doi:10.1200/JCO.2018.36.15_suppl.105  
Reche, P. A., & Reinherz, E. L. (2005). PEPVAC: a web server for multi -epi[INVESTIGATOR_679749]. TCGAbiolinks: an 
R/Bioconduct or package for integrative analysis of TCGA data, 33 (suppl_2), W138 -
W142. doi:10.1093/nar/gki357  
Reck, M., Rodriguez -Abreu, D., Robinson, A. G., et al. (2016). Pembrolizumab versus 
Chemotherapy for PD -L1-Positive Non -Small -Cell Lung Cancer. N Engl J Med, 3 75(19), 
1823 -1833. doi:10.1056/NEJMoa1606774  
Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. (2017). Atezolizumab versus docetaxel in 
patients with previously treated non -small -cell lung cancer (OAK): a phase 3, open -label, 
multicentre randomised control led trial. Lancet, 389 ([ZIP_CODE]), 255 -265. 
doi:10.1016/S0140 -6736(16)[ZIP_CODE] -X 
Rizvi, N. A., Hellmann, M. D., Snyder, A., et al. (2015). Cancer immunology. Mutational 
landscape determines sensitivity to PD -1 blockade in non -small cell lung cancer. Science 
([LOCATION_001], NY), 348 (6230), 124 -128. doi:10.1126/science.aaa1348  
Sandler, A., Gray, R., Perry, M. C., et al. (2006). Paclitaxel -carboplatin alone or with 
bevacizumab for non -small -cell lung cancer. N Engl J Med, 355 (24), 2542 -2550. 
doi:10.1056/NEJMoa061884  
Savas , P., Hughes, B., & Solomon, B. (2013). Targeted therapy in lung cancer: IPASS and 
beyond, keepi[INVESTIGATOR_679750]. J Thorac 
Dis, [ADDRESS_919902] 5 , S579 -592. doi:10.3978/j.issn.2072 -1439.2013.08.52  
Scagliotti, G. V.,  De Marinis, F., Rinaldi, M., et al. (2002). Phase III randomized trial comparing 
three platinum -based doublets in advanced non -small -cell lung cancer. J Clin Oncol, 
20(21), 4285 -4291. doi:10.1200/JCO.2002.02.068  
Scagliotti, G. V., Parikh, P., von Pawel, J ., et al. (2008). Phase III study comparing cisplatin plus 
gemcitabine with cisplatin plus pemetrexed in chemotherapy -naive patients with 
advanced -stage non -small -cell lung cancer. J Clin Oncol, 26 (21), 3543 -3551. 
doi:10.1200/JCO.2007.15.0375  
Schiller, J. H., Harrington, D., Belani, C. P., et al. (2002). Comparison of four chemotherapy 
regimens for advanced non -small -cell lung cancer. N Engl J Med, 346 (2), 92 -98. 
doi:10.1056/NEJMoa011954  
Seymour, L., Bogaerts, J., Perrone, A., et al. (2017). iRECIST: guidel ines for response criteria 
for use in trials testing immunotherapeutics. Lancet Oncol, 18 (3), e143 -e152. 
doi:10.1016/s1470 -2045(17)[ZIP_CODE] -8 
Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 
348(6230), 56 -61. doi:10.1126/ science.aaa8172  
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., et al. (2005). Erlotinib in previously treated 
non-small -cell lung cancer. N Engl J Med, 353 (2), 123 -132. doi:10.1056/NEJMoa050753  
Simon, R. (1989). Optimal two -stage designs for phase I I clinical trials. Control Clin Trials, 
10(1), 1 -10. doi:10.1016/0197 -2456(89)[ZIP_CODE] -9 
Smith, M. V., Lee, M. J., Islam, A. S., et al. (2007). Inhibition of the PI3K -Akt signaling 
pathway reduces tumor necrosis factor -alpha production in response to titanium  particles 
in vitro. J Bone Joint Surg Am, 89 (5), 1019 -1027. doi:10.2106/JBJS.F.[ZIP_CODE]  
CONFIDENTIAL    
Protocol ADXS -503-101 
122 Socinski, M., & Kowanetz, M. (2018). IMPower150: efficacy of atezolizumab plus bevacizumab 
and chemotherapy in 1L metastatic nonsquamous NSCLC across key subgroups . Paper  
presented at the AACR 2018 Annual Meeting; April 14 -18, 2018, Chicago, Illinois, [LOCATION_003].  
Sonje, M. B., Abram, M., Stenzel, W., et al. (2010). Listeria monocytogenes (delta -actA mutant) 
infection in tumor necrosis factor receptor p55 -deficient neonatal mice.  Microb Pathog, 
49(4), 186 -195. doi:10.1016/j.micpath.2010.05.012  
Soria, J. C. (2018). Osimertinib in Untreated EGFR -Mutated Advanced Non –Small -Cell Lung 
Cancer. N Engl J Med, 378 (2), 113 -125. doi:10.1056/NEJMoa1713137  
Stein, M., Fong, L., Tutrone, R., et al. (2018). KEYNOTE -046: ADXS -PSA plus pembrolizumab 
(pembro) in m etastatic castration -resistant prostate cancer (mCRPC). J Clin Oncol, 
36(15), 5019. doi:10.1200/JCO.2018.36.15_suppl.5019  
Stinchcombe, T. E. (2007). Targeted therapy of advanced non -small cell lung cancer: the role of 
bevacizumab. Biologics, 1 (3), 185 -194.  
The Cancer Genome Atlas [TCGA]. (2012). Comprehensive genomic characterization of 
squamous cell lung cancers. Nature, 489 (7417), 519 -525. doi:10.1038/nature11404  
The Cancer Genome Atlas [TCGA]. (2014). Comprehensive molecular profiling of lung 
adenocarci noma. Nature, 511 (7511), 543 -550. doi:10.1038/nature13385  
Wallecha, A., Singh, R., & Malinina, I. (2013). Listeria monocytogenes (Lm) -LLO 
immunotherapi[INVESTIGATOR_679751] -derived suppressor 
cells and regulatory T cells in th e tumor microenvironment. J Immunother, 36 (9), 468 -
476. doi:10.1097/CJI.0000000000000000  
Weber, R., Fleming, V., Hu, X., et al. (2018). Myeloid -Derived Suppressor Cells Hinder the 
Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front Immunol, 9 , 1-9. 
doi:10.3389/fimmu.2018.[ZIP_CODE]  
Winkler, U., Jensen, M., Manzke, O., et al. (1999). Cytokine -release syndrome in patients with 
B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an 
anti-CD20 monoclonal antibody (rituximab, ID EC-C2B8). Blood, 94 (7), 2217 -2224.  
Winslow, D. L., & Steele, M. L. (1984). Listeria bacteremia and peritonitis associated with a 
peritoneovenous shunt: successful treatment with sulfamethoxazole and trimethoprim. J 
Infect Dis, 149 (5), 820.  
Wood, L. M., &  Paterson, Y. (2014). Attenuated Listeria monocytogenes: a powerful and 
versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol, 
4(51). doi:10.3389/fcimb.2014.[ZIP_CODE]  
Zappa, C., & Mousa, S. A. (2016). Non -small cell lung cancer: c urrent treatment and future 
advances. Transl Lung Cancer Res, 5 (3), 288 -300. doi:10.[ZIP_CODE]/tlcr.2016.06.07  
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006). Cancer despi[INVESTIGATOR_53899]: 
immunoselection and immunosubversion. Nat Rev Immunol, 6 (10), 715 -727. 
doi:10.1038/nri1936  
 
 
.
CONFIDENTIAL    
Protocol ADXS -503-101 
123 13. Summary of Changes Within Protocol Amendment  4 
# Section  Revision  Rationale  
1 Throughout  • Editorial changes and corrections  
• Part B:  includes 2 parts: dose -escalation (part of Safety Phase) and dose -expansion  of 
dose level 1  (part of Efficacy Phase). Part B -escalation to DL2 is contingent upon 
sponsor’s decision to commence this segment of the study.  
• Revised text and Figure [ADDRESS_919903] updated expansion phase of Part B DL1 
• Part B and Part C : Clarification of eligibility criteria and use of same timepoints for  tumor 
scans and biomarker s in both parts , as priming with ADXS -503 before pembrolizumab is 
no longer needed in Part C .  
• Part B and Part C: Reduced biomarker plan with reduced collection of blood samples, 
mandatory tumor tissue at baseline (archival or fresh) and no on -therapy biopsies  • To provide  additional clarity  
• To expand on prior plans of 
extending investigatio ns of the 
efficacy signals seen in Part B 
safety phase in a dose -
expansion efficacy phase, with 
further details added for clarity 
in this regard . Accrual in Part 
B DL2 may occur pending 
Sponsor decision, however, 
accrual is ongoing in the 
efficacy po rtions  of the study.  
• Confirmatory scans of 
progression are mainly used in 
research studies to characterize 
primary and secondary 
resistance in pts failing 
checkpoint inhibitor (CPI) 
therapy. But, in the clinic, it is 
not always feasible or practical 
to wait for another scan to  start  
rescue therapy just to try to 
document 
“pseudoprogression”, which 
happens in 5% of pts.   
2 Trial Summary/ 
2.2/Figure 1/ 
4/5.1/5.1.3/6.1/  
9.4.1  
Appendix 2  Part B  : Revised  dose-expansion eligibility criteria:  
• Screening (baseline), which corresponds to the most recent tumor assessment that is 
consistent with PD (according to RECIST v1.1) while on treatment with pembrolizumab 
monotherapy as last treatment,  or while receiving combination therapy with 
pembrolizumab + platinum -based chemotherapy  as last treatment  or pembrolizumab + 
pemetrexed as maintenance therapy , as last treatment in the metastatic setting.  
• Subjects receiving pembrolizumab + platinum -based chemotherapy or pembrolizumab + 
pemetrexed, w ill continue pembrolizumab monotherapy every 3 weeks; other drugs • Clarification of patient 
population enrolled, 
especially given recent 
changes in treatment standard 
landscape and 
pembrolizumab’s 
approvals/PI [INVESTIGATOR_679752].  Thus, 
allowing subjects undergoing 
or co mpleted pembrolizumab 
CONFIDENTIAL    
Protocol ADXS -503-101 
124 # Section  Revision  Rationale  
washed -out for 3 weeks.  
• No evidence of rapid disease progression/clinical deterioration that would preclude 
continuation of pembrolizumab monotherapy  for up to [ADDRESS_919904] treatment  
Part B  and Part C :  
• Added: Mandatory f resh or archival formalin -fixed paraffin embedded (FFPE) tumor 
tissue, either a block or unstained slides along with a matching blood at baseline, for 
performance of sequencing analysis.  
• Blood samples for exploratory immune correlative studies (eg, RNAseq, cfDNA,  flow 
cytometry and ELISPOT analysis) may be collected in up to 25 total patients from Part B 
and Part C during Screening, at Week 1, 2, 5, and 8.  To monitor the durability of T cell 
responses, subsequent blood samples for PBMCs may be taken at Week 25 (±1 week) 
and/or at end of treatment.  
• Language removed from inclusion criteria Table 3 for coagulation testing: ”PT/INR and 
aPTT must be measured during Screening. Subsequent testing is to be performed only as if 
clinically indicated”.  
Part C :  
PD-L1 expression in baseline tumor samples changed from ≥50% to Tumor P roportion Score 
(TPS) ≥1% as determined by [CONTACT_13247] -approved test  + platinum -based 
chemotherapy or currently 
receiving pe mbrolizumab + 
pemetrexed as their last 
therapy  
• Coagulation times will not be 
part of eligibility criteria. 
There have been no reports of 
coagulation abnormalities 
associated with 
administration of Lm 
constructs in legacy studies 
nor in the safety phase of this 
study. However, the 
coagulation times can be 
evaluated at any timepoint by 
[CONTACT_737], as clinically 
indicated.  
• PD-L1 TPS ≥1% is FDA 
approved for the use of 
pembrolizumab in first line 
therapy of NSCLC  
3 Trial Summary/  
2.2/ 
3.5/5.1/5.1.3/6.1/  
9.4.[ADDRESS_919905] dose within 12 weeks  of initial tumor assessment 
showing PD (on pembrolizumab monotherapy, pembrolizumab + platinum -based 
chemotherapy and/or  pembrolizumab +  pemetrexed).  Consistent with current clinical 
practice .  
4 Trial Summary/  
Figure 1 /5.1.1  Part B:  Accrual in DL1 dose -expansion and Part C  will occur in parallel , and updating 
Figure with changes related to Part B dose -escalation  and expansion   Clarification  
5 Trial Summary/ 2.2/4 Part C:  Included in Exploratory objectives of correlative studies .  Clarificatio n 
CONFIDENTIAL    
Protocol ADXS -503-101 
125 # Section  Revision  Rationale  
6 Trial Summary/  
2.1/2.2/ 5.1.2/7.1.1/  
7.1.2/7.1.3/9.2.1 .3/ 
[IP_ADDRESS].1.2  Oral antibiotics will be administered starting approximately 48 hours  after each ADXS -503 
infusion instead o f 72 hours.  To further decrease the risk of  
formation of  listeria biofilms  on 
allowed medical devices and/or 
in the development of  delayed 
listeremia . ADXS -[ADDRESS_919906] 
immunogenicity can be elicited 
within this period of time and it 
is not necessary to wait 72 hours 
to start an tibiotics.  
7 Trial Summary/  
5.1/5.1.3/6.1/9.4.1  Part B:  (dose -escalation and dose -expansion) screening/ baseline  tumor imaging is most 
recent tumor assessment consistent with progressive disease (PD) according to RECIST v1. 1 
while receiving pembrolizumab alone, pembrolizumab + platinum -based chemotherapy or 
pembrolizumab + pemetrexed  as maintenance therapy , after platinum -based chemotherapy in 
the metastatic setting.  To confirm PD while on therapy 
with  pembrolizumab 
monothera py or in combination 
therapi[INVESTIGATOR_014] . Definition of PD by 
[CONTACT_393] v1.[ADDRESS_919907] 
clinical practice   
8 Trial Summary/  
9.4.1  Part B:  Screening (baseline), which corresponds to the most recent tumor assessment that is 
consistent with PD (according to RECIST v1.1) while on treatment with pembrolizumab 
monotherapy as last treatment,  or while receiving combination therapy with pembrolizumab + 
platinum -based chemotherapy or pembrolizumab + pemetrexed as maintenance therapy , as 
last treatment in the metastatic set ting. Subsequent scans will be performed in all subjects at 
Week 8 (±7 days), at Week 16 (± 7 days), followed by [INVESTIGATOR_135] 9 weeks (±7 days) after the start 
of ADXS -503 + pembrolizumab until confirmed PD or treatment discontinuation, whichever 
occurs later.  
Part C:  After Screening,  at Week 8 (±7 days), at Week 16 (± 7 days), followed by [INVESTIGATOR_135] 9 
weeks (±7 days) after the start of ADXS -503 + pembrolizumab  until confirmed PD or 
treatment discontinuation, whichever occurs later.  
 
 Standard of clinical practice   
Scans are now conducted at 
similar timepoints in Part B and 
Part C. Data from Part B 
suggests that there is no need to 
prime Part C patients with 
ADX S-[ADDRESS_919908] dose of 
pembrolizumab. Hence, both 
drugs will start on Week 1 in 
patients from Part C as it has 
been done for Part B patients.  
 
   
CONFIDENTIAL    
Protocol ADXS -503-101 
126 # Section  Revision  Rationale  
9 Trial Summary/ 2.2/ 
5.1.3/ 6.1/8.1.1/ 9.4.1  • Parts  A, B, and C: Deleted Tumor imaging must be repeated ≥4 weeks after initial PD 
while on therapy.  
• Removed: In Part A and Part C, tumor imaging must be repeated ≥[ADDRESS_919909]’s clinical condition warrants (see Section 8.1.1 and Section 9.4.1). In Par t B, a 
confirmatory scan will be performed between 4 -8 weeks after the initial assessment of PD 
on treatment with pembrolizumab monotherapy (to confirm PD or determine CR, PR or 
SD), as described above.  
Part B: Deleted requirement for confirmatory scan 4 -8 weeks after the initial assessment 
of PD on pembrolizumab monotherapy.  Following language  was removed : 
• “Only subjects who have progressed within 6 months of starting pembrolizumab 
monotherapy may require a confirmatory scan within 4 -8 weeks after the init ial scan 
showing PD before starting ADXS -503, if the Investigator considers it necessary. ….”  
• Subjects will receive at least four weeks of treatment with ADXS 503 plus pembrolizumab 
before the new confirmatory scan is done. Based on the computer scan the d ecision is 
made to continue study treatment” Under eligibility criteria, “Only subjects who have 
progressed within six months of starting pembrolizumab monotherapy may require a 
confirmatory scan within fou r - eight weeks after the initial scan showing PD and before 
starting advances 503, if the investigator considers it necessary “, has been removed  
 Confirmatory scans of PD are 
not mandatory  in patients   
progressing while on  checkpoint 
point inhibitor (CPI)  as last 
therapy . Confirmatory scans  are 
used in clinical research  to 
characterize primary and 
secondary resistance to CPIs 
(Kluger H et.al.. Journal for 
ImmunoTherapy of Cancer 
2020). The scans can define 
“pseudo progression” in the 
former category, which is an 
event that only happens in 5% of 
patients. And it is unlikely that 
pts with secondary resistance -
who have had a response to 
CPIs for more than [ADDRESS_919910]  
10 Trial Summary  
2/2.2/5.1.3/6.1/9.5 Parts  A, B, and C: Blood and biopsy samples may be collected for correlative studies.  For all 
Part B and Part C patients: Mandatory fresh or archival formalin -fixed paraffin embedded 
(FFPE) tumor tissue, either a block or unstained slides along with a matching blood at 
baseline, for performance of sequencing analysis.  
Added,  “During Screening for subjects in Part B and Part C tumor tissue collection with 
matched blood at screening is mandatory  for all patients in the study. A fresh tumor biopsy 
must be obtained if clinic ally feasible, in the opi[INVESTIGATOR_679753]. If a fresh biopsy cannot be obtained during Screening, the most recently acquired 
archived tumor biopsy sample may be used for analysis (date of biopsy within 3 years of 
Screening). The baseline biopsy must be  from a location that has not been radiated . Sufficient 
tumor samples should be acquired to allow biomarker testing (eg, at least unstained  12-15 
unstained slides). Tumor tissue and matching b lood samples collected during Screeni ng will 
be used for sequencing analysis” . 
 
On-therapy tumor tissues biopsies will no longer be collected between weeks [ADDRESS_919911] informative 
biomarker assessments/  
correlative work for exploratory 
objectives, and clarifications of 
current text .  
It has been challenging to 
collect on -therapy biopsies due 
to the nature and localization of 
the tumors  and the be nefit/risk 
ratio is low.  
Age of archival biopsy accepted 
for eligibility has been extended 
from 2 to 3 years to provide 
flexibility.  
CONFIDENTIAL    
Protocol ADXS -503-101 
127 # Section  Revision  Rationale  
 
Blood samples for exploratory immune correlative studies (eg, RNAseq, cfDNA,  flow 
cytometry and ELISPOT analysis) may be collected in up to 25 total patients from Part B and 
Part C during Screening, at Week 1, 2, 5, and 8. To monitor the durability of T cell responses, 
subsequent blood samples for PBMCs may be taken at Week 25 (±1 week) and/or at end of 
treatment.  Evaluation of cytokines, 
FluoroSpot, 
immunohistochemistry of PD -
L1 at a central lab and multiplex 
immunofluorescence will no 
longer be performed .  
11 Trial Summary  
2.2/6.1 Part B and Part C: Clinical site must provide documentation of tumor PD -L1 expression and 
EGFR mutation and/or ALK translocation status as evaluated by [CONTACT_8415] -approved tests in all 
patients.  B aseline tumor samples must express PD -L1 [TPS (Tumor Proportion Score) ≥1%] 
as determined by [CONTACT_13247] -approved test at a local laboratory facility, with no EGFR or ALK 
genomic tumor aberrations for subjects to be eligible for Part C. If the site is unable to provide 
this source documentation, PD -L1 expression and/or EGFR /ALK testing should be performed 
per institutional standard of care (see Section 9.4.1 and Section 9.5).  Clarification that PD -L1 
expression can be documented 
from the medical records and -if 
not available - to do so by 
[CONTACT_679819] a local 
laboratory facility using FDA 
approved tests.  No central 
laboratory is currently needed to 
test PD -L1, because it is 
standard of care.   
12 2.2/9.5  Part C: Clinical site must provide documentation of tumor EGFR mutation and/or ALK 
translocation status for subjects with non -squamous NSCLC, AND if clinically indicated. If 
the site is unable to provide this source documentation, EGFR /ALK testing should be 
performed per institutional standard of care.  Clarification  
13 2.2/9.5  Part B: dose-expansion: removed Blood samples for cytokine/chemokine and FluoroSpot 
analyses at Screening and on -therapy.    
 
 
 
 
 
 
 
 
 Cytokines were relevant to 
evaluate safety during dose 
escalation .FluoroSpot assays in 
dose escalation and -in some pts 
in Part B dose expansion - 
further documented MOA . 
Collection of blood for 
FluoroSpot and cytokines/  
chemokines  are therefore  no 
longer needed , reduc ing blood 
collection by ~ 160 mL during 
the course of therapy . 
Exploratory objectives  
CONFIDENTIAL    
Protocol ADXS -503-101 
128 # Section  Revision  Rationale  
14 2.2/ 9.5 Part B  dose-expansion and Part C:  Blood samples for exploratory immune correlative 
studies (eg, RNAseq, cfDNA,  flow cytometry) may be collected in up to 25 total patients from 
Part B and Part C during Screening, at Week 1 (ie, right before the first infusion) and 7 days 
(±2 days) after the end of each of the first 3 ADXS -503 infusions (Weeks 2, 5, and 8) and 
EOT. S amples for cfDNA are only collected at week 1 if samples are not collected during 
screening. To monitor the durability of T cell responses, subsequent blood samples for 
PBMCs may be taken at Week 25 (±1 week) and/or at end of treatment  Optimized e xplorator y 
objectives  focusing in 
sequencing and flow cytometry 
analyses of peripheral blood at 
baseline and on -therapy.  These 
will be correlated with 
sequencing analysis of the 
matching tumor tissue at 
baseline  
15 2.3 Deleted  as Combined SoA of Part B and Part C  Evaluation of Scans and 
Biomarkers is now conducted at 
the same timepoints as there is 
no longer priming with ADXS -
503 one week in advance of 
dosing pembrolizumab in Part C 
patients.  
16 3.4.4/ 3.5  Updated clinical experience and safety data  from the ADXS -503-001 Trial  To ensure availability of up -to-
date d ata  
17 4 Part B:  Added “dose escalation” to safety objectives  Clarification  
18 4/5.1.1  Part B:  Added “dose expansion” to efficacy objectives.  Clarification  
19 4 Part C:  Added to objective to characterize subject immunological activity and genomic 
profiles  Exploratory objectives  
20 5.1.2 / 10.1  Part B: Added Part B  dose-expansion to Efficacy Phase  
Part B expansion – Expanding the patient population and enrollment based on Simon ’s Two -
stage  design, where at Stage I of Simon ’s design, 18 subjects will be accrued in this study 
arm. Sponsor may decide to accrue addition al 25 subjects for a total of 43 patients in Stage II.  
Part B study objectives - Include evaluation of preliminary antitumor activity of ADXS - 503 
plus pembrolizumab as a primary objective  
In the efficacy phase (Part B -dose expansion and Part C combined),  up to approximately 165 
subjects may be enrolled. In Part B dose expansion, up to 43 subjects will be enrolled in the 
Simon ’s Two-stage study cohort and up to a total of [ADDRESS_919912] therapy 
at Stage 1. Then, depending on 
the results, the combination 
could be further evaluated in 
Stage 2 an d beyond , if pre -
established GO criteria is met  
CONFIDENTIAL    
Protocol ADXS -503-101 
129 # Section  Revision  Rationale  
21 5.1.3  Added: In “ Part B  dose-expansion and” Part C , ... 
 
“Clinical site must provide documentation of tumor PD -L1 expression and EGFR mutation 
and/or ALK translocation status as evaluated by [CONTACT_8415] -approved tests in Part B and Part C 
patients.  Participation in both parts will be dependent upon supplying tumor tissu e (from 
fresh biopsy or archival) from a location that has not been radiated. Formalin -fixed specimens 
obtained either at the time of or after the diagnosis of metastatic disease will be required for 
performance of sequencing analysis. In Part C, biopsies obtained PRIOR to receipt of 
neoadjuvant/adjuvant chemotherapy are NOT permitted. Only subjects whose tumors express 
PD-L1 (TPS ≥1%) as determined by [CONTACT_679820] -approved test, will be eligible 
for enrollment in Part C. Furthermore, documentati on of EGFR mutation and/or ALK 
translocation status will be required for subjects with non -squamous NSCLC. If the clinical 
site is unable to provide this source documentation, PD -L1 expression and EGFR /ALK testing 
should be performed in all Part C patients  per institutional standard of care using FDA -
approved tests before enrollment. See Section 9.5.  Clarification and addition of 
correlative work  
 
PD-L1 expression with FDA -
approved tests can now be 
conducted at local laboratory 
facilities as it is standard of care. 
No need for central lab testing  
 
PD-L1 expression in baseline 
tumor samples changed from 
≥50% to Tumor Proportion 
Score (TPS) ≥1% as determined 
by [CONTACT_13247] -approved test  
22 5.2.2  Part B  dose-expansion: Added rationale for design  Clarification  
[ADDRESS_919913] before addition of 
pembro based on results from 
Part B  
24 5.3 Increased number of subjects enrolled  Part B expansion following a 
Simon ’s Two-stage design  
25 7.1.2/  
7.1.3  Part C : Starting at Week 1 (±2 days), ADXS -503 and pembrolizumab will be administered on 
the same day  Not necessary to prime with 
ADXS -503 (see 18 above)  
 
CONFIDENTIAL    
Protocol ADXS -503-101 
130 # Section  Revision  Rationale  
26 7.1.2/  
7.1.3  Part B and Part C Infusion of ADXS -503 can be through the infusion line used for 
pembrolizumab.  
A single infusion line can be used for pembro lizumab  and ADXS -503. Language added in 
Section 7.1.2. “For enrolled patients with difficulty to access veins, one infusion line for 
pembrolizumab may be used provided it is  flushed after the pembrolizumab infusion,  at pre-
infusion and post -infusion of ADXS -[ADDRESS_919914] be removed before infusing ADXS -503”. 
 
The central port or ce ntral venous catheter can be used to withdraw blood for correlative 
analysis . 
 There is no reason to have [ADDRESS_919915] ug 
solution, and possibly infection 
at the catheter site can be 
prevented for patients with vein 
access difficulty.  And patients in 
Part B can be with disease 
control on therapy for over a 
year, which prompts the 
clinicians to preserve IV access 
as much as  possible.  
27 Trial Summary/ 2.2/ 
5.1/5.1.3/ 7.1.2  Dosing scheme for Part B and Part C: Upon Investigator assessment and discretion, the 
schedule of therapy with 1x108 CFU of ADXS -503 + [ADDRESS_919916] year of 
therapy Q3W will be enough to 
keep immunogenicit y if we 
reduce the frequency of 
administration of the two drugs 
during the second year.  
28 7.7.1/ 6.2 
[IP_ADDRESS]/ [IP_ADDRESS].1.1  
[IP_ADDRESS].1.2  Added erythromycin and fluoroquinolones as an alternative antibiotic treatment s in subjects 
with known intolerance and/or allergy to Bactrim and ampi[INVESTIGATOR_10312]. The exclusion criteria has 
been modified accordingly.  
 Refer to IB Section 4.2.1; based 
on documenting dual 
hypersensitivity to ampi[INVESTIGATOR_679754]/SMZ  and the activity of 
other antibiotics with anti -
Listeria  effect.  
CONFIDENTIAL    
Protocol ADXS -503-101 
131 # Section  Revision  Rationale  
29 6.2 Exclusion Criteria  
#13 Hernia mesh, and some metal plates are now listed under more com mon devices permitted.  To provide flexibility at 
enrollment without 
compromising safety  
30 2.1, 9.4.2  Added: “•During the Lm surveillance Follow -up Period, subjects will be contact[CONTACT_679821] 3 months (±2 week) for [ADDRESS_919917] experienced for several 
days, the following symptoms that could potentially be associated with delayed listeremia  and 
require prompt attention at the research site : fever or chills, headache, nausea, confusion or 
changes in alertness (for over 72  hours). As part of EOT procedures, upon completing the Lm 
Surveillance period, site staff should instruct subjects to contact [CONTACT_679822], as applicable.  
 Clarification that the follow -up 
period will also include Lm 
monitoring to continue 
assessments for potential 
listeremia during the telephone 
calls or text messages or an app  
inquiring survival status, in 
addition to instructions provided 
to patients following the 1 -year 
follow -up period.   
To provide instructions fo r Lm 
surveillance ( LmS) monitoring  
addressing FDA request 
(emailed August 10, 201 8).  
This for Lm surveillance 
strategy is consistent with the 
agreement between FDA and 
Advaxis of a 1 -year LmS being 
sufficient, per the FDA written 
responses (dated 10 November 
2020) to the questions in a Type 
C Meeting (meeting information 
package submitted in SN0177 to 
IND 13,712).  
31 10.1 Added s ample size calculation for Part B  dose-expansion : 
The sample size in Part B dose -expansion at dose level 1 (DL -1) will use Simon's optimal 
Two-stage design (Simon, 1989 ). The Part B dose -expansion will be carried out in [ADDRESS_919918] the null  hypothesis and claim that the treatment 
is promising. The design controls the type I error rate at 0.05 and yields a power of 0.8.  
 Part B expansion following a 
Simon’s Two -stage design 
based on a target response rate 
of 25%  
CONFIDENTIAL    
Protocol ADXS -503-101 
132 # Section  Revision  Rationale  
 r1 n1 r n Type I error  Power  PET(p0)  EN(p0)  
Optimal  2 18 7 43 0.48 0.8003  0.7338  24.7 
Note: r1 = the first stage threshold to stop the trial for futility; n1 = number of accrual subjects for stage 
I; n = total number of subjects; r = overall threshold to stop the trial for futility; EN(p0) = expected 
sample size for the cohort when the true response rate is p0; PET(p 0) = probability of early termination 
when the true response rate is p0 . 
32 Appendix 4  Added: “Any SAE that occurs within the follow -up period, that is associated  with a case of 
confirmed delayed listeremia during this Lm surveillance study, once becoming aware of any 
blood culture that is positive for Lm during the Lm surveillance monitoring period, must be 
reported within 24 hours to the Sponsor, so that the Spon sor can promptly send a notification 
via email and/or voicemail to both FDA and Centers for Disease Control and Prevention 
(CDC) concurrently, whether or not it fulfills expedited reporting requirements.”  Increased SAE monitoring 
during Lm Surveillance  
 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
133 14. Appendices  
  
CONFIDENTIAL    
Protocol ADXS -503-101 
134 Appendix 1 Abbreviations and Terms  
AE Adverse event  
ALK  Anaplastic lymphoma kinase  
ALT/SGPT  Alanine aminotransferase  
ANC  Absolute neutrophil count  
APC  Antigen presenting cell  
aPTT  Activated partial thromboplastin time  
AST/SGOT  Aspartate transaminase  
β-HCG  Beta human chorionic gonadotropin  
BRAF   B-Raf proto -oncogene  
BCG  Bacillus Calmette –Guérin vaccine  
BSL-[ADDRESS_919919] overall response  
C Degrees Celsius  
CBC  Complete blood count  
cfDNA  Cell free D NA 
CFU  Colony forming units  
cHL chronic Hodgkin lymphoma  
CMP  Complete Metabolic Panel  
CNS  Central nervous system  
CONSORT  Consolidated Standards of Reporting Trials  
CPK  Creatine phosphokinase  
CR Complete response  
eCRF  Electronic case report form  
CrCl  Creatinine clearance  
CRP  C-Reactive Protein  
CRS  Cytokine release synd rome 
CSR  Clinical study report  
CT Computed tomography  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919920]  Hematopoietic stem cell transplant  
IB Investigator’s Brochure  
ICF Informed consent form  
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919921] -level  
NSAID  Non-steroidal anti -inflammatory drug  
NSCLC  Non-small cell lung cancer  
OFA  Oncofetal antigen  
ORR  Objective response rate  
OS Overall survival  
PAMP  Pathogen -associated molecular pattern  
PBMC  Peripheral blood mononuclear cell  
PBS Phosphate buffered saline  
PD Progressive disease  
PD-1 Programmed death receptor -1 
PD-L1/ PD-L2 Programmed death -ligand 1 / Programmed death -ligand 2  
PFS Progression -free survival  
PI3K  Phosphoinositide 3 -kinase  
PK Pharmacokinetic  
PR Partial response  
prn pro re nata; when necessary  
PT Prothrombin time  
RECIST  Response Evaluation Criteria in Solid Tumors  
ROS1  ROS proto -oncogene -[ADDRESS_919922] diameters  
T1DM  Type 1 diabetes mellitus  
t1/[ADDRESS_919923]  Upper limit of normal  
US, [LOCATION_003]  [LOCATION_002] of America  
USP United State Pharmacopeia  
VEGF  Vascular endothelial growth factor  
WBC  White blood cell count  
WHO  World Health Organization  
WOCBP  Women of Child -Bearing Potential  
 
 
  
CONFIDENTIAL    
Protocol ADXS -503-101 
139 Appendix 2 Clinical Laboratory Tests  
• The tests detailed in Table 2.1 and Table 2.2 will be performed by [CONTACT_12357]  
• Laboratory values  for subject  inclusion in the study are detailed in Table 2.1 
• Safety laboratory assessments to be performed during the study are detailed in Table 2.2 
• Additional tests may be performed at any time during the study as deemed necessary by 
[CONTACT_679823]  
• Investigators must document their review of each laboratory report.  
Table 2.1: Organ Function Requirements for Study Inclusion  
System  Laboratory Value  
Hematologic  
Absolute neutrophil count (ANC) a ≥1 x 109/L (Parts A and B); ≥1.5 x 109/L (Part C)  
Platelets a ≥75 x 109/L (Parts A and B); ≥100 x 109/L (Part C)  
Hemoglobin a ≥9 g/dL or ≥ 5.6 mmol/L  
WBC a ≥2000/ µL  
Renal  
Serum creatinine OR 
Measured or calculated creatinine clearance 
(CrCl). Note: GFR can also be used in place of 
serum creatinine or CrCl  ≤1.5 x upper limit of normal (ULN) OR 
 
≥50 mL/min  for subjects with serum creatinine levels >1.[ADDRESS_919924] b 
Hepatic  
Serum total bilirubin  ≤1.[ADDRESS_919925] (except subjects with Gilbert Syndrome, who 
must have total bilirubin <[ADDRESS_919926])  
AST (SGOT) and ALT (SGPT)  <[ADDRESS_919927] (Parts A and B); <1.[ADDRESS_919928] (Part C)  
Endocrine  
Thyroid stimulating hormone (TSH)  Within normal limits (Parts B and C  only). c 
Coagulation  
International Normalized Ratio (INR) or  
Prothrombin Time (PT)  ≤1.[ADDRESS_919929] is receiving anticoagulant 
therapy as long as PT or INR is within therapeutic range of 
intended use of anticoagulants  
aANC, platelets, hemoglobin, or WBC requirement cannot be met by [CONTACT_679804], or growth factor 
support (G -CSF, erythropoietin, etc.) within [ADDRESS_919930] may still be eligible if T3 and free T4 are within normal limits.  
CONFIDENTIAL    
Protocol ADXS -503-101 
140 Table 2.2: Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Platelet Count   RBC Indices : 
Mean Corpuscular 
Volume (MCV)  
Mean Corpuscular 
Hemoglobin (MCH)  
% Reticulocytes  WBC count with 
Differential : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Absolute Neutrophil 
Count (ANC)  Red Blood Count (RBC)  
Hemoglobin  
Hematocrit  
Clinical 
Chemistry  Blood Urea 
Nitrogen (BUN)  Potassium  Aspartate 
Aminotransferase  
(AST)/  Serum 
Glutamic -Oxaloacetic 
Transaminase  (SGOT)  Total bilirubin and 
direct bilirubin (if 
total bilirubin is 
elevated above the 
upper limit of normal)  
 Creatinine  Sodium  Alanine 
Aminotransferase  
(ALT)/  Serum 
Glutamic -Pyruvic 
Transaminase  (SGPT)  Total Protein  
 Glucose  Calcium  Alkaline phosphatase  Lactate dehydrogenase 
(LDH)  
 Carbon dioxide 
(CO 2 or 
bicarbonate)  Chloride    
Routine 
Urinalysis  • Specific gravity  
• Glucose, protein, blood  
• Microscopic examination (if blood or protein is abnormal)  
Other Tests  • Follicle -stimulating hormone and estradiol (as needed for WOCBP only)  
• Urine (confirmed by [CONTACT_679824])  human chorionic gonadotropin 
(βHCG) pregnancy test (as needed for WOCBP only)  
• Coagulation profile (PT/INR and aPTT) is required only at Screening and 
subsequently as clinically indicated  
• Part B and Part C: Total Triiodothyronine (T3) or Free T3 (FT3); Fre e T4, 
Thyroid stimulating hormone (TSH)  
Lm blood 
culture : • A blood sample  will be collected at 7 days (±3 days) after completion of the [ADDRESS_919931] be entered into the eCRF.  
  
CONFIDENTIAL    
Protocol ADXS -503-101 
141 Appendix 3 Study Governance Considerations  
Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
• Consensus ethic al principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences ( CIOMS) International Ethical Guidelines  
• Applicable ICH G ood Clinical Practice  (GCP) Guidelines  
• Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigator Brochure , and other relevant 
documents must be submitted to an IRB/IEC by [CONTACT_112245]/IEC before the study is initiated.  
• Any amendments to the protocol will require IEC/IRB approval before implementation of 
changes made to t he study design, except for changes necessary to eliminate an 
immediate hazard to study participants .  
• The investigator will be  responsible for  the following : 
o Providing written summaries of the status of the study to the IRB/ IEC annually or 
more frequently  in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/EC  
o Notifying the IRB/IEC of SAE or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
o Overall conduct of the study at the site and adherence  to requireme nts of 21 CFR, 
ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if  
applicable), and all other applicable local regulations  
Financial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, acc urate financial 
information in accordance with local regulations to allow the sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing in formation on financial interests during the course of 
the study and for 1 year after completion of the study.  
Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally aut horized representative and answer all  questions regarding 
the study.  
• Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of  informed consent that meets the requirements of [ADDRESS_919932] ( HIPAA ) requirements , where applicable , and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained 
before the part icipant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
CONFIDENTIAL    
Protocol ADXS -503-101 
142 • Participants must be re -consented to the most current version of the ICF(s)  during th eir 
participa tion in the study.  
• A copy of the ICF(s)  must be provided to the participant or the participant’s leg ally 
authorized representative.  
If participants will be asked to consent to optional exploratory research using the remainder of 
mandatory samples, include text that addresses the use of remaining mandatory samples for 
optional exploratory research.  
The ICF will contain a separate section that addresses the use of remaining mandatory samples 
for optional exploratory research. The investigator or authorized de signee will explain to each 
participant the objectives of the exploratory research. Participants will be told that they are free 
to refuse to participate and may withdraw their specimens at any time and for any reason during 
the storage period. A separate signature [CONTACT_22862] a participant's agreement to 
allow any remaining specimens to be used for exploratory research. Subjec ts who decline to 
participate in optional exploratory research will not provide this separate signature.  
Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_456]. Any participant records 
or datasets that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identi fiable will not be 
transferred.  
• The participant must be informed that his/her personal study -related data will be used by 
[CONTACT_10999]. The level of disclosure must 
also b e explained to the part icipant.  
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_336110]. 
Publication Policy  
• The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect  proprietary information and to 
provide comments.   
• The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multicenter stu dies only in their entirety and not as individual site data. In 
this case, a coordinating investigator [INVESTIGATOR_12992].  
• Authorship will be determined by [CONTACT_679825].  
Dissemination of Clinical Study Data  
This study will be registered and results posted on www.clinicaltrials.gov . The sponsor has 
proprietary interest in the study. Authorship and manuscript composition will reflect joint 
CONFIDENTIAL    
Protocol ADXS -503-101 
143 coope ration between study investigator(s) and sponsor personnel. Authorship will be established 
prior to the writing of the manuscript. As this study may be multicenter, no individual 
publication will be allowed prior to completion of the final report of the mu lticenter study, 
except as agreed with the sponsor.  
Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor  or designee electronically ( eg, laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
[CONTACT_617880].  
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• The inve stigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections  and provid e direct access to source data documents.  
• The sponsor  or designee is responsible for the data management of this study includin g 
quality che cking of the data.  
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
• Records and documents, including signed ICF , pertaining to the conduct of this study 
must be retained by [CONTACT_679826], institution procedures, or the period 
specified by [CONTACT_456] , whichever is lon ger. No records may be destroyed during the 
retention period without  the written approval of the sponsor . No records may be 
transferred to another location or party without written notification to the sponsor.  
Source Documents  
• Source documents provide evid ence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the investigator’s site.  
• Data reported on the CRF  or entered in the eCRF  that are transcribed from source 
documents must be consis tent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.  
Study and Site Closure  
The sponsor or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
CONFIDENTIAL    
Protocol ADXS -503-101 
 
144 Appendix 4 Adverse Events: Definition s and Procedures for Recording,  
Evaluating, Follow -up and Reporting  
Definition of AE 
AE Definition  
• An AE is any untoward medical occurrence in a patient  or clinical study participant, 
temporally associated with the use of a medicinal product, whether or not considered related 
to the medicinal product.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory findin g), symptom, or disease (new or exacerbated) temporally associated with 
the use of a medicinal product.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments ( eg, radiological scans, vital signs measurements), including those that 
worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the Investigator (ie, not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase 
in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even though it 
may have been present bef ore the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 
Events NOT  Meeting the AE D efinition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
which are asso ciated with the underlying disease, unless judged by [CONTACT_679827]’s condition.  
• The disease/disorder being studied or expected progression.  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or cond ition(s) present or 
detected at the start of the study that do not worsen.  
 
 
 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
145 Events Meeting the ESI Definition for this Trial  
• Signs and symptoms during or after treatment infusion : Any of the following 
events , if they were  considered to be treatment -related and began within 24 hours 
after study treatment, and were ≥ Grade 3:  hypotension, hypoxia, encephalopathy 
or organ toxicity .  
• Immune -related adverse events (irAE): ≥Grade 3  treatment -induced events  (acute, 
sub-acute or la te occurring)  that involve inflammatory reactions that were 
mediated through the action of T cells on the subject’s tissues or organs . 
• Delayed listeremia: The presence of Lm in a blood culture after treatment with 
ADXS -503. Once becoming aware of any blood  culture that is positive for Lm 
during the Lm surveillance monitoring period , the Sponsor must be notified 
within 24 hours so that the Sponsor can promptly send a notification via email 
and/or voicemail to both FDA and Centers for Disease Control and Prevention 
(CDC) concurrently, whether or not it fulfills expedited reporting req uirements. 
Additional testing may be performed by [CONTACT_679828]-based immunotherapy 
drug. NOTE: this does not include the presence of Lm in a blood culture 
within the first [ADDRESS_919933] me dical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires  inpatient  hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually involving at 
least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that 
CONFIDENTIAL    
Protocol ADXS -503-[ADDRESS_919934] been appropriate in the physician’s office or outpatient setting. Complications 
that occur during hospi[INVESTIGATOR_42244]. If a complication prol ongs hospi[INVESTIGATOR_679755], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” 
occurred or was necessary, the AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing co ndition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent  disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting,  diarrhea , influenza, and 
accidental trauma ( eg, sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial and persistent disruption . 
e. Is a congenital anomaly/birth defect  
f. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate i n other situations such as important medical events that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_679756] l isted in 
the above definition. These events should usually  be considered serious . 
Examples of such events include  intensive treatment in an emergency room or at home for 
allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_18543], 
or development of drug dependency or drug abuse . 
Recording AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, i t is the responsibility of the I nvestigator to review all 
documentation ( eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to the 
event.  
• The I nvestigator will then record all relevant AE/SAE information in the eCRF . 
• It is not acceptable for the I nvestigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor  in lieu of completion of the AE/SAE eCRF page.  
• There may be instances when copi[INVESTIGATOR_679757] . In this case, all participant identifiers, with the exception of the 
participant number, will be blinded on the copi[INVESTIGATOR_679758] . 
• The I nvestigator will attempt to establish a diagnosis of the event based on signs, symptom s, 
and/or other clinical information. In such cases, the diagnosis (not the individual 
signs/symptoms)  will be documented as the AE/SAE . 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
147 Considerations for reporting treatment -related toxicity  
• Investigators must  use their best judgement to appropriately co de and treat individual 
AEs that occur during or after treatment infusion .  In particular, it’s important to 
record individual components of AEs that occur on the day of dosing. Instead of 
groupi[INVESTIGATOR_679759], such as “infusio n reaction” or 
“cytokine release syndrome”, each term must be reported as a verbatim AE term 
with an assessment of severity, seriousness, and relationship to study treatment.  This 
reporting is important, because it provides essential information regarding  the nature 
of observed toxicity, and facilitates the application of appropriate and specific 
management strategies . 
 
Assessment of Intensity  
National Cancer Institute Common Terminology Criteria for Adverse Events ( NCI-CTCAE 
v4.03 ) will be used to evaluate AEs and SAEs.  
Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique 
clinical descriptions of severity for each AE based on this general guideline:  
 
Grade 1 : Mild; asymptomatic or mild symptoms ; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2 : Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL*.  
Grade 3 : Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabl ing; limiting self -care ADL**.  
Grade 4 : Life-threatening consequences; urgent intervention indicated.  
Grade 5 : Death related to AE.  
 
A Semi -colon indicates ‘or’ within the description of the grade.  
A single dash ( -) indicates a grade is not available.  
Activities of Daily Living (ADL)  
 *Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing money, 
etc.  
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medica tions, and not 
bedridden.  
 
Assessment of Causality  
• The I nvestigator is obligated to assess the relationship between study treatment and each 
occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship convey s that there are facts , evidence , and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The I nvestigator will use clinical judgment to determine the relationship.  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
148 • Alternative causes, such as underlying disease (s), concomitant therapy, and other risk 
factors, as well as  the temporal relationship of the event to study treatment administration 
will be considered and investigated.  
• The I nvestigator will also consult the IB / Product Label  (if applicable)  in his/her assessment.  
• For each AE/SAE , the Investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred , and the Investigator has minimal 
information to include in the initial report to the EDC tool. However, it is very important 
that the Investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the EDC tool . 
• The Investigator may change his/her opi[INVESTIGATOR_9242] -up information 
and send an SAE follow -up report with the updated causality assessment . 
• The causality assessment is one of the criteria used when determining regulator y reporting 
requirements.  
 
Follow -up of AE and SAE  
• The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_679829]/or causality of the AE or 
SAE as fully as possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study  or during a re cognized follow -up 
period, the I nvestigator will provide a certificate of death, if available.  
• New or updated information will be recorded in the originally completed eCRF.  
• The I nvestigator will submit any updated SAE data to the EDC tool within 24 hours of 
receipt of the information from the time the consent /assent  is signed through [ADDRESS_919935] dose  of study treatment, regardless of relatedness.  
Reporting of SAE  to the Sponsor  or Designee  
SAE Reporting to Sponsor  
• If a site receives a report of a new SAE from a study participant or receives updated data on 
a previously reported SAE , the site can report this information to the sponsor appointed 
Pharmacovigilance service provider.  Detailed instructions for such reporting will be 
provided separately to sites.   
• Adverse reactions will be reported  to FDA according to 21 CFR 312.32 . 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
149 Appendix 5 Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following m enarche and until becoming post menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpi[INVESTIGATOR_1656], and bilateral oophorectomy.  
Women in the following cate gories are not considered WOCBP  
1. Premenopausal female with 1 of the fol lowing:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
Note:  Documentation can come from the site personnel’s: (1) review of participant’s 
medical records ; (2) medical examination ; or (3) medical history inter view.  
2. Premenarchal  
 
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a postmenopausal state in women not 
using hormonal contrac eption or hormonal replacement therapy (HRT). However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
 
• Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non -hormonal highly effe ctive contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.  
Contraception Guidance  
• Male participants with female partners of c hild-bearing potential are eligible to 
participate in this study if they agree to use a highly effective method of contraception 
during the treatment period and for at least [ADDRESS_919936] dose of study 
treatment.  
 
• Women of childbearing potential are eligible to participate in this study if they agree to 
use 2  highly effective methods of contraception consistently and correctly as described 
in the table below.  
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
150 Highly Effective Contraceptive Methods That Are User Dependent  b 
Failure rate of <1% per year when used consistently and correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition 
of ovulation  
• oral 
• intravaginal  
• transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation  
• oral 
• injectable  
Highly Effective Methods That Are User Independent  b 
• Implantable progestogen -only hormonal contraception associated with inhibition of ovulation  
• Intrauterine device (IUD)  
• Intrauterine  hormone -releasing system (IUS)  
• bilateral tubal occlusion  
• Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.   
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The reliability 
of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and 
usua l lifestyle of the participant.   
NOTES:  
a) Typi[INVESTIGATOR_35818]. Use should be 
consistent with local regulations regarding the use of contraceptive methods for clinical study 
participants .  
b) Two highly effective methods of contrac eption should be utilized during the treatment period and for 
at least [ADDRESS_919937] dose of study treatment .  
 
Pregnancy Testing  
• WOCBP  will only be included in the study after a negative highly sensitive pregnancy test . 
• Additional pregnancy tes ting should be performed as described in the SoA and as required 
locally. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy 
test will be required.  
• Pregnancy testing, with a minimum sensitivity of  25 IU/L or equivalent units of βHCG will 
be performed locally.  
Collection of Pregnancy and Lactation Information  
• The Investigator will collect pregnancy/lactation information on any female participant or 
female partner of a male participant who becomes pregnant or breastfeeds while 
participating in this study and for at least [ADDRESS_919938] dose of study treatment.  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
151 • Information will be recorded on the appropriate form and submitted to the Sponsor 
appointed Pharmacovigilance provider  within 24 hours of learning of a participant's 
pregnancy or lactation case.  
• The pregnancy will be followed to determine the outcome of the pregnancy. The 
Investigator will collect follow -up information on the participant and neonate, which will be 
forwarded to the Sponsor appointed Pharmacovigilance provider . Generally, follow -up will  
not be required for longer than 6 to 8 weeks beyond the estimated delivery date.  
• Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.  
• While pregnancy and lactation itself are not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or SAE.  
• A spontaneous abortion is always considered to be an SAE and will be reported as such.  
• Any SAE occur ring as a result of a post -study pregnancy which is considered reasonably 
related to the study treatment by [CONTACT_737], will be reported to the EDC tool  as 
described in Appendix 4 . While the Investigator is not obligated to actively seek this 
information in former study participants, he/she may learn of an SAE through spontaneous 
reporting.  
Any female participant who becomes pregnant or breastfeeds  while participating in this study 
will discontinue study treatment.  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
152 Appendi x 6 Recommended Management Guidelines for Infusion Reactions   
NCI CTCAE v4.03 Grade  Management  
Grade 1   
Mild transient reaction; infusion interruption not 
indicated; intervention not indicated.  Increase monitoring of vital signs as medically indicated until the subject  is deemed 
medically stable in the opi[INVESTIGATOR_689].  
Grade 2   
Therapy or infusion interruption indicated but 
responds promptly to symptomatic treatment (eg, 
antihistamines, NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated for ≤24  hrs. 1. Stop Infusion and monitor symptoms.  
Additional appropriate medical therapy may include but is not limited to:  
 IV fluids  
 Antihistamines  
 NSAIDS  
 Acetaminophen  
 Narcotics  
2. Increase monitoring of vital signs as medically indicated until the subject  is 
deemed medically stable in the opi[INVESTIGATOR_689].  
 
If symptoms resolve within one hour of stoppi[INVESTIGATOR_679760], the infusion may be 
restarted at 50% of the original infusion rate. Otherwise dosing will be held until 
symptoms resolve and the subject  should be pre -medicated for the next scheduled dose . 
ADXS -503-Related : continue with protocol -described pre -medication for next infusion . 
Pembrolizumab -Related:  Subject may be pre -medicated 1.5 h (+/ - 30 mins) prior to the 
next infusion with:  
• Diphenhydramine 50 mg orally (or equivalent dose of antihistamine)  
• Acetaminophen 500 -1000 mg orall y (or equivalent dose of antipyretic)  
If despi[INVESTIGATOR_679761] -medication the subject developments recurrent  Grade [ADDRESS_919939]  should be permanently discontin ued from pembrolizumab treatment.  
 
Grade 3   
Prolonged (eg, not rapi[INVESTIGATOR_86025]/or brief interruption of 
infusion); recurrence of symptoms following initial 
improvement; hosp italization indicated for clinical 
sequelae . 
 
 
 
 
 
 
 1. Stop Infusion  and monitor symptoms . 
Additional appropriate medical therapy may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Epi[INVESTIGATOR_238]  
2. Increase monitoring of vital signs as medically indicated until the subject  is 
deemed medical ly stable in the opi[INVESTIGATOR_689].   
3. Hospi[INVESTIGATOR_13021].   
ADXS -503-Related : Subjects who experience a Grade 3 infusion -related toxicity that is 
considered by [CONTACT_679830] -503, may be discontinued from 
study treatment. Discussion with the Sponsor is recommended.  
Pembrolizumab -Related: Subjects who experience a Grade 3 infusion -related  toxicity 
that is considered by [CONTACT_679831], should be 
permanently discontinued from pembrolizumab treatment.  
Grade 4  
Life-threatening  consequences ; urgent intervention 
indicated .  
Subject s who experience a Grade [ADDRESS_919940] ug administration.  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
153 Appendix 7 Grading and Management Guidelines for Acute Hypotension, Hypoxia, Encephalopathy, 
Organ Toxicity, Fever and Constitutional Symptoms  
The grading scale and toxicity management criteria below are adapted from criteria proposed by [CONTACT_38181]:  Chimeric Antigen Receptor 
(CAR) Cell Therapy Toxicity Assessment and Management - Adult  (10/31/2017)  
Table 7.1. Grading Scale for Hy poxia, Hypotension, and Organ Toxicity  
Grade  Description of Severity  
1 Fever (temperature > 38○C) or Grade 1 organ toxicity  
2 Symptoms require and respond to moderate intervention  
Oxygen requirement FiO 2 < 40%,  and/or subject requires intermittent supplemental oxygen,   
              OR 
Hypotension responsive to IV fluids or low -dose of one vasopressor to maintain systolic blood pressure > 90 mmHg,  
 OR 
Grade 2 organ toxicity  
3 Needs oxygen to maintain O 2 saturation > 90% Oxygen requir ement FiO 2 ≥ 40% and/or requiring BiPAP,  
 OR 
Hypotension  refractory to management for Grade 2 or where hospi[INVESTIGATOR_59029] ,  
 OR 
Grade 3 organ toxicity or Grade 4 transaminitis per CTCAE v4.03  criteria  
4 Life-threatening signs and symptoms  
 OR 
Requirement for ventilator support to maintain O 2 saturation > 90%   
 OR 
Grade 4 organ toxicity (excluding Grade 4 transaminitis) per CTCAE v4.03 criteria  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
154 Table 7.2. Management Guidelines for Acute Hypotension, Hypoxia, Organ Toxicity, Fever and 
Constitutional Symptoms  
 
Toxicity 
Grade  Sign/Symptom  Treatment  Instructions for Interruption 
of ADXS -503  Modification for 
Subsequent infusions  
1 Hypotension  • Supportive care  Not applicable  • Increase pretreatment 
IV fluids ( eg, 500 ml 
-1L normal saline)  
1 Fever;  
Constitutional symptoms;  
Grade 1 organ toxicity  • Symptomatic management of 
constitutional symptoms and organ 
toxicity  
• Acetaminophen and hypothermia 
blanket as needed for fever  
• Ibuprofen if fever is not controlled 
with above, use with caution or 
avoid if thrombocytopenic  
• IV fluids as needed  
• Consider the IL -[ADDRESS_919941] 
tocilizumab  for persistent (>3 days) 
or refractory fever  
 
 
 
 
 
 
 Not applicable  • No modification  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
155 Toxicity 
Grade  Sign/Symptom  Treatment  Instructions for Interruption 
of ADXS -503  Modification for 
Subsequent infusions  
 
2  
Hypotension  • Fluids (500 – 1000 mL normal 
saline to keep systolic blood 
pressure > 90 mmHg)  
• If hypotension persists despi[INVESTIGATOR_679762] a low dose pressor, 
administer the IL -[ADDRESS_919942] 
tocilizumab (8 mg/kg IV over 1 
hour)  
• If hypotension persists after IV flu id 
bolus, administer a vasopressor ( eg, 
epi[INVESTIGATOR_238] 0.5 mg IM), and 
consider transfer to ICU  
• If hypotension persists despi[INVESTIGATOR_126863], treat with a high -dose 
corticosteroid.  
•  If there are signs of hypo -perfusion 
or if there is rapid deterioration i n 
the opi[INVESTIGATOR_107832], may use 
dexamethasone 10 mg IV every 6 
hours  
• Increase frequency of monitoring 
vital signs  
 
 
 
 
 
 • Immediately interrupt 
ADXS -503 until AE(s) 
resolve to Grade ≤ 1 but for 
no less than 72 hours  
 
• Permanently discontinue 
ADXS -503 if there is no 
improvement of AE(s) to ≤ 
Grade 1 within 7 days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 • Extend infusion time 
to 2 hours  
• Increase pretreatment 
IV fluids ( eg, 500 m L 
– 1L normal saline)  
• Incorporate 
Glucocorticoid - 
Hydrocortisone or 
equivalent - 50 mg, 
IV, as premedication  
 
2 Hypoxia  • Use supplemental oxygen as needed  • No modifications  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
156 Toxicity 
Grade  Sign/Symptom  Treatment  Instructions for Interruption 
of ADXS -503  Modification for 
Subsequent infusions  
 
 
 
  
 
 
 • Use tocilizumab 8 mg/kg IV with or 
without corticosteroids as with 
Grade 2  hypotension  (described 
above)  
• Increase frequency of monitoring 
vital signs  
• Restrict the administration of IV 
fluid if possible  See above  • Discussion with 
Sponsor 
recommended  
2 
 
 
 
 
 
 
 
 Fever,  
Constitutional symptoms; 
Grade 2 organ toxicity  
 
 
 
 
  
• Appropriate supportive care  
• Manage organ toxicity as per 
standard guidelines  
• Use tocilizumab 8 mg/kg IV  with or 
without corticosteroids as described 
above for Gr ade 2 hypotension  
• Manage fever and constitutional 
symptoms as noted above for Grade 
1 toxicity  
 
 
 
 
 
 
  
• Extend infusion time 
to 2 hours  
• Consider increasing 
doses of prophylactic 
medications  
• Discussion with 
Sponsor 
recommended, but 
not required  
3 
 Hypotension  
 • IV fluid bolus (as for Grade 2 
hypotension) and tocilizumab 
(8mg/kg IV over 1 hour)  • Immediately interrupt 
ADXS -503  • Discuss with Sponsor  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
157 Toxicity 
Grade  Sign/Symptom  Treatment  Instructions for Interruption 
of ADXS -[ADDRESS_919943]’s hemodynamic status.  
However, IV fluid 
administration in the presence of 
hypoxia may lead to increased 
pulmonary edema (see guidance 
for hypoxia above)  
o Tocilizumab IV may not be 
administered if it was used 
within the previous 8 hours  
• Transfer subject for inpatient 
management  
• High dose vasopressors ( eg, 
Dopamine 10 µg/kg/min)   
• If hypotension worsens or is 
unresponsive to above measures, 
administer high dose corticosteroids 
(methylprednisolone or 
dexamethasone)  
• Monitor for neurologic signs and 
symptoms.  Consult neurology to 
assess for signs of elevated 
intracranial pressure  (eg, 
papi[INVESTIGATOR_044]) /cerebral involvement . 
See Table s 7.3 and 7.4 below for 
grading and management of 
encephalopathy   
• Increase frequency of monitoring 
vital signs  • Permanently discontinue 
ADXS -503 if there is no 
improvement in AE(s) to ≤ 
Grade 2 within 5 days or 
AE ≤ Grade 1 within 7 days  
 
 
 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
158 Toxicity 
Grade  Sign/Symptom  Treatment  Instructions for Interruption 
of ADXS -503  Modification for 
Subsequent infusions  
3 Hypoxia  • Use supplemental oxygen  
• Use tocilizumab 8 mg/kg IV with or 
without corticosteroids as in 
hypotension  
• Increase frequency of monitoring 
vital signs  
• Restrict the administration of IV 
fluid if possible  • Immediately interrupt 
ADXS -503  
 • Discuss with Sponsor  
3 Fever,  
Constitutional symptoms; 
Grade 3 organ toxicity  
 • Appropriate supportive care  
• Manage organ toxicity as per 
standard guidelines  
• Use tocilizumab 8 mg/kg IV , 
corticosteroids  
• Manage fever and constitutional 
symptoms above for Grade 1 
toxicity  • Immediately interrupt 
ADXS -503  
 • Discuss with Sponsor  
4 Hypotension  • IV fluid bolus (as for Grade 2 
hypotension) and tocilizumab  
• High -dose methylprednisolone  • Immediately interrupt 
ADXS -503  
 • Permanently 
discontinue ADXS -
503 
4 Hypoxia  • Mechanical ventilation  
• Tocilizumab, high -dose 
methylprednisolone, and supportive 
care • Immediately interrupt 
ADXS -503  
 • Permanently 
discontinue ADXS -
503 
4 Fever,  
Constitutional symptoms; 
Grade 4 organ toxicity  • Appropriate supportive care  
• Manage organ toxicity as per 
standard guidelines  • Immediately interrupt 
ADXS -503  
 • Permanently 
discontinue ADXS -
503 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
159 Toxicity 
Grade  Sign/Symptom  Treatment  Instructions for Interruption 
of ADXS -503  Modification for 
Subsequent infusions  
 • Tocilizumab, high -dose 
methylprednisolone, and supportive 
care  
• Manage fever and constitutional 
symptoms as noted for Grade 1 
above  
• Increase frequency of monitoring 
vital signs  
 
* Tocilizumab is a humanized, immunoglobulin G1k (IgG1k) anti -human IL -6R mAb approved for treatment of adult patients with moderately to severely active 
rheumatoid arthritis (RA) who have had an inadequate response to Disease -Modifying Anti -Rheumatic Drug s (DMARDs), for the treatment of active 
polyarticular juvenile idiopathic arthritis (PJIA), and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 ye ars of age and older, and for the treatment 
of adults and pediatric patients 2 years of age  and older with chimeric antigen receptor (CAR) T cell -induced severe or life -threatening cytokine release 
syndrome.  
 
Tocilizumab works by [CONTACT_43629] -6 binding to both cell -associated and soluble IL -6 receptors  (Actemra®, 2020 ; Grupp 2013 ; Lee 
2014 ; Winkler 1999 ). 
 
Dosing guidelines for tocilizumab are provided below.  
 
Tocilizumab Dosing Guidelines  (Actemra®, 2020 ) 
 
• 8 mg/kg IV; maximum dose/infusion = 800 mg . 
 
• If the subject’s condition does not improve or stabilize within 8 hours of the tocilizumab dose, administration of a second dose 
of tocilizumab should be considered.  A total of three doses can be administered in a 24 -hour period (maximum 800 mg/dose), 
and a maximum of 4 doses total can be a dministered . 
 
• Tocilizumab may  be administered with corticosteroids.  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
160 Table 7.3. Grading Scale for Encephalopathy  
Grade  Description of Severity  
1 Neurological assessment score (see below) – Mild (7 -9) 
2  Neurological assessment score (see below) – Moderate (3 -6) 
3 Neurological assessment score (see below) - Severe (0 -2) 
OR 
Stage 1 or 2 papi[INVESTIGATOR_044]1 with CSF opening pressure less than 20 mmHg  
4 Neurological assessment score Critical / obtunded  
OR 
Stage 3, 4, or 5 papi[INVESTIGATOR_044]1 or CSF opening pressure greater than or equal to 20 mmHg or cerebral edema  
CARTOX 10 -point neurological assessment (Assign one point for each task performed correctly; score of 10 = normal)  
● Orientation to year, month, city, hospi[INVESTIGATOR_307], President: 5 points  
● Name 3 objects (point to clock, pen, button): 3 points  
● Ability to write a standard sentence ( eg, Our national bird is the bald eagle): 1 point  
● Count backwards from 100 by [CONTACT_134218]: 1 point  
1 Papi[INVESTIGATOR_679763]én scale  
CSF = cerebrospi[INVESTIGATOR_679764] -503-101 
 
161 Table 7.4. Management Guidelines for Encephalopathy  
 
Toxicity  Grade  Treatment  Instructions for 
Interruption of ADXS -503 Modification for 
Subsequent Infusions  
1 ● Vigilant supportive care; aspi[INVESTIGATOR_134174]; IV 
hydration  
● Withhold oral intake of food/medicines/fluids and assess 
swallowing  
● Convert all oral medications and/or nutrition to IV if 
swallowing is impaired         
● Avoid medications that cause CNS depressi on     
● Low doses of lorazepam (0.25 -0.5 mg IV every 8 hours) 
or haloperidol (0.5 mg IV every 6 hours) may be used for 
agitated patients with careful monitoring                       Not applicable  Discuss with Sponsor  
 ● Neurology consultation                                 
● Daily CARTOX 10 -point neurological assessment as in 
Table 7.3                           
● Fundoscopic exam to assess for papi[INVESTIGATOR_044]  
● MRI brain with and without contrast; diagnostic lumbar 
punctur e with OP; MRI spi[INVESTIGATOR_679765]; CT of 
brain may be performed if MRI brain is not feasible             
 
 
 
   
CONFIDENTIAL    
Protocol ADXS -503-101 
 
162 Toxicity  Grade  Treatment  Instructions for 
Interruption of ADXS -503 Modification for 
Subsequent Infusions  
2 ● Supportive care and neurological workup as per Grade 1  
● IL-[ADDRESS_919944]  (tocilizumab1), if associated with other 
events such as refractory hypotension and/or hypoxia  
● Dexamethasone or methylprednisolone if refractory to 
tocilizumab1 therapy, when it is administered  
● Consider ICU transfer if associated with other events 
such as hypotension or hypoxia  • Immediately interrupt 
ADXS -503  
 Discuss with Sponsor  
3 ● Supportive care and neurological workup as per Grade 1  
● ICU transfer is recommended  
● Tocilizumab1, if associated with concurrent refractory 
hypotension and/or hypoxia and if not administered 
previously  
● Dexamethasone or methylprednisolone around the clock, 
if symptoms worsen despi[INVESTIGATOR_679766]. Continue 
corticosteroids until improvement to Grade 1 and then taper 
or stop.  
● Low grade (Stage 1 or 2) papi[INVESTIGATOR_679767] 20 mmH g, acetazolamide as per Institutional 
guidelines  
● Consider repeat neuro -imaging (CT or MRI) every 2 -3 
days if persistent event greater than or equal to Grade 3  
 
 
 • Immediately interrupt 
ADXS -503 
• Permanently 
discontinue ADXS -
503  Not applicable  
4 ● Supportive care and neurological workup as per Grade  1 • Immediately interrupt Not applicable  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
163 Toxicity  Grade  Treatment  Instructions for 
Interruption of ADXS -503 Modification for 
Subsequent Infusions  
● ICU monitoring; consider mechanical ventilation for 
airway protection  
● Tocilizumab1 and repeat neuro -imaging as per Grade 3  
● High dose methylprednisolone  
● For high -grade (Stage 3, 4, or 5) papi[INVESTIGATOR_679768], CSF OP 
greater than or equal to 20 mmHg, or cerebral edema, 
follow Institutional guidelines for high dose steroids, 
hyperventilation, hyperosmolar therapy, metabolic profile; 
CT scan daily.  ADXS -503 
• Permanently 
discontinue ADXS -
[ADDRESS_919945] (tocilizumab) administration - See Table 7.2  
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
164 Appendix 8 General Approach for Managing  Immune -Related Adverse 
Events  Associated with  ADXS -503 
Immune -
Related AE  Withhold/Discontinue ADXS -
503? Supportive Care  
Grade 1  • No action . • Provide symptomatic 
treatment . 
 
Grade 2  • May withhold ADXS -503. • Consider topi[INVESTIGATOR_679769] . 
 
 
Grade 3 and 
Grade  4 • Withhold ADXS -503. 
• Discontinue if unable to 
reduce corticosteroid dose 
to <10 mg per day 
prednisone equivalent 
within 12 weeks of toxicity . • Systemic corticosteroids are 
indicated in addition to 
appropriate symptomatic 
treatment. May utilize 1 to 
2 mg/kg prednisone or 
equival ent per day.  
• Steroid taper should be 
considered once symptoms 
improve to Grade [ADDRESS_919946] Label  (Keytruda® ) for pembrol izumab and 
can be found on the Keytruda ® website at https://www.keytruda.com/   
 

CONFIDENTIAL    
Protocol ADXS -503-101 
 
166  
 
 
 
 

CONFIDENTIAL    
Protocol ADXS -503-101 
 
167 Appendix 10 Assessment of Disease  
Tumor response will be evaluated at the tumor imaging timepoints specified in the SoA. Tumor 
response will be evaluated by [CONTACT_737] (or designee) according to RECIST  v1.1 as the basis 
for the primary analysis of tumor response -based endpoints  (Eisenhauer, 2009 ). Exploratory 
analysis of tumor -response will be performed by [CONTACT_1034] (or designee) according to iRECIST  
(Seymour, 2017 ). See Section 9.4.1 . 
Baseline Tumor Assessment  
The baseline tumor burden (unidimensionally measured or evaluable disease) will be assessed 
during the  pre-treatment Screening evaluations. The I nvestigator will identify prospectively, the 
lesions to be followed in order to evaluate the subject ’s response to therapy (see 
Target/Non -target Lesions ). Baseline i maging areas will  include the chest, abdomen, pelvis and 
any additional known sites of dis ease. Subject s with known CNS metastases and subjects  with 
signs or symptoms suggestive of brain metastasis should be evaluated with imaging of the brain at 
baseline . 
Tumor Imaging  
Computed tomography (CT) and magnetic resonance imaging (MRI) will be consi dered the best 
currently available and reproducible methods to measure target lesions selected for response 
assessment. Lesions on chest x -rays will be acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776]; however, CT is preferable. Ultrasound is not an acceptable 
method to measure disease.  
Target/Non -Target Lesions  
All measurable lesions, up to a maximum of 2 lesions per organ and up to 5 lesions in total, should 
be identified as target lesions to be measured and re corded at baseline. The target lesions should 
be representative of all involved organs. Target lesions will be selected based on their size ( lesions  
with the longest diameter s) and suitability for accurate repeated measurements. At baseline, a sum 
of the l ongest diameters for all target lesions will be calculated and recorded as the baseline tumor 
burden. The baseline sum will be used as the reference point to determine the objective tumor 
response of the target lesions.  
One exception to the above escribed  approach is related to pathological lymph nodes. Pathological 
lymph nodes are defined as measurable lesions and may be identified as target  lesions if the 
criterion of a short axis of ≥[ADDRESS_919947] a short axis <10 mm are considered non -pathological and 
should not be recorded or followed.  
Measurable lesions other than the target lesions  (including pathologic lymph nodes)  and all sites 
of non -measurable disease will be identified as non -target lesions and will be recorded at baseline. 
Non-target lesions will be evalua ted at the same assessment time points as target lesions.  
Measurable and Non -Measurable Lesions and Disease  
Measurable lesions will be those that can be accurately measured in at least one dimen sion (longest 
diameter in the plane of measurement is to be recorded)  with a minimum size of:  
CONFIDENTIAL    
Protocol ADXS -503-101 
 
168 • [ADDRESS_919948]/MRI scan - (CT/MRI scan 
slice thickness no greate r than 5 mm)  
• 10 mm for lesions assessed  clinically by [CONTACT_7872] (lesions which cannot be 
accurately measured with calipers should be recorded as non -measurable)  
• [ADDRESS_919949] x -ray  
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥[ADDRESS_919950] scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in subsequent assessments , only 
the short axis will be measured and followed.  
Non-measurable lesions/disease will be all other lesions (or sites of disease), including small 
lesions (longest diameter <10 mm or pathological lymph nodes with a ≥10  mm but <15 mm short 
axis) , as well a s truly non -measurable lesions . Truly  non-measurable lesions include: 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, 
lymphangitic involvement of skin or lung, abdominal masses identified by [CONTACT_679832] .  
Special Considerations Regarding Lesion Measurability  
Bone Lesions  
• Bone scan, PET scan, or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can  be used to confirm the presence or 
disappearance of bone lesions.  
• Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue components, 
that can be evaluated by [CONTACT_86123].  
• Blastic bone lesions are non -measurable . 
Cystic Lesions  
• Lesions that meet the criteria for radiographically defined simple cysts should not be  
considered as malignant lesions (neither measurable nor non -measurable) since they are, 
by [CONTACT_108], simple cysts.  
• ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable  
lesions, if they meet the definition of measurabili ty described above. However, if non -
cystic lesions are present in the same subject , these are preferred for selection as target 
lesions . 
Lesions with Prior Local Treatment  
Tumor lesions situated in a previously irradiated area, or in an area subjected to locoregional 
therapy, are usually not considered measurable unless there has been demonstrated progression in 
the lesion . 
Response in Target  Lesions (RECIST v1.1) 
At baseline, the sum of the longest diameters (SumD) of all target lesions (up t o 2 lesions per 
organ, up to 5 lesions total) is measured.  At each subsequent tumor assessment, the response in 
target and new measurable lesions is defined  as follows:   
CONFIDENTIAL    
Protocol ADXS -503-101 
 
169 • Complete Response (CR): Disappearance of all target lesions. Any pathological lymph 
nodes (whether target or non -target) must have reduction in short axis to <10 mm.  
• Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters.  
• Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must also 
demonstrate an absolut e increase of at least 5 mm.  (Note: the appearance of one or more 
new lesions is also considered progression).  
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest  sum diameters while on study.  
Response in Non -Target  Lesions (RECIST v1.1) 
While some non -target lesions may actually be measurable, they need not be measured and instead 
should be assessed only qualitatively.  
• Complete Response (CR): Disappearance of all non-target lesions and normalization of 
tumor marker level. All lymph nodes must be non -pathological in size (<10 mm short 
axis).  
• Non-CR/Non -PD: Persistence of one or more non -target lesion(s) and/or maintenance of 
tumor marker level above the normal limi ts.  
• Progressive Disease (PD): Unequivocal progression of existing non -target lesions. (Note: 
the appearance of one or more new lesions is also considered progression).  
 
Tumor -Response According to iRECIST  
For a description of tumor -response evaluation according to iRECIST , and the differences 
between iRECIST and RECIST v1.1, r efer to :  
 
Seymour L, Bogaerts J, Perrone A, et al.  iRECIST: guidelines for response criteria for use in 
trials testing immunotherapeutics.  Lancet Oncol . 2017; 18:e143 -52.75 
 
CONFIDENTIAL    
Protocol ADXS -503-101 
 
170 Appendix 11 ECOG Performance Status  
ECOG Performance Status  
Grade  Status  
0 Fully active, able to carry on all pre -disease performance without 
restriction . 
1 Restricted in physically strenuous activity but ambulatory and able 
to carry out work of a light or sedentary nature, eg, light house work , 
office work . 
2 Ambulatory and capable of all self -care but unable to carry out any 
work activities. Up and about mor e than 50% of waking hours . 
3 Capable of only limited self -care, confined to bed or chair more than 
50% of waking hours . 
4 Completely disabled. Cannot carry on any self -care. Totally 
confined to bed or chair . 
5 Dead . 
Reference: (Oken, 1982 ) 
 